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Breast cancer is the most common cancer type in women population affecting a large 
number of women worldwide. Due to its highly heterogenous molecular characteristics, there is 
not a default treatment strategy for breast cancer. Almost two third of breast cancer cases are 
estrogen receptor positive ER (+). Majority of breast cancer specific deaths in women with ERα 
(+) tumor occur due to metastases that are resistant to endocrine therapy. There is a critical need 
for novel therapeutic approaches to prevent or delay recurrence of ERα (+) tumors. The overall 
objective of this dissertation project is to define the interaction among endocrine resistance, 
nuclear export system, and cellular metabolic pathways, and to evaluate the metabolic impact of 
combinational ER and XPO1 targeting by using combination of endocrine therapy agents and a 
XPO1-specific small molecule inhibitor (Selinexor-SEL) in different endocrine resistant ER (+) 
breast cancer cell lines. The long term goal is to develop effective treatment strategies to overcome 
endocrine resistance in ER (+) breast cancer.  
In the first part of this project, we focused on the characterization of XPO1 protein in 
tamoxifen resistance. In this part, we used endocrine-sensitive and -resistant breast cancer cell 
lines (in vitro) and tumor xenograft models (in vivo) to test our hypothesis. Our results showed 
that expression profile of XPO1 protein has a pivotal role in the progression of tamoxifen 
resistance in ER (+) breast cancer cell models. We found out that XPO1 protein modulates 
tamoxifen resistance due to its function to determine subcellular localization of important kinases.   
In the second part of the project, we investigated how nuclear export system contribute to 
tamoxifen resistance development by testing with a novel combinational targeting strategy using 
4-OHT and SEL in Luminal B type breast cancer cell lines, and to investigate the metabolic 
outcomes of this novel therapy. To test our hypotheses, we used actual patient tumor samples and 
endocrine-sensitive and -resistant breast cancer cell lines (in vitro). Our findings indicated that 
XPO1 expression is significantly higher in Luminal B subtype compared to other molecular 
subtypes. We demonstrated that combined targeting of XPO1 and ERα rewires metabolic 
pathways (e.g. Akt pathway), and shuts down both glycolytic and mitochondrial pathways that 
would eventually lead to autophagy. 
Lastly, we assessed the impact of other endocrine therapy options alone or in combination 
with Selinexor on metabolism in different endocrine resistant breast cancer cell lines and possible 
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metastatic organ sites. We used 3-D cell culture models and endocrine-sensitive and -resistant 
breast cancer cell lines (in vitro). Using a combination of transcriptomics, kinase arrays, 
metabolomics and metabolic flux experiments, we identified glutamine metabolism pathways to 
be rewired during endocrine resistance. In limited media conditions mimicking nutrient deprived 
tumor microenvironment, endocrine resistant cells were more dependent on mitochondria for 
energy production. Their glucose and fatty acid dependency decreased in the presence of SEL and 
cells were more dependent on glutamine. The effect of glutamine was dependent on conversion of 
the glutamine to glutamate and mitochondrial complex 1 activity. In order to examine metabolites 
that might result in the observed phenotype we performed GC/MS whole metabolite profiling and 
identified amino acid metabolism pathways to be upregulated when cells were treated with SEL.   
In conclusion, our study indicated that remodeling metabolic pathways to regenerate new 
vulnerabilities in endocrine resistant breast tumors is novel, and given the need for better strategies 
for improving therapy response of relapsed ERα(+) tumors, our findings show great promise for 
uncovering the role ERα-XPO1 crosstalk plays in reducing cancer recurrences. 
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CHAPTER 1: INTRODUCTION 
 
1.1. Overview 
ER is known to be present in 75% of breast cancers and is considered the most common 
drug target and prognostic marker defining breast cancer subtypes [1]. Effective and well-tolerated 
endocrine therapies were developed to avoid negative effects of radiation and chemotherapy, 
including tamoxifen, which is a selective estrogen receptor modulator (SERM) used to treat pre- 
and post-menopausal women with ER-positive tumors [2]. Although tamoxifen has been used to 
extend disease-free survival of millions of women over the last forty years, approximately 40% of 
these tumors eventually relapse after a 10-year continuous tamoxifen treatment [3, 4]. Besides, 
selective estrogen degraders (SERDs), like fulvestrant, are also commonly used for the treatment 
of ER (+) breast cancers. Even though there are different endocrine and targeted therapy options 
to treat breast cancer in clinic, drug resistance against these treatments has become the most 
prevalent problem due to long treatment procedure. In fact, most breast cancer deaths occur due to 
recurrent tumors that become more aggressive and tend to metastasize to distant organs [5]. 
Therefore, novel studies are needed to investigate possible mechanisms of drug resistance. Many 
proposed mechanisms exist to explain the mechanism of this resistance, such as dysregulations in 
tamoxifen metabolism, mutations to ESR1 and even specific proteins that can recognize ER-
tamoxifen complexes, and alterations in protein kinase signaling [5]. Since many of these 
mechanisms are related with cell cycle progression and E2-related hyperactivation in cell cycle, 
these pathways have become the most pivotal targets for combined treatments in clinic. If we look 
at current clinical practices, combination of endocrine therapies with CDK4/6 inhibitors, such as 
Palbociclib, has become a gold standard to treat endocrine resistant breast cancers. Even though 
resistance and metastasis are the two main negative outcomes of endocrine treatment, the 
molecular mechanisms underlying these obstacles are still not clear. A significant number of 
studies in the last decade have addressed possible intracellular pathways that may be the reason 
behind endocrine resistance [6]. Dysregulation of the nuclear transport pathways are considered 
one of the proposed mechanisms due to causing alterations in the subcellular localization of some 
tumor suppressor proteins and hormone receptors [7]. As a nuclear export element, exportin 1 
(XPO1) has been proposed to be used as a biomarker for the development of tamoxifen resistance. 
Also, the overexpression of XPO1 has been shown to be associated with tamoxifen resistance in 
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luminal B type breast tumors, and combined targeting of ER and XPO1 showed promising effects 
to overcome tamoxifen resistance in ER (+) breast tumors [7]. The main aim of this project was to 
understand the molecular mechanism behind the success of targeting ER and XPO1 together. 
The contribution of this research was significant because we identified a novel mechanism of 
endocrine resistance, which shows a clear crosstalk between nuclear export system, intracellular 
kinase pathways, and cellular metabolism. This mechanism specifically elucidated the metabolic 
impact of combinational ER and XPO1 targeting in endocrine-resistant breast cancer cells. In 
addition, this project provided information about ‘deregulating cell metabolism’ during drug 
resistance as one of the emerging hallmarks of cancer. The major positive benefit of this study was 
to understand how ER-mediated nuclear export contributes to the development of tamoxifen 
resistance. The delineation of this mechanism gave us an idea about the key targets of intracellular 
signaling during tamoxifen resistance, which we can inhibit by using our combinational targeting 
strategy. Further, this study allowed us to identify the metabolic alterations promoting cell survival 
in the endocrine-resistant tumors. Moreover, the findings obtained from this study may be 
applicable not only for breast cancer but also for other cancer types in which XPO1 is 
overexpressed, such as therapy resistant leukemia and prostate cancer. In summary, this project 
allowed us to extend our knowledge about intracellular regulation of drug resistance in breast 
cancer treatment and gave us a direction to develop more hypothesis in this field. 
The overall objective of this project is to define the interaction among endocrine resistance, 
nuclear export system, and cellular metabolic pathways, and to evaluate the metabolic impact of 
combinational ER and XPO1 targeting by using different endocrine agents and XPO1-specific 
Selinexor (SEL) in endocrine-resistant breast cancer cells. All research steps and their outcomes 
were summarized in Table 1.  
 Each chapter of this project was dedicated to answer several questions related to endocrine 
resistant in different cohort of breast cancer patients. In the first part of this research, we focused 
on the molecular differences between endocrine-resistant and -responsive tumors. In the second 
part, we investigated the molecular mechanism behind the success of ER and XPO1 targeting in 
de novo tamoxifen-resistant breast cancer cells to mimic the situation of pre-menopausal breast 
cancer patients, who have never responded to tamoxifen treatment. In the last part, we concentrated 
on the effect of this combined treatment strategy on metastatic breast cancer cells. To do this, we 
aimed to study the benefit of this combined treatment in patients who developed resistance against 
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different endocrine agents and have advanced metastatic breast cancer profiles. Research strategies 
and outcomes of each aim were extended in the following paragraphs. 
Aim 1 was developed to identify and characterize the role of nuclear export mechanism in 
tamoxifen resistance. There were three main research questions under this aim (Figure 1.1). Firstly, 
we investigated the link between XPO1 expression and cell proliferation rate in tamoxifen- 
sensitive and tamoxifen-resistant breast cancer cells. Secondly, we identified the role of XPO1 on 
subcellular localization of ERK5 during tamoxifen resistance development. Lastly, we determined 
the effect of individual and combinational ER and XPO1 targeting on the subcellular localization 
of ERK5 protein in tamoxifen-resistant breast cancer cells. These results were published in a paper, 
which was titled as “ERα-XPO1 crosstalk controls tamoxifen sensitivity in tumors by altering 
ERK5 cellular localization”[7]. This study showed that XPO1 overexpression increased cell 
proliferation in de novo tamoxifen-resistant breast cancer cells. Also, we identified that nuclear 
localization of active kinases changes during tamoxifen resistance progression (Figure 1.2). 
Aim 2 was planned as a follow-up study to understand how nuclear export system 
contribute to tamoxifen resistance development by testing with a novel combinational targeting 
strategy using 4-OHT and SEL in Luminal B type breast cancer cell lines, and to investigate the 
metabolic outcomes of this novel therapy. There were five main research questions under this aim 
(Figure 1.3). Firstly, we identified how XPO1 is associated with poor disease outcome in ER+ 
breast cancer cells, and we compared XPO1 expression in different breast cancer subtypes. 
Secondly, we investigated the effect of ER and XPO1 targeting on gene expression profiles and 
the general kinase pathways in tamoxifen-resistant breast cancer cells. Thirdly, we looked at the 
effect of ER and XPO1 targeting specifically on different phosphorylation sites of Akt protein. 
After that, we studied the effect of ER and XPO1 targeting on general metabolic phenotypes and 
glycolytic and mitochondrial metabolic pathways in tamoxifen-resistant breast cancer cells. Lastly, 
we investigated which death pathways are activated via ER and XPO1 targeting. The results of 
these research questions were published in a paper, which was titled as “Combined Targeting of 
Estrogen Receptor Alpha and XPO1 Prevent Akt Activation, Remodel Metabolic Pathways and 
Induce Autophagy to Overcome Tamoxifen Resistance”. In this study, we found that XPO1 gene 
signature is upregulated specifically in Luminal B subtype of breast cancer cells, and combined 
targeting ERα and XPO1 modulates Akt signaling to rewire tumor cell metabolism and induce 
autophagy (Figure 1.4). 
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Aim 3 was prepared to assess the impact of other endocrine therapy options alone or in 
combination with Selinexor on metabolism in different endocrine resistant breast cancer cell lines 
and possible metastatic organ sites. There were six main research questions under this aim (Figure 
1.5).  Firstly, we looked at cell viability of different endocrine resistant breast cancer models under 
treatment of different endocrine therapy agents alone or in combination. Secondly, we determined 
metabolic cell phenotypes of different endocrine resistant breast cancer models. Thirdly, we 
monitored oncosphere formation profile/capacity of endocrine resistant breast cancer cell lines in 
3D metastatic organ models. The fourth research question addressed the point of how cellular 
metabolic phenotype of endocrine resistant breast cancer cells change in different metastatic organ 
sites. Furthermore, we investigated the mechanism of single agent resistance against Selinexor. 
Lastly, we focused on the molecular mechanism behind the success of combined ER and XPO1 
targeting. The results of these research questions will be published in a separate research paper. 
Main conclusion of this part is that combined ER and XPO1 targeting is an effective strategy to 



















1.2. Table and Figures 
Table 1.1. Summary of research aims and their outcomes 
Type of Study Aim Publication 
Characterization and 
identification of the role of XPO1 
in tamoxifen resistance  
- 
Identification of the differences 
between endocrine-resistant and -
responsive breast tumors in terms 
of nuclear transport system 
Aim 1: To identify the role 
of nuclear export 
mechanism in tamoxifen 
resistance. 
K. Wrobel*, Y. C. Zhao*, E. 
Kulkoyluoglu*, K. L. A. Chen, K. 
Hieronymi, J. Holloway, S. Li, T. Ray, P. S. 
Ray, Y. Landesman, A. E. Lipka, R. L. 
Smith, and Z. Madak-Erdogan, “ERα-XPO1 
crosstalk controls tamoxifen sensitivity in 
tumors by altering ERK5 cellular 
localization.,” Mol. Endocrinol., 2016 (*Co-
first author) (published) 
Identification of the role of XPO1 
in  
de novo resistance 
Aim 2: To understand how 
nuclear export system 
contribute to tamoxifen 
resistance development 
Kulkoyluoglu-Cotul, E.; Smith, B.P.; 
Wrobel, K.; Zhao, Y.C.; Chen, K.L.A.; 
Hieronymi, K.; Imir, O.B.; Duong, K.; 
O'Callaghan, C.; Mehta, A.; Sahoo, S.; 
Haley, B.; Chang, H.; Landesman, Y.; 
Madak-Erdogan, Z. Combined Targeting of 
Estrogen Receptor Alpha and XPO1 Prevent 
Akt Activation, Remodel Metabolic 
Pathways and Induce Autophagy to 
Overcome Tamoxifen 
Resistance. Cancers 2019, 11, 479. 
(published) 
Identification of the role of XPO1 
in metastatic organ sites 
Aim 3: To assess the 
impact of these individual 
and combinational 
treatment strategies on 
metabolism in endocrine-
resistant ER (+) breast 
cancer cells and in the body 
Kulkoyluoglu-Cotul, E.; Smith, B.P.; 
Santaliz-Casiano, A.; Tunc E.; Zuo, Q.; 
Duong, K.; Ramesh R.;  Park B.H.; 
Landesman, Y.; Madak-Erdogan, Z. Role of 
mitochondria and glutamine metabolism in 
therapy resistance: Combined targeting of 
estrogen receptor alpha and exportin 1 in 

































Figure 1.5. Summary of the methods and results in Aim-3. 
 11 
 





1. S. Nilsson and J. A. Gustafsson, "Estrogen receptors: therapies targeted to receptor 
subtypes," Clin Pharmacol Ther, vol. 89, pp. 44-55, Jan 2011. 
2. V. C. Jordan, "Targeting antihormone resistance in breast cancer: a simple solution," Ann 
Oncol, vol. 14, pp. 969-70, Jul 2003. 
3. W. Gu, N. Dong, P. Wang, C. Shi, J. Yang, and J. Wang, "Tamoxifen resistance and 
metastasis of human breast cancer cells were mediated by the membrane-associated 
estrogen receptor ER-alpha36 signaling in vitro," Cell Biol Toxicol, vol. 33, pp. 183-195, 
Apr 2017. 
4. X. Chen, X. Zha, W. Chen, T. Zhu, J. Qiu, O. D. Roe, et al., "Leptin attenuates the anti-
estrogen effect of tamoxifen in breast cancer," Biomed Pharmacother, vol. 67, pp. 22-30, 
Feb 2013. 
5. V. K. Arora, E. Schenkein, R. Murali, S. K. Subudhi, J. Wongvipat, M. D. Balbas, et al., 
"Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen 
receptor blockade," Cell, vol. 155, pp. 1309-22, Dec 5 2013. 
6. M. Chang, "Tamoxifen resistance in breast cancer," Biomol Ther (Seoul), vol. 20, pp. 256-
67, May 2012. 
7 K. Wrobel, Y. C. Zhao, E. Kulkoyluoglu, K. L. Chen, K. Hieronymi, J. Holloway, et al., 
"ERalpha-XPO1 Cross Talk Controls Tamoxifen Sensitivity in Tumors by Altering ERK5 





CHAPTER 2: LITERATURE REVIEW PART I: 
NUCLEAR AND EXTRA NUCLEAR-INITIATED ESTROGEN RECEPTOR 
SIGNALING CROSSTALK AND ENDOCRINE RESISTANCE IN BREAST CANCER 
 
2.1. Abstract 
Estrogens regulate function of reproductive and non-reproductive tissues in healthy and 
diseased states including breast cancer. They mainly work through estrogen receptor alpha (ER) 
and/or estrogen receptor beta (ER). There are various ER targeting agents that have been used 
for treatment of ER (+) breast tumors. The impact of direct nuclear activity of ER is very well 
characterized in ER (+) breast cancers and development and progression of endocrine resistance. 
Recent studies also suggested important roles for extranuclear-initiated ER pathways, which 
would decrease the potency and efficiency of ER targeting agents. In this mini-review, we will 
discuss the role of nuclear and extra-nuclear ER signaling and how they relate to therapy resistance 
in breast cancer. 
Key words: Breast cancer, Estrogen receptor, 17- Estradiol, Tamoxifen resistance 
 
Highlights 
 ER signals through nuclear and extranuclear ER-initiated signaling cascades. 
 
 Crosstalk between two pathways regulate metabolic and developmental programs. 
 
 Tamoxifen is still widely used in clinic to treat breast cancer. 
 
 ERα-initiated kinase signaling play a role in therapy resistance in breast cancer. 
 
 
This part is a part of publication, Kulkoyluoglu, E., Madak-Erdogan, Z., Nuclear and extranuclear-initiated estrogen 







Estrogen receptor alpha (ER) and estrogen receptor beta (ER) are members of the Type 
I nuclear receptor superfamily. They regulate 17β-estradiol (E2)-mediated transcriptional 
activation of responsive genes. In the last three decades, various agonists and antagonists have 
been designed for the treatment of ER-positive breast cancer. Although long-term usage causes 
resistance, tamoxifen is still the most popular endocrine agent for ER (+) breast cancer treatment. 
This mini-review aims to highlight recent studies that uncovered the importance of ER and kinase 
signaling pathway crosstalk in therapy resistance for breast cancer. 
 
2.3. Estrogen Receptors (ERs) 
2.3.1. ER function in physiology 
Estrogen receptors belong to the Type I Nuclear Receptor Super Family that comprises 
classical steroid receptors. There are two different forms of estrogen receptors, known as estrogen 
receptor alpha (ER) and estrogen receptor beta (ER). Both receptors can act as transcription 
factors or initiate extranuclear-initiated kinase signaling cascades. ER is the first steroid receptor 
to be discovered by Jensen in 1958. After almost 20 years another ER was discovered [1, 2]. They 
are encoded by genes that are on different chromosomes, have tissue specific expression profiles, 
and have distinct functions. While ER is mainly expressed in breast, uterus, prostate, brain, liver, 
adipose tissue and bones, ER is widely expressed in the ovary, prostate, testes, lung, thymus, 
spleen, bone marrow, salivary gland and vascular epithelium. ER and ER usually act in opposite 
ways. In breast tumors, ER expression is high, but presence of ER correlates with better 
prognosis by modulating the effects of ER [3]. Estrogens play critical roles for maintenance and 
development of reproductive and non-reproductive tissues since lack or excess of estrogens cause 
various pathological conditions human breast, ovarian, colorectal, prostate and endometrial 
cancers, osteoporosis, atherosclerosis, metabolic syndrome and Alzheimer’s disease [4, 5]. ER 
is a major player in breast cancer, and its expression correlates with better prognosis [6]. 
 
2.3.2. ER structure 
ERα (NR3A1) and ERβ (NR3A2) are encoded by two different genes called Esr1 (on 
6q21.5) and Esr2 (on 14q.21), respectively. ER and ER isoforms show tissue-specific 
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expression and they also have been shown to form heterodimers on binding estrogen receptor 
elements (EREs). Although there is a high homology between DBDs (~95%) and LBDs (~50%) 
of ER and ER, N-terminal domains show only 15% sequence similarity [7]. ESR1 gene consists 
of 8 exons and it is located on chromosome 6q25.1. It is expressed under control of 6 tissue-specific 
promoters. The full-length size protein product is 66 kDa [8]. Starting from N-termini, ER has 6 
domains which are named from A to F. A/B domains are the N-terminal domain and have 180 
amino acids functioning as AF-1.This region possesses a molecular recognition region (ID region), 
mostly carrying a random coil structure [9]. The N-termini domain can activate transcription even 
in the absence of the hormone by means of phosphorylation of the receptor at serine-118 and 
serine-167 residues by MAPK and Akt pathways, respectively. AF-1 domain can also modulate 
the response to SERMs together with the domain F called AF-2. Both A/B and E domains are 
required for full agonist action [10, 11]. C domain is referred DNA binding domain (DBD) and 
located between amino acid 181 and 263. It has an evolutionary conserved helix-loop-helix 
structure, which has two cysteine rich zinc finger motifs that interact with a palindromic 
(GGTCAnnnTGACC) sequence on DNA. The ER DBDs have two sub-domains which are 
different in term of structure and function. Proximal box, P-box, is the first sub-domain which is 
responsible for the interaction with the sugar-phosphate backbone on the major DNA groove of 
the ERE. D-box is the second sub-domain and it is important for receptor dimerization [7, 12]. 
Between amino acids 264 and 302, resides the D domain and carries a nuclear localization signal. 
This hinge region serves as a flexible connection between DBD and LBD. E/F domains between 
amino acid 303 and 533 are LBD and they consist of 12 helices which is critical for hormone 
binding and dimerization. On the far C-termini of ER, there is F domain serves as AF-2. This 
region works synergistically to maximize transactivation function together with AF-1 [7]. 
Recently, several mutations in F-domain were identified in more than 30% of the metastatic ER_ 
(+) tumors. These mutations render the receptor constitutively active and decreases inhibition of 
the receptor action by currently available endocrine therapies [13-17]. 
 
2.3.3. ER ligands 
17β-estradiol (E2) is synthesized from cholesterol and it is the endogenous ligand of ERs. 
Estrogen was purified and crystalized by Edward Doisy and Alfred Butenandt nearly 
simultaneously in 1929 and later 17β-estradiol (E2) biosynthesis was shown to be achieved by 
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aromatase enzymes mostly in the ovaries, adipose and adrenal tissue [18]. With the discovery of 
the chemical structure of estrogen by using new molecular biology techniques, a variety of 
physiologic effects on different tissue types were also identified. These studies showed that 
estrogen was a good candidate to manage menopausal symptoms of women during 1970s. In these 
studies, it was shown that 17β -estradiol (E2) is a steroid hormone, whose synthesis is regulated 
by 17-hydroxysteroid dehydrogenase. The human aromatase is encoded by CYP19A1 gene and 
the size of the full protein is about 123 kDa. First exon is expressed in tissue-specific manner [19]. 
Tissue-specific expression of aromatase regulates 17β -estradiol (E2) synthesis in the body.  
The LBD domain of ERs bind to both agonists and antagonists, but helix 12 has distinct 
orientations with different ligands. Upon agonist binding, including the 17β-estradiol (E2) and the 
synthetic nonsteroidal estrogen diethylstilbestrol (DES) to ERs, helix 12 on LBD folds against 
helices 3 and 11 which allows maximal coactivator binding on TAD. However, this coactivator 
binding pocket is disrupted with antagonist binding such as selective estrogen receptor modulators 
(SERMs). In this region, long hydrophobic groove on helix 12 becomes available for corepressor 
binding [20, 21]. Tamoxifen and raloxifene are two SERMs and they can act either as an agonist 
or as an antagonist in different tissues [22]. Raloxifene acts as an ER antagonist in the breast and 
uterus, yet it has agonistic effects on bone structure, which provides increase in mineral density to 
improve menopausal osteoporotic outcomes. Tamoxifen is the most commonly used endocrine 
agent which is still prescribed to treat premenopausal and postmenopausal breast cancer patients. 
Tamoxifen has tissue specific activity; it is antagonistic in breast tissue, yet it acts as an agonist in 
the uterus. While it blocks AF-2, it can activate AF-1 in tissue specific manner [23]. In addition, 
with long-term usage, cancer cells might develop tamoxifen resistance. The molecular mechanism 
behind tamoxifen resistance is an active area of research by many labs and several mechanisms 
will be discussed in Section 3.3. 
 
2.3.4. Post-translational modifications (PTMs) and interacting partners of ER 
ER activity can be modulated by posttranslational modifications and/or differential 
interactions with coactivator or corepressors. [24-27]. ER is phosphorylated at different serine 
residues on N-terminal transactivation domain, DBD and a Tyr residue in the LBD [28-33]. 
Kinases downstream of mitogen-activated protein kinase (MAPK) pathway and protein kinase 
pathway (PKA) increases phosphorylation of ERs [31, 34-36]. The DBD of ER is also acetylated 
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by p300 coactivator associated factor (PCAF) on four highly-conserved lysine residues which 
control the transcriptional activity of ER [37]. In addition, palmitoylation of human ER protein 
on Cys-447 enables membrane association of the receptor. Studies using mice that has mutation 
on this residue showed that membrane-specific loss of function resulted in female infertility with 
abnormal ovarian function and abrogated significant vascular actions of E2 [38]. Moreover, 
palmitoylation affects dimerization, protein-protein interaction partners and E2-dependent 
degradation of the receptor as well as the phosphorylation of the ER Ser-118 residue [39, 40]. 
Sumoylation is another important PTM and it usually promotes autophagy and apoptosis under 
stress conditions. In parallel to this function, sumoylation of ERs leads to transactivation of some 
cell death-related genes in presence of endogenous ligands [41]. Regulation of ER degradation is 
also controlled by ubiquitination. In recent articles, it has been shown that, E2-mediated ER 
degradation requires ubiquitination of residues such as leucine 429 and alanine 430 on LBD [42]. 
A comprehensive evaluation of PTMs of ERα in breast cancer revealed several sites associated 
with better clinical outcome for tamoxifen therapy, whereas other phosphorylation sites were 
associated with poorer clinical outcome. ERα acetylation and sumoylation have also been shown 
to be important predictors of breast cancer outcomes [43].  
Numerous ERα interacting partners have been identified in the last two decades. Steroid 
receptor co-activator (SRC-1) was the first nuclear receptor co-activator to be identified; it 
stimulates transcriptional activation by binding to AF-2 region of nuclear receptors including ER 
in presence of the ligand [44]. In the late 1990s, SRC-3 and receptor interacting protein 140 
(RIP140) were identified as two important key co-regulators of both ER and ERβ [45, 46]. ERs 
also interact with other transcription factors, nuclear receptors and coregulators associated with 
these proteins. Vitamin D receptor interacting protein (DRIP)/thyroid hormone receptor associated 
proteins (TRAP) complex, nuclear receptor corepressor (NCoR) and silencing mediator for 
retinoid and thyroid receptor (SMRT) interact with ER_ through AF-2 domain [47 49]. Recent 
studies also showed that ER physically interacts with c-MYC through AF-1 to stabilize estrogen-
mediated signaling networks [50]. The retinoic acid receptor alpha (RAR) was also shown to be 
in ER complex and is important for maintenance of ER-cofactor interactions. These data suggests 
that ERα interacts with different nuclear receptors to provide effective transcriptional activity in 
breast cancer cells [51]. 
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2.4. ER activated pathways 
2.4.1. Nuclear initiated pathways 
In the absence of ligand, ER binds to heat-shock proteins in the cytoplasm. In presence 
of the hormone, ER disassociates from HSPs, translocates into the nucleus and binds to EREs on 
the genome. Once ER binds to EREs, it recruits other co-regulators to form a transcriptional 
regulatory complex. Then, the complex recruits basal transcription machinery and RNA 
Polymerase II to the proximal promoter region. Some of the genes lack any ERE-like sequences 
and they require another transcription factor to provide the scaffold for ER to indirectly bind to 
DNA. Most of the primary E2-responsive genes are activated through the direct/indirect interaction 
between ER and DNA. On the other hand, secondary E2-responsive genes are the ones whose 
expression depends on a transcription factor, which is activated by ERs [52, 53]. Many studies 
identified E2-regulated genes using genome-wide cDNA microarray and high-throughput RNA 
sequencing technologies [46, 53-62]. The majority of these analyses focused on upregulated genes 
and several of them characterized different mechanisms by which ERα represses transcription [63-
65]. 
 
2.4.2. Extracellular initiated pathways 
Estrogens are also capable of activating extranuclear-initiated kinase signaling, which 
contributes to gene transcription, cytoskeletal remodeling, cell proliferation and cell survival [57-
59, 66, 67]. G-protein coupled ERs (GPER or GPR30) which are located on plasma membrane 
[68] activate MAPK and PI3K pathways in the presence of estrogens [69]. G protein coupling 
enables rapid estrogen activated signals to be transmitted by phospholipase C-dependent IP3 
production, which cause an increase in the level of second messengers like calcium and nitric oxide 
(NO) in several endometrial, granulosa, smooth muscle, duodenum cell lines [70, 71]. Recent 
studies have shown that GPR30 specifically binds to estrogens and is able to mediate non-genomic 
estrogen actions through epidermal growth factor receptor (EGFR) pathway, the Notch signaling 
pathway and the mitogen-activated protein kinases (MAPK) pathway [72, 73].  
Most recent studies have shown that ERs control cell metabolism and cell proliferation 
through modulation of other transcription factors and developmental pathways. For example, ER 
regulates hypoxia-inducible factor 1 (HIF-1) pathway associated with antiestrogen response in 
breast cancer [74]. Yu et al. have also found that ER regulates genes targeted by Hedgehog 
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signaling pathway [75]. Membrane receptor actions are important in estrogen-mediated regulation 
of cardiovascular system and nervous system [76, 77]. For example, the membrane-initiated rapid 
E2 signaling is effective in hypothalamic and hippocampal neurons and this mechanism regulates 
energy balance, thermoregulation and proliferation in neural tissue by inducing neural protection 
[78, 79].  
Besides secondary messenger signaling, ER upregulates cell proliferation and cell 
migration through interactions with IGF-1R and mitogen-activated protein kinase (MAPK) 
pathway in various cancer cell lines [80-83]. The interactions between ER localized at the plasma 
membrane and various specific membrane proteins, such as modulator of non-genomic activity of 
estrogen receptor (MNAR), Shc, EGF and IGF-1 receptors play important roles in non-genomic 
estrogen signaling [84-87]. Not only plasma membrane proteins, but also membrane lipids are 
associated with the small amount of ER localized on the plasma membrane. Sphingosine-1 
phosphate kinase (SphK1) is an enzyme which produces sphingosine-1 phosphate (Sph1) and very 
recent studies show that increased SphK1 expression is associated with E2-dependent activation 
of MAPK and intracellular Ca2+ mobilization in ERα-positive MCF-7 breast cancer cells [88, 89].  
Endogenous ligand 17-β-E2 activates both nuclear and extranuclear-initiated ER pathways. 
Recent studies using estrogens conjugated to dendrimers that would stay outside the nucleus [60, 
90] or modifying the ligand structure so that the ligand cannot form long-lived stable coregulator 
complexes [59] achieved preferential activation of these pathways. These tools were very useful 
and enabled researchers to show functions of extranuclear ER-initiated pathways are important in 
vascular protection, bone physiology and metabolic tissue function [59, 91, 92] (Figure 2.1). 
 
2.5. The Role of Estrogen Receptor in Breast Cancer 
2.5.1. Breast Cancer Incidence and Risk Factors 
According to ASCO, in 2016, almost 240,000 women will be diagnosed with breast cancer 
and 40,000 deaths due to breast cancer will occur in the United States [93]. Due to delayed 
childbearing and decreased number of births, the long-term incidence of breast cancer has 
increased during the last decade. Yet, breast cancer mortality decreased by means of early detection 
and newly developed treatment strategies [94]. Unmodifiable risk factors can be sourced from both 
hereditary and hormonal dysfunctions. The most important genetic determinant of breast cancer is 
BRCA1 and BRCA2 tumor-suppressor gene mutations which are inherited in an autosomal 
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dominant manner. p53, PTEN and CHEK2 mutations are also other key markers of breast cancer 
development [95-98]. Another important risk factor is age. Statistics show that the lifetime breast 
cancer risk for a women increases with advancing age [99, 100]. Besides hereditary factors, 
hormonal factors also contribute to the risk factors of breast cancer. The effect of high estrogen 
and progesterone exposure in different stages of lifespan increases the risk of breast cancer [101]. 
However, almost 80% of breast cancers stem from modifiable factors such as obesity, high-fat 
intake and excess alcohol consumption [102-104]. 
 
2.5.2. Molecular Heterogeneity of Breast Cancer 
Breast tumors display varying degrees of molecular heterogeneity since different subtypes 
are initiated from different cell types in the breast tissue [105-107]. In the clinic four main subtypes 
are used for classification and treatment decision of tumors: luminal A and B, HER-2 (human 
epidermal growth factor)/ERBB2 and triple negative/basal like. This classification is based on 
presence of ERs and HER-2 receptors in the tumor [108]. Almost two thirds of breast cancers are 
categorized under luminal type [109, 110]. The luminal A/B types are ER (+) whereas, triple 
negative/basal-like and HER-2 types do not express ER. Luminal A type tumors grow slowly and 
almost 90% of these tumors can be treated with estrogen receptor mediated targeting strategies. 
Compared to luminal A type, luminal B tumors are more aggressive; their progesterone receptor 
(PR) expression is lower and they respond poorly to hormone therapy. Gene expression profiling 
studies elucidated that luminal B type might display both luminal A type and HER-2 form 
characteristics. For example ESR1, FOXA1 and BCL2 gene expression profiles in luminal B type 
is similar with luminal A type. On the other hand, luminal B type tumors also have similar MK167, 
BIRC5 and cyclin B1 gene expressions like HER-2 subtype [111]. In clinic, luminal B type tumors 
are characterized by having ER+/HER2-/Ki67+ profile [112]. HER-2 oncogene is overexpressed 
in 70% of HER-2 type tumors which leads to activation of downstream signaling pathways. HER-
2 amplified tumors have low prognosis rate because of their complex signaling features. In triple 
negative/basal like tumors, there are no hormone receptors (estrogen, progesterone) or HER-2 
receptors, therefore they tend to be more aggressive. There are several subtypes of triple negative 
breast cancers. One of these subtypes is basal-like tumors. However, not all basal like tumors are 
triple negative [110]. Since they do not have a potential therapy target, survival rate of the patients 
who have triple negative tumors is lower than patients who have ER (+) tumors [113]. 
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Mutations in ER (+) tumors are considerably more diverse within luminal A and luminal 
B tumors than within ER-negative subtypes. Recent studies that identified novel mutations in 
breast tumors showed that the overall mutation rate was lowest in luminal A tumors. PIK3CA, 
MAP3K1, GATA3, TP53, CDH1 and MAP2K4 are the genes are mostly mutated in luminal A 
subtype. Luminal B tumors also have a diverse array of mutated genes such as TP53 and PIK3CA 
[107]. These mutations contribute to molecular heterogeneity, and this in turn introduces new 
challenges as increased heterogeneity is associated with increased therapy resistance. 
 
2.5.3. Tamoxifen and Mechanisms of therapy resistance in breast cancer 
The tamoxifen (ICI46, 474) was synthesized by Dora Richardson in Arthur L. Walpole’s 
research team in 1962 to develop anti-estrogen compounds as contraceptive pill. Later studies 
showed that tamoxifen was very effective in treating late stage ER-positive breast cancers [114]. 
Tamoxifen was the first targeted therapy for breast cancer and it improved the survival rates of 
many women and man who had early and late stage ER (+) breast tumors. Using gene expression 
analyses, researchers detected a large body of genes which are affected from endocrine therapy. 
These genes are related to cell proliferation, metabolism and cell invasion and inflammation and 
immune response [115].  
Although tamoxifen has been used for years as the best treatment option for ER (+) breast 
cancer, studies showed that long-term tamoxifen usage eventually causes relapse in 40% of the 
patients. [116].There are several hypotheses to explain the reason behind therapy resistance against 
tamoxifen in ER (+) breast cancers, which can be grouped under 4 main groups: alterations of ER 
expression and functions, metabolism of tamoxifen, alterations in co-regulatory proteins and 
signaling pathways and miRNAs.  
The first proposed mechanism is related to direct interaction between tamoxifen and LBD 
of ESR1. Mutations in LBD domain of ER+ is present about 30% of patients with metastatic ER 
(+) breast cancer [117-122]. Specific ER mutations, such as Tyr537Ser, Tyr537Asn and 
Asp538Gly cause resistance to antiestrogens by changing the LBD of the ER [17]. Some of these 
mutations also affected the activation status of signaling pathways, such as IGF-1 [119]. ER also 
seems to be important for tamoxifen resistance. Several studies showed that certain splice variants 
of ER expressions are correlated with worse outcomes in advanced breast tumors [123, 124]. 
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Some studies suggested that transcriptional repression due to long-term tamoxifen usage might 
cause overpopulation of ER-negative tumor cells in tumor environment.  
Metabolism of the tamoxifen in the tumor or inability of the body to produce functional 
metabolites are other mechanisms that were proposed for resistance to tamoxifen. In several 
studies about tamoxifen resistance reported that lower tamoxifen concentration inside of the tumor 
relative to plasma concentrations is correlated with worse outcome in breast tumors [124]. On the 
other hand, some studies suggested that increased concentration of certain tamoxifen metabolites 
can cause agonistic effects in the cancer cell [125].  
The third hypothesis for tamoxifen resistance is related to the alterations in co-regulatory 
proteins and signaling pathways. MAPK, hedgehog, PI3K/Akt and mTOR pathways have been 
implicated in tamoxifen resistance. [116, 126]. For instance, some studies reported that high HER-
2 levels in tamoxifen resistant tumors is associated with high expression of AIB1 (SRC-3) [127]. 
Moreover, high AIB1 expression is thought to be associated with a worse disease outcome in 
tamoxifen-treated patients because of HER-2-related agonistic effect on ER [128]. Other 
coactivators and corepressors, such as RIP140 [129], NCoR [130] and Nkx3-1 [131] were 
implicated in tamoxifen resistance since their levels correlated with tamoxifen resistance in tumor 
samples. In addition, some transcriptional factors (e.g. GATA3 and GREB1) were shown to play 
a role in regulation of ER-target genes leading to endocrine therapy resistance [132, 133]. Like 
various types of co-regulatory proteins, major signaling pathways also contribute to generate 
tamoxifen resistance. Several MAPKs (e.g. like ERK1, ERK2 and ERK3) and ribosomal S6 kinase 
(RSK) phosphorylate AF-1 domain of ERs and activates estrogen-dependent expression [134, 
135]. The activation of growth factor signaling elements contribute to tamoxifen resistance. For 
instance, the direct interaction between IGF-1 receptor and membrane ERs activates estrogen 
signaling leading to tamoxifen resistance [80]. Furthermore, the interaction between ER and 
HER2 cause phosphorylation of epidermal growth factor receptor (EGFR) [136]. Besides all these 
factors, E2-mediated cellular localization changes of critical signaling kinases were also found 
crucial in generation of tamoxifen resistance [57, 137, 138].  
As an important regulators of gene expression, the role of miRNAs in tamoxifen resistance 
has been studied for a while. Recent studies showed that certain miRNAs are regulated by 
tamoxifen treatment. In fact, some studies suggested that specific miRNA expression patterns (e.g. 
miR-375, miR-221/222, miR-200, miR-342, miR-519a, miR-22, miR-301, miR-15a/16) can be 
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used as tamoxifen-resistance markers [139-146]. All of these studies concluded that miRNAs may 
regulate the sensitivity of breast cancer cells to tamoxifen. 
 
2.5.4. ER (+) breast cancers and possible therapy alternatives 
Currently, there are several endocrine therapy approaches to treat ER (+) breast tumors 
such as steroidal and non-steroidal aromatase inhibitors (AI), SERMs (e.g. raloxifen) and selective 
estrogen receptor down-regulators (SERDs) (e.g. fulvestrant). First of all, AIs are used to block 
estrogen production especially in post-menopausal women. Aromatase enzymes catalyze estrogen 
biosynthesis from androgens in both ovaries and adrenal glands and AIs inhibit these enzymes by 
competing for the natural substrate binding sites. Clinical studies showed that it is an effective 
strategy specifically for treating post-menopausal women whose tumors are already resistant to 
tamoxifen [147]. SERMs are receptor antagonists which occupy estrogen receptors and inhibit 
endogenous estrogen production. SERMS such as tamoxifen and raloxifen are used to treat pre-
menopausal or post-menopausal patients, who have increased side-effects with AIs [148]. SERDs 
are also routinely used as endocrine therapy agents in clinic. Rather than endogenous estrogen 
inhibition, they block the effects of estrogen at the levels of the receptor by causing degradation 
of the receptor itself. Tamoxifen is a partial antagonist of ER_ in breast tissue and an agonist in 
endometrium. Unlike SERMs, SERDs like fulvestrant do not have this partial agonist activity in 
any other tissue [149, 150]. 
 
2.6. Concluding Remarks 
Studies investigating the details of ER signaling pathways are fundamental for developing 
new therapeutic strategies against endocrine resistant breast cancer. Despite several different ER 
targeting strategies developed in the last three decades, tamoxifen is still one of the best endocrine 
agents. It is still widely used in premenopausal women and postmenopausal women who 
experience major side effects with aromatase inhibitors. One-third of these patients will have a 
recurrence that will decrease survival of the patient. Many labs are still working to develop 
strategies to overcome tamoxifen resistance in breast cancer patients. The majority of these 
research efforts have focused on targeting signaling pathways, such as PI3K and mTOR. However, 
resistance develops in this setting, too and in this case the arising tumors are even harder to 




Figure 2.1. The basic estrogen signaling cascades of nuclear and extracellular initiated pathways. Estrogen receptor signaling works as other nuclear 
receptor signaling pathways. E2 binds to ER and then they form a homodimer structure. After that, this ligand-receptor complex can act in two ways. This 
system has genomic and non-genomic regulatory roles in the cells
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CHAPTER 3: LITERATURE REVIEW PART II: 




Estrogens and estrogen receptors regulate metabolism in both normal and diseased 
physiological states. Metabolic characteristics of intrinsic breast cancer subtypes change based on 
their estrogen receptor expression. The crosstalk between estrogen signaling elements and several 
key metabolic regulators alter metabolism in breast cancer cells, which enable tumors to rewire 
their metabolism to adapt to poor perfusion, transient nutrient deprivation and increased acidity. 
This leads to selection of drug-resistant and metastatic clones. In this review, we will discuss 
studies revealing the role of estrogen signaling elements in drug resistance development and 
metabolic adaptation during breast cancer progression. 
Key words: Breast cancer, cancer metabolism, drug resistance, estrogen signaling, metabolic 




 Different breast cancer subtypes have different metabolic phenotypes 
 Estrogen receptors modulate expression of genes important for metabolic regulation 
 Extra-nuclear estrogen receptors regulate kinase signaling pathways as well as mitochondrial 
metabolism to impact cancer cell metabolism 
 Metabolic rewiring is an inherent property of endocrine resistance albeit whether it is a driver 
or consequence of endocrine resistance is not clear 
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Estrogens and estrogen receptors (ERs) regulate metabolism in both normal and diseased 
physiological states. Despite lack of sexual reproduction, invertebrates possess ER-like proteins to 
regulate their metabolic processes, which shows the importance of ER signaling elements for non-
reproductive functions including metabolism [1]. Metabolic changes in postmenopausal women 
after estrogen loss suggests that estrogen signaling regulates energy metabolism [2]. Nutrient 
availability is one of the important parameters for cell cycle progression and proper energy 
metabolism. Thus, cells constantly check the amount of nutrients in their microenvironment. Since 
cancer cells proliferate in an uncontrolled way, they develop different strategies to keep their 
proliferation rate stable even in limited nutrient conditions. This concept is called metabolic 
plasticity. In 2011, Hanahan and Weinberg updated their milestone review to include metabolic 
plasticity as an emerging cancer hallmark called ‘deregulation of cellular energetics’ [3]. Tumors 
reprogram their metabolism to adapt to poor perfusion (lack of enough blood supply), leading to 
transient nutrient deprivation, and increased acidity. During adaptation to environmental stress, 
drug resistant and metastatic clones are selected for [4, 5].  Given the scope of this review, we will 
extensively focus on the impact of estrogen signaling elements on the metabolic alterations during 
breast cancer progression. We caution the readers that majority of studies reported here are fairly 
recent and still require rigorous validation, yet they contribute to a comprehensive framework that 
might explain some of the clinical observations regarding ER (+) tumors. 
 
3.2.1. Molecular Subtypes in Breast Cancer: Breast cancer classification and patient 
stratification is critical in terms of determining treatment strategy in clinic. Breast tumors are 
classified into two groups: In situ (20% of all cases) and invasive breast tumors (80% of all cases). 
Based on their location, in situ breast cancers are further classified into two groups: ductal 
carcinoma in situ (DCIS, about 80% of in situ breast cancers) and lobular carcinoma in situ (LCIS, 
about 20% of in situ breast cancers). About 20-50% of DCIS tumors can eventually turn to an 
invasive carcinoma [32]. Invasive breast cancers have the capacity to spread to other organs in the 
body. Estrogen Receptor (ER), Progesterone Receptor (PR) and Human epidermal growth factor 
receptor 2 (HER2) expression is used in the clinic to determine breast cancer subtype.  In addition, 
expression levels of Ki67 is also utilized to decide treatment options for patients. Based on 
expression of these biomarkers, invasive breast tumor are divided into four main molecular 
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subtypes of breast cancer: Luminal A, luminal B, HER2-enriched, and triple negative 
(TNBC)/basal-like [33, 34]. Luminal A subtype is hormone receptor positive (HR+), HER2 
negative (HER2 (-), and has low Ki-67 signature. It has relative better prognosis and can be 
managed by endocrine therapies. Luminal B subtype is also HR (+), but it can be either HER2 (+) 
or HER2 (-) with higher Ki-67 expression and relatively worse prognosis and less response to 
endocrine agents. The HER2-enriched subtype is HR (-) and HER2 (+), and has worse prognosis 
compared to luminal subtypes. It is treated with HER2 targeting agents in the clinic. TNBC/basal-
like subtype has no hormone receptor or HER2 expression, and it is more common in African-
American women and in the individuals with BRCA1 mutation [34]. Overall, this is the most 
aggressive subtype with limited targeted therapy options in the clinic. Clinical studies showed that 
more than 75% of all breast cancers express ER and/or PR, and approximately 10-15% of them 
also express HER2 [35].  
 
3.2.2. Metabolic Genes Mutated in Different Breast Cancer Subtypes: Mutation profiles of 
metabolic genes are different in different breast cancer subtypes. In general, TP53 and MYC 
mutations are most commonly found in HER2 (+) and basal-like/TNBC subtypes [10] [33], 
whereas, 40-50% of luminal-type tumors have mutations in PI3K/Akt/mTOR pathway elements 
(e.g., PIK3CA, PIK3R1, PTEN, AKT1) [34]. PI3KCA and MAP3K1 are the most frequently 
mutated genes in this subtype [35]. On the other hand, glycolytic enzymes (e.g. HK3, GPI, 
GAPDH, PGK1, ENO1), glycolysis regulator (PDK1) and pentose phosphate pathway enzymes 
(PGD, TKT, RPIA) are the main metabolic genes with mutations in ER (-) breast cancers [72]. 
Lipid metabolism related genes (e.g., CPT-1A and FASN ) are upregulated in HER2 (+) subtype, 
whereas IDH1 [73] and AKT3 mutations are the most common ones in basal like/TNBC [74] 
subtype. 
 
3.3. Metabolic Differences in Breast Cancer Subtypes 
There are four intrinsic molecular subtypes of breast cancer: luminal A, luminal B, HER2 
(+), and basal like/triple negative breast cancer (TNBC) [6]. Each tumor subtype has a distinct 
proliferation rate, metastatic capacity, and metabolic phenotype and genotype (Table 3.1). 
Transcriptomics combined with metabolomics analyses identified altered metabolite levels and 
associated metabolic-pathways in different subtypes. 
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3.3.1. Glucose-metabolizing pathways: In a recent study, tumor samples across 33 different 
cancer types were analyzed and categorized based on mRNA expressions of seven major metabolic 
pathways. Patients with tumors that have upregulated carbohydrate, nucleotide, and 
vitamin/cofactor metabolism had a worse prognosis, while the ones with upregulated lipid 
metabolism had a better prognosis [7]. Additional studies showed that ribulose 5-phosphate, 
fumarate, 2-HG, glutamate/glutamine ratio, serine metabolites, kynurenine, MAG, and most of the 
phospholipid and sphingolipids are more abundant in TNBC subtype compared to luminal subtype 
[8-10]. Consistent with these results, transporters involved in macronutrient uptake and metabolic 
enzymes, such as GLUT1, SLC1A5, SLC7A5, GLS1, and PGDH are upregulated in TNBC [11-
13]. Since preclinical studies suggests that TNBC relies more on the glucose metabolism, this also 
creates a metabolic vulnerability that can potentially be targeted by metformin [14, 15]. Similarly, 
pentose phosphate pathway intermediates, such as G6PDH and 6PGL, are also upregulated in 
HER2 (+) and TNBC subtypes compared to luminal ones [16, 17]. Metabolic differences are also 
present in a certain subtype. A recent study identified lower TCA cycle, oxidative phosphorylation 
in glycolysis pathways and activities in luminal A invasive lobular carcinoma subtype of tumors 
compared to luminal A invasive ductal carcinoma subtype of tumors [18].  
 
3.3.2. Amino Acid-metabolizing pathways: Amino acid metabolism is also different amongst 
different breast cancer subtypes. MYC amplification is the main regulator of glutamine-related 
metabolic rewiring. MYC facilitates excess glutamine uptake by inducing the expression of 
glutamine transporters and glutamine-metabolizing enzymes in breast cancers [19]. This molecular 
mechanism is upregulated in luminal B, TNBC and HER2 (+) subtypes compared to luminal A 
subtypes [20]. Interestingly, inhibition of ASCT2/SLC1A5-mediated transport with 
pharmacological inhibitors reduces glutamine uptake only in TNBCs and not in luminal subtypes 
[21]. 
MYC also upregulates serine, glycine, tryptophan uptake and synthesis of one-carbon 
units, resulting in a more active TCA cycle in HER2 (+) and TNBC breast cancer subtypes  [8, 
22]. Functional genomics studies revealed that serine synthesis pathway is essential in breast 
cancer cells, and enzymes responsible for serine and glycine biosynthesis, such as PGDH, PSP, 
and SHMT, are expressed in ER (-) breast cancers more than ER (+) ones [13, 23]. Cancarini et 
al. demonstrated the impact of one-carbon metabolism-associated vitamins in different breast 
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cancer subtypes. Overall, high vitamin B intake lowered breast cancer risk in all subtypes. Notably, 
folate has a protective effect against ER (+) PR (+) and HER2 (-) breast cancers whereas thiamine 
is protective against HER2 (+) breast cancers [24].  
 
3.3.3. Lipid-metabolizing Pathways: Due to high metabolic demand, lipid provision is essential 
for cancer cells. Since cell proliferation rate is directly related with intrinsic tumor biology and 
tumor microenvironment, genes associated with lipid metabolism are differentially expressed in 
different subtypes. Kim et al. showed that while HER2 (+) subtypes have the highest PLIN1, CPT-
A1, and FASN expression, TNBC subtype tumors have the lowest expression of these genes [25]. 
Similarly, ACLY, FASN, and SCD1 are overexpressed in HER2 (+) subtype, whereas TNBC 
subtypes express less ACLY, suggesting that de novo lipid synthesis is upregulated in HER2 (+) 
subtype [26]. However, there are contradictory studies suggesting FASN overexpression as a 
targetable therapy option for TNBCs as well [27].  
In addition to lipid metabolism-related enzymes, the levels of lipid metabolites also differ 
depending on the subtype. Several groups reported that inhibition of 27-hydroxycholesterol 
synthesis decreases proliferation in ER (+) breast cancers, but not in ER (-) cancers [28, 29]. 
Furthermore, several studies showed that various phospholipids and sphingolipids were 
upregulated in ER (-) subtypes relative to ER (+) ones, and higher phospholipid concentrations 
correlated with high tumor grade [30, 31]. Overall, these studies indicated that TNBC and HER2 
(+) subtypes adapt to a more active metabolic phenotype compared to luminal subtype to sustain 
high metabolic demands during rapid cell proliferation.  
 
3.4. The Crosstalk between Macronutrient Metabolism and Estrogen Signaling 
3.4.1. Regulation of Glucose metabolism: In cancer cells, upregulation of key glucose 
transporters and glycolytic enzymes support the synthesis of the building blocks required for cell 
proliferation, causing a metabolic shift towards glycolysis, which is known as the ‘Warburg Effect’ 
[36-38]. Hypoxia-dependent upregulation of ER signaling stimulates the expression of glucose 
transporters (GLUT-1, GLUT-2, and GLUT-5) in breast cancer cells [37]. MCF-7 cells switch 
their metabolic pathways in response to 17-estradiol (E2) and glucose availability. High glucose 
level in the media activates AKT signaling and suppresses TCA cycle. [39]. E2 treatment 
upregulates c-Myc-hnRNP axis and expression and activity of glycolytic enzymes, such as 
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PFKFB3, resulting in increased F26BP and glucose uptake [40] [41]. In breast cancer cells, E2 
regulates the balance between glycolysis and OXPHOS by upregulating PDH in the lack of glucose 
[39]. E2 also promotes addiction to PPP by upregulating G6PD enzyme, in breast cancer cells [42]. 
Lactate production is also upregulated by E2 in breast cancer cells [43]. HK and PFK expressions 
were also shown to be positively correlated with estrogen receptor expression in breast carcinomas, 
and inhibition of HK results in high toxicity in breast cancer cells [44-46]. In addition to two classic 
nuclear estrogen receptors, GPER-1 the membrane G-protein coupled ER, has been shown to 
control estrogen-mediated angiogenesis by upregulating PFKFB3 [47] (Figure 3.1).  
 
3.4.2. Regulation of amino acid metabolism: Glutamine is the most abundant amino acid in the 
serum and preferentially consumed by breast tumors in an ER-dependent manner [11, 48]. 
Although there is a limited amount of studies showing the crosstalk between estrogen signaling 
and amino acid metabolism, clinical studies showed that ER (+) tumors were glutamine-enriched 
and glutamate-reduced compared to ER (-) breast tumors [11, 12, 49]. Specifically, enzymes 
responsible for glutamine synthesis (GS, GDH) are upregulated in ER (+) breast cancer cells 
relative to ER (-) ones [50, 51]. Conversely, glutamine uptake and enzymes related with glutamine 
catabolism (GLS) were shown to be upregulated in ER (-) breast tumors [52]. Accordingly, 
glutaminase inhibitor treatment was reported to have a better antitumor effects on ER (-) breast 
cancer cells [53]. Besides glutamine, dietary arginine supplementation and upregulated ASL levels 
are associated with high cell proliferation rate in breast tumors, and inhibition of ASL activity was 
shown to inhibit ER (-) breast cancer growth [54]. Asparagine is directed to TCA cycle during 
adaptation to glutamine depletion in metastatic ER (-) murine breast cancer cells [55, 56]. Leucine 
deprivation inhibits cell proliferation and induces apoptosis in ER (+) breast cancers by decreasing 
FASN expression [57]. These results suggest that there is a complex crosstalk between estrogen 
signaling and amino acid synthesis pathways (Figure 3.1). 
 
3.4.3. Regulation of lipid metabolism: Clinical observations showed that higher levels of E2 
lead to decreased fat accumulation, whereas ovariectomy, anti-estrogen therapy or menopause has 
the inverse effect in females [58]. Both E2 treatment and ERα/ERβ overexpression suppress 
lipogenesis and triglyceride accumulation via competitive binding to PPAR in adipose tissue and 
various hormone-related cancers [59-61]. These effects are due to upregulation of leptin and 
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STAT-3 genes in the liver, and XBP in endocrine-related cancers [62-64]. Additionally, estradiol 
downregulates CD36, a transporter for free fatty acids, expression in breast cancer cells [65]. 
FASN and ACC-1 are overexpressed in breast cancer cells compared to normal cells, and their 
inhibition is proposed as a potential therapy in breast cancers [66, 67]. Also, inhibition of SCD-1 
was shown to inhibit breast tumor growth [68]. In addition to changes in lipid metabolism 
pathways, specific free fatty acids were shown to impact energy status and cell viability in breast 
cancer cells. Anacardic acid but not oleic acid or salicylic acid inhibited cell viability in ER(+) 
cells by reducing cellular respiration[69].  Lastly, biosynthesis of choline, which is a vitamin-like 
essential nutrient and an important element in the plasma membrane, was found to be regulated by 
ERα [70].  
The effect of estrogen signaling on lipid metabolism is not unidirectional. Inhibition of 
FASN suppresses E2-stimulated cell growth and survival in breast cancer cells via activation of 
apoptotic pathways and inactivation of oncogenic PI3K/Akt pathway [71]. Many groups showed 
that 27-hydroxycholesterol could act as a ligand for ER and promotes cell proliferation via ER 
signaling in breast cancers [28, 29]. In conclusion, there is a bidirectional signaling between 
estrogen signaling and lipid metabolism. More studies are required to elucidate the molecular 
mechanism behind this crosstalk (Figure 3.1).  
 
3.5. The Crosstalk between Metabolic Regulators and Estrogen Signaling   
Estrogen signaling globally affects organ systems and any dysregulation in estrogen 
signaling may cause major pathologic conditions. At molecular level, this global effect of estrogen 
signaling can be explained with its complex crosstalk with other major cellular pathways (Figure 
3.2). 
 
3.5.1. ER-HIF1α crosstalk: Hypoxia-inducible factor (HIF) is a central regulator of oxygen 
homeostasis in the cell. As the tumor grows, due to diffusion limit of oxygen, the tumor core 
becomes hypoxic. This lack of oxygen activates a transcriptional complex involving HIF-1, 
deregulating numerous genes that are crucial for metabolic adaptation, angiogenesis, and 
eventually metastasis [75]. High HIF-1 expression in tumors is associated with poor disease 
outcome and higher mortality in breast cancer patients [76]. Recently, HIF-1 was shown to be a 
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transcriptional target of ERα and high HIF-1α expression, conferring tamoxifen resistance in ERα 
(+) tumors [77]. In return, hypoxia response reduces ERα expression and cell proliferation [78]. 
Other studies showed that HIF-1α and ERα transcriptionally regulate a common group of genes 
[79]. In addition to ERα, GPER-1, which mediate the non-genomic effects of estrogens, promote 
HIF-dependent transcription and stimulate glycolysis in endocrine-regulated cells [79, 80]. This 
well-established cross-talk enables new therapeutic approaches to treat hypoxic ER (+) breast 
cancers [78, 81].  
 
3.5.2. ER-Ras/Raf/MAPK crosstalk: Ras/Raf/MAPK pathway is one of the most studied signal 
transduction pathway in the cell, which acts as a highway for the communication of intracellular 
and extracellular environment. The oncogenic role of Ras/Raf/MAPK pathway is very well studied 
in breast cancers, however, the role of ERα in this pathway is still elusive. Studies comparing the 
expression levels of the members of Ras/Raf/MAPK pathway in different breast cancer subtypes 
reported that patient samples with overexpression of Ras and MAPK proteins are more invasive 
and they have lower ERα expression [82]. Consistent with this data, most of the transgenic in vivo 
models overexpressing Ras develop ER (-) breast tumors. Ando et al. recently developed an in 
vivo breast cancer mouse model expressing a constitutively active Ki-Ras in the mammary tissues. 
This model developed ER (+) adenocarcinomas with luminal A subtype breast cancer 
characteristics [83]. FASN activation by mutant KRAS was shown in lung cancer, and similar 
effects of Ras/MAPK pathway activation in ER (+) breast cancer remains to be explored [84].  
 
3.5.3. ER-PI3K/Akt/mTOR crosstalk:  PI3K/Akt/mTOR pathway is the key regulator of all 
cellular characteristics which are essential for the vitality of a cell, such as proliferation, 
metabolism, motility, survival and apoptosis. Components of PI3K/AKT/mTOR pathway, 
including PIK3CA, PTEN, PIK3R1 and AKT1 are mutated in nearly 25% of breast tumors and 
are associated with drug responses in ER (+) and ER (-) tumors [85-87]. Estrogens stimulate this 
pathway to regulate migratory and invasive characteristics of ER (+) tumors [88, 89]. In return, 
mTOR signaling regulates the expression level and activity of ERα. Also, mTOR acts as a co-
regulator for ERα [90, 91]. In one mode of action, PI3K pathway regulates ER-dependent 
transcription in breast cancer cells through KMT2D epigenetic regulator, and its inhibition 
activated the methyltransferase activity of KMTD2, leading to the activation of ER [92]. PI3K 
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inhibition increases ER level and activity [86, 92], and PI3K inhibitor-endocrine agent 
combinations were tested with minor success in clinical trials to treat women with endocrine-
resistant disease (NCT01339442, NCT02273973) [93, 94]. There are ongoing clinical trials with 
next generation PI3K inhibitors (NCT01971515, NCT03056755, NCT02684032 and 
NCT02437318) in advanced hormone receptor positive breast cancers and most recently positive 
results were reported from these trials [95, 96].   
 
3.5.4. ER-p53 crosstalk: p53 is the most well-known tumor suppressor protein in the cell. This 
pathway responds to extracellular and intracellular stress conditions and controls cell cycle 
checkpoints. ERs and p53 directly regulate expression of each other. Further, E2-induced cell 
proliferation was shown to be regulated by p53 or via direct interaction between ERα homodimers 
and p53 hetero-complex [97, 98]. Recent studies showed that the ERα-p53-mediated 
transcriptional regulation was attenuated by ERβ due to a physical interaction between ERβ and 
p53 [99]. Somatic loss of ERβ accelerates the formation of p53-deficient mammary tumors, 
suggesting a protective role of ERβ against breast tumorigenesis [100].  
 
3.5.5. ER-c-MYC crosstalk: c-MYC is a pathway that regulates cell growth and proliferation. 
More recently, it was shown to orchestrate metabolic pathways, which supply nutrients and other 
required elements to activate DNA replication and cell division. c-MYC is a proto-oncogene and 
a direct target and co-regulator of ERα in breast cancer [101]. The upregulation of c-MYC and its 
downstream effectors are associated with poor disease outcome, high metastatic capacity, and 
endocrine resistance in breast tumors [102]. ERα and c-MYC act synergistically to induce cell 
proliferation [103, 104]. A recent study found that ER and HER2 (+) crosstalk regulates glutamine 
metabolism through c-MYC in AI-resistant cells [105].  
 
3.6. Metabolic Alterations in Endocrine-Resistant Breast Tumors  
SERMs, SERDs, and aromatase inhibitors are the first-in-line treatment strategy for ER (+) 
tumors [106]. However, one-third of all breast tumors eventually develop a resistance to these 
treatments. Drug-resistant and metastatic clones are selected as tumors reprogram their metabolism 
to adapt to poor perfusion, transient nutrient deprivation, and increased acidity. Identification of 
the crosstalk between estrogen receptor signaling and endocrine resistance-driven metabolic 
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alterations is critical to overcome resistance. Moreover, the distinct metabolic programs define 
metastatic organ sites in breast cancer cells, for example, activation of Akt and glycolytic pathways 
were seen in liver specific metastases emphasizing the importance of unique metabolic pathway 
adaptations in cancer cells [107]. 
Metabolic enzymes, which facilitate reactions in the committed steps of glycolysis, are 
misregulated and are potential targets in recurrent breast tumors. PFKFB3 is an activator of PFK1, 
which is the key regulator of the second committed step in glycolysis. Several groups showed that 
targeting PFKFB3 may be a potential strategy to overcome endocrine resistance [47, 108]. 
Inhibition of HK2, which facilitates the first committed step of glycolysis, is associated with 
retarded growth of tamoxifen-resistant breast tumors. Tamoxifen resistance is driven by HIF-1α 
hyperactivation via modulation of Akt/mTOR and/or AMPK signaling pathways [109]. Of note, a 
novel epigenetic modulator NSD2 gene is upregulated in tamoxifen-resistant cells, leading to 
methylation of promoters of key glucose metabolic enzymes such as HK2 and G6PDH as well as 
TIGAR [110]. These results reveal that endocrine resistance is promoted by multiple mechanisms 
inducing glycolytic flux in breast cancers.  
Mitochondrial respiration rates are higher in endocrine-resistant cells compared to parental 
controls. In tamoxifen-responsive cells, 4-hydroxy-tamoxifen (4-OHT) treatment reduces 
mitochondrial activity[111]. Elevated ERα expression increases NRF-1 and TFAM expressions, 
leading to increased OXPHOS activity in endocrine resistant tumors [112, 113]. In addition, 
tamoxifen-stimulated mitochondrial ER has an antagonist role in breast cancer cells by increasing 
ROS concentrations in the mitochondria [114]. Also, enhanced mitochondrial function and 
oxidative stress lead to tamoxifen resistance in MCF-7 breast cancer cells, and GCLC and NQO1 
were suggested as potential biomarkers to target mitochondrial activation in tamoxifen resistance 
[115]. A recent biomarker study proposed more than 60 genes, including mitochondrial ribosomal 
and mitochondrial complex proteins,  as novel mitochondrial biomarkers to predict early treatment 
failure and recurrence in patients who were treated with tamoxifen [116]. Horizontal transfer and 
packaging of mitochondrial DNA are significantly associated with therapy resistance 
development. Additionally, mitochondrial DNA acts as an oncogenic signal in cancer-stem cells 
by sustaining OXPHOS-dependent endocrine therapy resistance [117]. Loss of one of the key 
tumor suppressor genes, RB1, is associated with repressed mitochondrial protein translation and 
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OXPHOS, leading to highly aggressive metastatic breast cancers with high OXPHOS activity 
[118]. 
Tumor-associated cells in the tumor microenvironment and fuel sources used for 
mitochondrial respiration are crucial in endocrine resistance. Cancer-associated fibroblasts (CAFs) 
enable cancer cells to survive by providing lactate and ketone bodies to enhance their 
mitochondrial activity. Inhibition of mitochondrial activity with metformin and arsenic trioxide 
(ATO) overcomes fibroblast-induced tamoxifen resistance in ER (+) breast cancer cell lines [119]. 
Additionally, increased PI3K/Akt pathway activity in CAFs facilitate multidrug resistance in both 
ER (+) and ER (-) breast tumors by exporting GPERs outside of the nucleus with a nuclear exporter 
called CRM1 (XPO1). This mechanism was suggested to sustain excess pyruvate and lactate 
concentrations due to enhanced glycolysis and mitochondrial activity during endocrine resistance 
development [120]. Of note, AFs also drive trastuzumab resistance in HER2 (+) breast cancers 
through expanding NFKB, JAK/STAT, and PI3K/Akt pathways with increasing IL-6 expression 
[121]. 
Drug-resistant breast cancer cells have a distinct amino acid signature compared to non-
resistant ones. The ratio between glutamine and glutamate levels is used as a biomarker for tumor 
aggressiveness and endocrine resistance in breast cancer cells [12, 105]. Aromatase inhibitor 
resistant breast cancer cell lines upregulate transporters involved in glutamine uptake [12, 105]. 
Also, tamoxifen-resistant cell lines are more sensitive to cysteine levels compared to tamoxifen-
sensitive ones [122]. Doxycycline-resistant MCF-7 breast cancer cells have higher levels of 
cysteine/methionine-regulating enzymes (such as CBS, MTHFR, and BHMT) than doxycycline-
sensitive ones. These studies highlight the success of the combination treatment strategies 
involving hormonal/targeted therapy agents with the enzymes targeting amino acid biosynthesis 
pathways. 
Lipid metabolism is also altered during the development of drug resistance. Inhibition of 
ACC-1 via leptin and TGFβ signaling causes elevation of acetyl-CoA, leading to recurrence and 
metastasis in breast cancer cells [123]. Furthermore, recent metabolic-profiling data from several 
breast cancer studies revealed that nucleic acid and cholesterol synthesis pathways are activated 
during tamoxifen resistance in breast cancer cells. Consistent with this data, combining 
cholesterol-lowering medicines with endocrine treatment was shown to improve metabolic 
outcomes in endocrine-resistant breast cancer cells [124]. Also, neutral lipids, lipid droplets, and 
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free cholesterol get accumulated in tamoxifen-resistant breast cancer cells compared to non-
resistant ones [125]. In addition, differences in lipid metabolic pathways provide novel 
vulnerabilities in ER (+) tumors that might be targeted with already existing inhibitors [126].  
 
3.7. Measurement of Metabolomics in Liquid Biopsies  
Emerging field of liquid biopsies to diagnose patients, follow-up treatment responses and 
monitor recurrence is gaining popularity in the clinic. The main idea of the liquid biopsy is to 
collect blood, saliva or urine samples from the patients to detect circulating tumor cells (CTCs) 
and/or other circulating factors (e.g. metabolites, DNA or RNA). Following collection of the 
samples, metabolites in these samples can be analyzed with a wide-array of techniques such as, 
sequencing, nuclear magnetic resonance (NMR) or liquid-or-gas chromatography (LC-GC). This 
approach can be used for early detection and genotyping of cancer cells [127], monitoring the 
metabolic effects of a treatment strategy, predicting drug response or resistance [128], metastatic 
capacity [129], or detecting certain targetable mutations for therapy selection in breast cancers. 
For example, comparison of plasma samples from breast cancer patients and healthy individuals 
showed that high levels of cortisol, glutamine, L-Arginine, linoleic acid, L-Lysine, L-valine, uric 
acid, tyrosine and phenylalanine were associated with breast cancer [130] [131]  
High levels of histidine, acetoacetate, glycerol, pyruvate, glycoproteins, mannose, 
glutamate and phenylalanine were reported to be associated with metastatic phenotype in breast 
cancers [129]. Recently, several clinical trials used identification of PI3KCA mutations in 
circulating tumor material to predict outcomes of inhibitor treatments targeting PI3K pathway 
[132].  
 
3.8. Concluding Remarks and Future Perspectives  
Estrogen signaling has a significant impact on how breast cancer cells rewire their 
metabolic pathways to meet their high energy demand during proliferation. These alterations can 
be seen in all aspects of macronutrients’ metabolism, including pathways associated with glucose, 
glutamine, and fatty acid metabolism. Early differences in metabolic phenotypes might inform 
clinicians about recurrence and have potential to be used as biomarkers in the clinic to aid in the 
therapy decisions of breast cancer. Liquid biopsy for circulating markers of metabolic phenotype 
of tumors offer early detection, monitoring and prediction of therapy responses in clinic. 
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Understanding how ERs regulate these pathways is crucial as this new knowledge will reveal new 
vulnerabilities to overcome drug resistance in different breast cancer subtypes. Specifically, the 
crosstalk between estrogen signaling elements and key metabolic regulators should be elucidated 
with more studies to better target ER (+) breast cancers by combining endocrine therapy options 



























3.9. Table and Figures 
 
Table 3.1: Molecular Differences in Different Breast Cancer Subtypes 
 





G6PDH and 6PGL are upregulated in 
HER2 (+) subtypes compared to 
luminal ones [16, 17]. 
 
Ribulose 5-phosphate, fumarate, 2-HG, 
glutamate/glutamine ratio, serine metabolites, 
kynurenine, and MAG are more abundant in 
TNBC subtype compared to luminal subtype [7]. 
 
GLUT1, SLC1A5, SLC7A5, GLS1 and PGDH 
are upregulated in TNBC [11-13]. 
 
G6PDH and 6PGL are upregulated in TNBC 







MYC is overexpressed in luminal B, 
compared to luminal A [19]. 
 
MYC is overexpressed in HER2 (+) 
compared to luminal A [19]. 
 
MYC-related serine, glycine, 
tryptophan uptake and synthesis of 
one-carbon units result in a more 
active TCA cycle in HER2 (+) [8, 21]. 
MYC is overexpressed in luminal B, HER2 (+), 
and TNBC compared to luminal A [19]. 
 
Inhibition of ASCT2/SLC1A5-mediated 
glutamine uptake is more effective in TNBCs 
than in luminal subtypes [20]. 
 
MYC-related serine, glycine, tryptophan uptake 
and synthesis of one-carbon units result in a 
more active TCA cycle in TNBC [8, 21]. 
 
Enzymes, responsible for serine-glycine 
biosynthesis, such as PGDH, PSP and SHMT 
are expressed more in ER- subtypes compared to 






decreases proliferation in ER (+) 
cancers, not in ER (-) cancers [27, 
28] *. 
Inhibition of 27-hydroxycholesterol 
synthesis decreases proliferation in 
ER (+) cancers, not in ER (-) 
cancers [27, 28] *. 
PLIN1, CPT-A1, ACLY, SCD1 and 
FASN expressions are the highest in 
HER2 (+) subtype [24, 25]. 
 
Phospholipid and sphingolipid levels 
are high in ER (-) breast cancers [7, 29, 
30] *. 
 
PLIN1, CPT-A1, ACLY and FASN expressions 
are the lowest in TNBC subtype [24, 25]. 
 
Phospholipid and sphingolipid levels are high in 
ER (-) breast cancers [7, 29, 30] *. 
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High vitamin B levels lowered risk 
of breast cancers in all subtypes 
[23]. 
 
Folate has a protective effect 
against ER (+) PR (+) HER2 (-) 
subtypes [23] *. 
 
High vitamin B levels lowered risk 
of breast cancers in all subtypes 
[23]. 
 
Folate has a protective effect against 
ER (+) PR (+) HER2 (-) subtypes 
[23] *. 
 
High vitamin B levels lowered risk of 
breast cancers in all subtypes [23]. 
 
Thiamine is protective against HER2 
(+) subtypes [23]. 
High vitamin B levels lowered risk of breast 




PIK3CA,  PIK3R1, PTEN, AKT1, 
MAP3K1 [34, 35] 
PIK3CA,  PIK3R1, PTEN, AKT1, 
MAP3K1 [34, 35] 
TP53, MYC [10, 33] 
HK3,GPI, GAPDH, PGK1, ENO1, 
PDK1, PGD, TKT, RPIA [72] 
CPT-A1, FASN [26] 
TP53, MYC [10, 33] 
HK3,GPI, GAPDH, PGK1, ENO1, PDK1, PGD, 
TKT, RPIA [72] 
IDH1, AKT3 [73, 74] 
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Figure 3.1: Metabolic enzymes, metabolites and macronutrient transporters regulated by estrogen signaling. The enzymes and macronutrient transporters, 
which are upregulated by estrogen signaling and high metabolite levels are shown with red characters. The enzymes and macronutrient transporters, which are 
downregulated by estrogen signaling macronutrient transporters and low metabolite levels are shown with blue characters. *High levels and expressions of 
metabolic enzymes, metabolites and macronutrient transporters in breast cancers. ACC: Acetyl-CoA carboxylase, ACS: Acetyl-CoA synthases, ACLY: ATP citrate 
lyase, ATP S.: ATP synthase, ASL: Argininosuccinate lyase, CD-36: Cluster of differentiation 36, CSAD: Cysteine sulfinic acid decarboxylase, CDO: Cysteine 
dioxygenase, FASN: Fatty acid synthase, FFA: Free fatty acid, G: Glucose, GL: Glutamine, GAPDH: Glyceraldehyde-3-phosphate dehydrogenase, G6P isomerase: 
Glucose-6-phosphate isomerase, G6PD: Glucose-6-phosphate dehydrogenase, GLUTs: Glucose transporters, GSL-1: Glutaminase-1, GS: Glutamine synthase, HK: 
Hexokinase, HMG-CoA: 3-Hydroxy-3-methylglutaryl-CoA, HMG-CoAR: 3-Hydroxy-3-methylglutaryl-CoA reductase, LDHA: Lactate dehydrogenase-A, LD: 
Lipid droplet, MAG: Monoacylglycerol, MAGL: Monoacylglycerol lipase, OAA: Oxaloacetate, PDH: Pyruvate dehydrogenase, PFKs: Phosphofructokinase, 
PFKBPs: Phosphofructokinase fructose biphosphatases, PGAM: Phosphoglycerate mutase, PGDH: Phosphoglycerate dehydrogenase, PKM2: Pyruvate kinase 




Figure 3.2:  Abnormal estrogen signaling stimulates cell proliferation and growth in the mammary tissue. This situation triggers various stress stimuli in a solid 
tumor, such as poor perfusion, transient nutrient deprivation and increased acidity. All these external factors activate different stress-associated pathways in the 
cell and eventually promotes cell proliferation and creates hypoxia in the core of the tumor. In addition, ER-dependent regulator mechanisms is not unidirectional. 
These pathways also regulate genomic, extra-nuclear and post-translational regulation of ERα, and upregulates several downstream targets to promote pathways 
associated with various hallmarks of cancer such as angiogenesis, metabolic deregulation, drug resistance and angiogenesis.
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CHAPTER 4: HYPOTHESIS AND OBJECTIVE 
 
4.1. Long-term goal 
The long-term goal of this research is to develop effective treatment strategies to overcome 
endocrine resistance in ER (+) breast cancer.  
 
4.2. Overall objective of the project  
The overall objective of this project is to define the interaction among endocrine resistance, 
nuclear export system, and cellular metabolic pathways, and to evaluate the metabolic impact of 
combinational ER and XPO1 targeting by using combination of endocrine therapy agents and a 
XPO1-specific small molecule inhibitor (Selinexor-SEL) in different endocrine resistant ER (+) 
breast cancer cell lines.  
 
4.3. Central hypothesis 
Our central hypothesis is that combined targeting of ER and XPO1 remodel metabolic 
pathways to induce cell death and overcome tamoxifen resistance 
 
4.4. Specific aims 
The central hypothesis of this work was evaluated with fourteen specific aims under three 
main parts. In the first part, we focused on the characterization of XPO1 protein in tamoxifen 
resistance. In the second part, we tried to elucidate the mechanism behind combined targeting of 
ER and XPO1 at a molecular level. We investigated which intracellular pathways are affected in 
tamoxifen resistant breast cancer cells from this combined treatment. In the third part, we expanded 
our focus area and assessed the effect of XPO1 targeting in metastatic breast cancer cells in 
combination with other endocrine therapy agents. To do this, we used 3D cell culture models to 
mimic actual metastatic breast tumor microenvironment. Also, we investigated the molecular 






PART I: To identify the role of nuclear export mechanism in tamoxifen resistance.                           
• Aim1-1: Investigate the link between XPO1 expression and cell proliferation rate in 
tamoxifen-resistant breast cancer cells. 
• Aim1-2: Identify the role of XPO1 on subcellular localization of ERK5 during tamoxifen 
resistance development. 
• Aim1-3: Determine the effect of individual and combinational ER and XPO1 targeting 
on the subcellular localization of ERK5 protein in tamoxifen-resistant breast cancer cells 
 
PART II: To understand how nuclear export system contribute to tamoxifen resistance 
development by testing with a novel combinational targeting strategy using 4-OHT and SEL 
in Luminal B type breast cancer cell lines, and to investigate the metabolic outcomes of this 
novel therapy. 
• Aim-2-1: Identify how XPO1 is associated with poor disease outcome in ER+ breast cancer 
cells. Compare XPO1 expression in different breast cancer subtypes.  
• Aim-2-2: Identify the effect of ER and XPO1 targeting on gene expression profiles and 
the general kinase pathways in tamoxifen-resistant breast cancer cells.  
• Aim-2-3: Identify the effect of ER and XPO1 targeting specifically on different 
phosphorylation sites of Akt protein. 
• Aim-2-4: Identify the effect of ER and XPO1 targeting on general metabolic phenotypes 
and glycolytic and mitochondrial metabolic pathways in tamoxifen-resistant breast cancer 
cells. 
• Aim-2-5: Investigate which death pathways are activated via ER and XPO1 targeting. 
 
Part III: To assess the impact of other endocrine therapy options alone or in combination 
with Selinexor on metabolism in different endocrine resistant breast cancer cell lines and 
possible metastatic organ sites. 
• Aim-3-1: Determine cell viability of different endocrine resistant breast cancer models 
under treatment of different endocrine therapy agents alone or in combination. 
• Aim-3-2: Determine metabolic cell phenotypes of different endocrine resistant breast 
cancer models. 
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• Aim-3-3: Determine oncosphere formation profile/capacity of endocrine resistant breast 
cancer cell lines in 3D metastatic organ models. 
• Aim-3-4: Investigate how cellular metabolic phenotype of endocrine resistant breast cancer 
cells change in different metastatic organ sites. 
• Aim-3-5: Investigate why Selinexor alone is not successful. 
• Aim-3-6: Investigate the mechanism behind the success of combined ERα-XPO1 targeting 




CHAPTER 5: EXPERIMENTAL PART I: 
ERα-XPO1 CROSSTALK CONTROLS TAMOXIFEN SENSITIVITY IN TUMORS BY 
ALTERING ERK5 CELLULAR LOCALIZATION 
 
5.1. Abstract 
Most breast cancer deaths occur in women with recurrent, estrogen receptor (ER)-α(+), 
metastatic tumors. There is a critical need for therapeutic approaches that include novel, targetable 
mechanism-based strategies by which ERα (+) tumors can be resensitized to endocrine therapies. 
The objective of this study was to validate a group of nuclear transport genes as potential 
biomarkers to predict the risk of endocrine therapy failure and to evaluate the inhibition of XPO1, 
one of these genes as a novel means to enhance the effectiveness of endocrine therapies. Using 
advanced statistical methods, we found that expression levels of several of nuclear transport genes 
including XPO1 were associated with poor survival and predicted recurrence of tamoxifen-treated 
breast tumors in human breast cancer gene expression data sets. In mechanistic studies we showed 
that the expression of XPO1 determined the cellular localization of the key signaling proteins and 
the response to tamoxifen. We demonstrated that combined targeting of XPO1 and ERα in several 
tamoxifen-resistant cell lines and tumor xenografts with the XPO1 inhibitor, Selinexor, and 
tamoxifen restored tamoxifen sensitivity and prevented recurrence in vivo. The nuclear transport 
pathways have not previously been implicated in the development of endocrine resistance, and 
given the need for better strategies for selecting patients to receive endocrine modulatory reagents 
and improving therapy response of relapsed ERα(+) tumors, our findings show great promise for 
uncovering the role these pathways play in reducing cancer recurrences. 
 
Key words: Endocrine resistance, Breast cancer, Glutamine deprivation, Combined drug 
targeting 
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The nuclear hormone estrogen receptor (ER)α is present in approximately 75% of human 
breast cancers and is considered one of the most critical predictive factor of breast cancer prognosis 
[1]. ERα is targeted by endocrine therapies, which are generally well tolerated [1]. Tamoxifen is 
one of the most effective therapeutics when a patient is diagnosed with ER-positive (ERα [+]) 
breast cancer. Although several recent trials showed that a combination of aromatase inhibitors 
(AIs) and ovarian suppression was effective in premenopausal breast cancer treatment, AIs also 
have significant adverse side effects in some postmenopausal women, such as increased joint pain, 
bone fractures, and cardiovascular disease risk [1–3] and the American Society for Clinical 
Oncology still recommends the use of tamoxifen for premenopausal women [3]. Therefore, 
tamoxifen remains an important endocrine therapy agent in both pre- and postmenopausal women 
and is expected to continue to be widely used for some time. 
The benefit of endocrine therapies is limited, as demonstrated by tumor recurrence in 30% 
of ERα (+) patients. The recurrence of cancer in ERα-negative (ERα [−]) patients is higher in the 
first 5 years after the diagnosis, yet for ERα (+) patients, there is a consistent long-term risk of 
death due to recurrent breast cancer and even a greater risk after 7 years [3]. In fact, most breast 
cancer deaths occur in women with recurrent ERα (+) metastatic tumors [5, 6]. Recurrence appears 
to result from the up-regulation of cytoplasmic-initiated/ERα-dependent kinase pathways that 
provide an alternative mechanism to support tumor cell proliferation and survival and renders 
tumor cells resistant to endocrine therapies [7–11]. Hormonal regulation of breast cancer involves 
crucial inputs from estrogens, acting through ERs, and growth factors, operating through growth 
factor receptors that regulate downstream protein kinase pathways. The relative regulatory inputs 
to/from these two pathways are thought to underlie the degree to which the cancers remain more 
indolent and responsive to endocrine therapies vs the acquisition of resistance to these therapies. 
In the latter situation, the up-regulation of protein kinases serves as a hallmark of endocrine-
resistant breast cancer [12,–15]. Also, whereas the presence of ERα is usually associated with a 
more favorable prognosis [16,–18], it is increasingly appreciated that not all ERα (+) breast cancer 
patients have a good outcome. A significant subset of patients with ERα (+) breast cancers, 
specifically those patients characterized as having a luminal B molecular subtype, also have high 
levels of protein kinase activity, do not respond to tamoxifen as efficiently, and have much less 
favorable disease-free survival, despite often being treated with additional chemotherapy [19,–22]. 
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ERK5, a member of the MAPK family, is present in most human breast tumors and is 
overexpressed in approximately 20% of these tumors [23]. It was also recently identified in a 
kinase screening study as a major factor that regulates circulating tumor cell invasiveness [24]. We 
have recently identified ERα as the key factor responsible for the activation and regulation of the 
subcellular localization of ERK5 [25]. In this previous work, we showed that its nuclear 
localization is abrogated by treatment with ERK5 or ERα inhibitors. Based on this information, 
we used a combinatorial approach in which we took advantage of our tamoxifen-sensitive and 
tamoxifen-resistant cell culture models, an animal model and data from patient samples to 
delineate the role of nuclear transport pathways, particularly exportin 1 (XPO1), in tamoxifen 
sensitivity and endocrine therapy resistance. We identified high levels of XPO1, the major nuclear 
exporter of the tumor suppressor proteins, as a biomarker for tamoxifen resistance and evaluated 
its inhibition as a novel means to enhance the effectiveness of endocrine therapies. Our findings 
suggest that a higher expression of selected nuclear export pathway proteins results in decreased 
residence times of important nuclear factors that might be involved in proper transcriptional 
responses to tamoxifen treatment, thus conferring resistance to tamoxifen. Enhanced export to the 
cytoplasm results in key proteins communicating with other components of the cancer cell 
machinery involved in cell motility and enhanced kinase signaling, which function to increase 
aggressiveness of these cells. Our results show that inhibition of nuclear export machinery would 
improve therapy responsiveness and delay the development of hormone targeted treatment 
resistance and recurrence. 
5.3. Materials and Methods 
5.3.1. Cell culture, adenovirus, small interfering RNA, and ligand treatments 
MCF-7 cells were grown in MEM with non-essential amino acids (NEAA) salts (Sigma), 
supplemented with 10% calf serum (HyClone) and 100 μg/mL penicillin/streptomycin 
(Invitrogen) [26]. T47D cells were grown in DMEM with 10% calf serum (HyClone) and 100 
μg/mL penicillin/streptomycin (Invitrogen). BT474 was cultured in American Type Culture 
Collection-recommended Hybri-care medium with 10% inactivated fetal bovine serum (FBS), 
sodium bicarbonate, and antibiotics. MDA-MB-468 and MDA-MB-134 cells were grown in 
Leibovitz's medium with 20% calf serum (HyClone) and 100 μg/mL penicillin/streptomycin 
(Invitrogen). HCC1500 cells were cultured in American Type Culture Collection-formulated 
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RPMI 1640 media with 10% FBS, sodium bicarbonate, and antibiotics. All cell lines were obtained 
from American Type Culture Collection. For experiments with 4-OHT treatment, the cells were 
maintained in the corresponding phenol red-free medium for at least 3 days and were then seeded 
at a density of 3 × 105 cells per 10-cm tissue culture dish (Corning) for 2 days before adenovirus 
infection. Recombinant adenoviruses were obtained from Applied Biological Materials Inc and 
were used to generate the MCF-7 cells expressing dominant-negative ERK5 or the overexpression 
XPO1 (AdXPO1) as described previously [25]. Adenovirus with a cytomegalovirus construct was 
used as an infection control (AdCMV). 
5.3.2. Immunofluorescence microscopy and data analysis 
MCF-7, MCF-7 TAM R, and BT474 cells were treated with Veh (0.1% EtOH) or 1 μM 4-
OHT in the presence or absence of 100 nM SEL for the indicated times. Cells were then washed 
in PBS and fixed on glass coverslips in 4% paraformaldehyde for 30 minutes and washed two 
times for 5 minutes in PBS. After incubation in acetone for 5 minutes, another PBS wash was 
performed and then cells were incubated with antibodies against XPO1 (Santa Cruz 
Biotechnology; 1:500), ERα (Santa Cru Biotechnology; 1:1000), ERK5 (Bethyl; 1:2000), or 
phospho-ERK5 (Upstate, Millipore; 1:500). The next day, the cells were incubated with goat anti-
mouse Alexa 568 or goat antirabbit Alexa 488 secondary antibodies. These slides were mounted 
and stained using Prolong Gold antifade with DAPI (Molecular Probes) to identify the nuclei. 
BT474 xenograft samples were paraffin embedded and sectioned (4–5 μm). After 
rehydration, antigen retrieval, and blocking, the slides were incubated with XPO1 antibody (Santa 
Cruz Biotechnology; 1:100). The next day, the slides were incubated with goat antimouse Alexa 
568 secondary antibody. These slides were mounted, and stained using Prolong Gold antifade with 
4,6-diamidino-2-phenylindole (DAPI) (Molecular Probes) to identify the nuclei. 
Samples were imaged using a 63×/1.4 oil DIC M27 objective in a Zeiss LSM 700 or 710 laser-
scanning confocal microscope (Carl Zeiss). The images were obtained in a sequential manner 
using a 488-Ar (10 mW) laser line for phosphorylated ERK5 (pERK5) signal (500–550 nm 
emission) and 555 nm (10 mW) laser line for ERα (600–650 nm emission). The individual 
channels were obtained using a sequential scanning mode to prevent bleed-through of the 
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excitation signal. Laser power, gain, and offset were kept constant across the samples and scanned 
in a high resolution format of 512 × 512 or 1024 × 1024 pixels with two/four frame averaging. 
Further quantification of the images was performed in Fiji software 
(http://fiji.sc/wiki/index.php/Fiji). Briefly, images were converted to eight bits for segmentation 
for each channel. Images for all channels were background subtracted using a rolling-ball method, 
with a pixel size of 100. Images were segmented using the DAPI channel. The DAPI images were 
contrast enhanced using the Otsu algorithm. To split touching nuclei and produce the final nuclear 
masks, the watershed algorithm was used. The resulting objects that had an area of less than 20 
pixels and were close to edges were considered noise and were discarded. The DAPI image was 
selected as the mask, and the signal from pERK5 and/or ERK5 signal was quantified in the nucleus. 
Three frames per treatment were quantified. Experiments were repeated two times. 
5.3.3. Cell Proliferation, cell cycle progression, invasion, motility, and soft agar assays 
For proliferation assays, cells were seeded on 96-well plates at a confluency 2000 cells/well 
(except MDA-MB-134: 5000 cells/well and HCC-1500: 7000 cells/well) in no-phenol red media 
with 5% charcoal-dextran (CD) FBS. Cells were treated on day 2 and day 5 with indicated 
concentrations of (Z)-4-hydroxytamoxifen (Sigma-Aldrich; number H7904) and/or SXR 
(Selleckchem; number S7252). On day 7 a water-soluble tetrazolium-1 (WST-1) assay (Roche) 
was used to quantify the cell proliferation ratio. Absorbance was measured at 450 nm using the 
BioTek Cytation5 plate reader. 
5.3.4. Western blot analysis in cell lines 
On day 1 the cells were seeded on 10-cm plates at a concentration of 100 000 per plate in 
no-phenol red media with 5% CD FBS. The media were changed on day 3. On day 6 whole-cell 
lysates were collected in radioimmunoprecipitation assay buffer (Thermo Scientific) with 1× 
Complete protease inhibitor (Roche). Samples were sonicated and boiled in sodium dodecyl sulfate 
loading buffer and then resolved on precast gels (Bio-Rad Laboratories) and transferred to a 
nitrocellulose membrane. Membrane was blocked in Odyssey blocking buffer (LI-COR). The 
following antibodies were used: pERK5 Thr218/Tyr 220 (number 3371; Cell Signaling), Lamin 
B1 (ab16048; Abcam), NUP153 (A301–789A), KPNA3 (A301–626A), NUP205 (A303–935A), 
RANGAP1 (A302–026A), KPNA2 (A300–483A), XPO1 (A300–469A), ERK5 (A302–656A), all 
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from Bethyl Laboratories, and ERK2 antibody (D-2 sc-1647; Santa Cruz Biotechnology) were 
used in 1:1000 dilution. β-Actin (Sigma; SAB1305546) was used in 1:10 000 dilution. The 
secondary antibodies were obtained from Odyssey and were used at a working concentration of 
1:10 000. The images of the membranes are obtained by a LI-COR Odyssey CLx infrared imaging 
device and software. To compare the levels of nuclear receptor signature genes in different cell 
lines, we normalized the signal from the signature protein to the β-actin signal. The average values 
and SEM from three experiments were reported. 
For the preparation of nuclear/cytoplasmic fractions, cells were seeded at 2 × 106 cells per 
10-cm dishes. The media were changed at day 2. At day 4, the cells were treated with Veh (0.1% 
EtOH) or 1 μM 4-OHT for 45 minutes. Whole-cell samples were suspended in cytosolic extraction 
buffer (10 mM HEPES, pH 7.9; 10 mM KCl; 0.1 mM EDTA; 0.1% Nonidet P-40; and 
protease/phosphatase inhibitors), and they were centrifuged at 12700 rpm for 10 minutes at 4°C. 
Cytosolic fractions were transferred into a fresh tube and kept on ice. The pellets were washed 
with cytosolic extraction buffer without Nonidet P-40 and phosphatase/protease inhibitors three 
times and dissolved in lysis buffer (0.5 M EDTA; 1 M Tris HCl; pH 8; 10% sodium dodecyl 
sulfate; 10% Empigen; and phosphatase/protease inhibitors). After a 10-minute incubation on ice, 
the nuclear fractions were sonicated once at 20% amplitude for 5 seconds and centrifuged at 12700 
rpm for 10 minutes. Supernatants (nuclear fractions) were transferred into fresh tubes. 
5.4. Results 
5.4.1. ERK5 nuclear localization is reduced during the course of tamoxifen resistance 
To characterize the state of the cellular localization of active ERK5 upon 4-OH-Tam 
treatment, we monitored the localization of ERK5 and pERK5 in a cell culture model of breast 
cancer endocrine resistance. We grew the initially tamoxifen-responsive MCF-7 cells in 
continuous 4-OHT treatment for 100 weeks. We and others have earlier demonstrated that this 
model mimics the development of endocrine resistance and for the characterization of molecular 
changes associated with the tamoxifen-resistant phenotype [26]. When we monitored the 
localization of ERK5 in cells that were in 4-OHT for 10, 50, and 100 weeks, we found that ERK5 
and pERK5 localization to the nucleus was lost progressively compared with parental MCF-7 cells. 
(Figure 5.1.A). This was consistent with an increased cytosolic localization of pERK5 as the 
resistance progressed (Figure 5.1.B).  
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5.4.2. XPO1 overexpression in MCF-7 and BT474 cell increase ERK5 activation 
Overexpression of XPO1 using an adenovirus system resulted in at least a 2-fold increase 
in the level of XPO1 mRNA and protein in MCF7 and BT474 cells increased active ERK5 levels 
in both of the cell lines (Figure 5.2.A). Moreover, XPO1 overexpression increased the proliferation 
of both cell lines, which was blocked by the XPO1 inhibitor (Figure 5.2.B). 
 
5.4.3. 4-OHT treatment increases nuclear pERK5 in MCF-7 cells, but cytoplasmic pERK5 
in BT474 cells. 
To test whether the 4-OHT-mediated localization of pERK5 was different in tamoxifen-
resistant and -sensitive cell lines, we treated MCF-7 cells and BT474 cells with Veh or 4-OHT for 
45 minutes and then isolated cytoplasmic or nuclear fractions. Western blot analysis of each 
fraction revealed that 4-OHT treatment resulted in an increase in nuclear pERK5 in MCF-7 cells, 
whereas active ERK5 was in cytoplasm in BT474 cells after 4-OHT treatment (Figure 5.3.A). To 
test whether this localization disparity in two cell lines was due to XPO1 activity, we treated 
BT474 cells with Veh or 4-OHT in the presence or absence of SEL for 45 minutes and then 
subjected cells to immunofluorescence analysis. This experiment showed that in the presence of 
4-OH-TAM, active ERK5 was completely extranuclear and treatment of the cells with the SXR 
relocated ERK5 back into the nucleus (Figure 5.3.B). 
 
5.5. Discussion 
In our studies, we found that as ERα (+) breast tumors acquire resistance to tamoxifen, a 
group of nuclear transport proteins including XPO1 will be upregulated, increasing ERK5 export 
from the nucleus. Thus, ERα, which is in the nucleus, will not have the partners to elicit proper 
transcriptional responses to tamoxifen and ERK5, which partners with other cytoplasmic proteins, 
will now contribute to tumorigenicity and tamoxifen resistance (Figure 5.4). The development of 
tamoxifen resistance is a major limitation to the effectiveness of treatment of hormone-responsive 
breast cancer. Whereas ERα presence is usually associated with a more favorable prognosis, it is 
increasingly appreciated that not all ERα (+) breast cancer patients have a good outcome. A 
significant subset of patients with ERα (+) breast cancers, such as those patients characterized as 
luminal B cancers that contain ER but also have high levels of protein kinase activity, have a much 
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less favorable disease-free survival. Blocking the activity of ER using selective ER modulators 
such as tamoxifen or raloxifene, or the ER-degrading agents fulvestrant or AIs, which reduce 
estrogen production, has proven highly effective in targeted treatment of hormone-responsive 
breast cancers [1, 27, 28].  
Our approach was built upon our initial findings that estrogens increase the nuclear 
localization of key signaling molecules like ERK5, and the absence of ERα renders ERK5 
extranuclear [25]. When outside the nucleus, ERK5 enhances the actin cytoskeleton reorganization 
and thus contributes to cell aggressiveness and motility, which are characteristics of breast cancers 
that are resistant to endocrine therapies. This study validated the hypothesis that nuclear export 
proteins level could be used as a marker for the risk of recurrence. Establishing XPO1 as a target 
for inhibition would enhance the effectiveness of endocrine therapies by maintaining tamoxifen 
sensitivity. Targeting the localization of key signaling molecules to cellular localizations in which 
they can be more efficiently used by ERα to increase efficiency of tamoxifen or other endocrine 
agents has a promise of higher efficacy and lower toxicity. 
Cancer cells of different tumor types have been shown to be more sensitive to XPO1 
inhibition than normal cells, including myeloma, in which ratjadone, another XPO1 inhibitor, is 
shown to be selective and kill myeloma but not normal cells [29, 30]. The inhibition of XPO1 in 
cervical cancer using another small molecule inhibitor, LMB, demonstrated the higher sensitivity 
of XPO1 inhibition in the cancer vs the normal cells [31]. XPO1 inhibitors might resensitize 
tamoxifen-responsive tumors to tamoxifen by modulating localization of these other factors as 
well. This could have a broad translational importance in the prevention and treatment of late-stage 
cancers. For example, in cancers in which ERK5 is localized to the cytoplasm, cellular 
aggressiveness can be downregulated by the pharmacological inhibition of XPO1, which results 
in a decreased nuclear export, thus allowing the return of ERK5 into the nucleus, in which it 
contributes to transcription and effective tamoxifen responsiveness. Thus, important advances in 
the therapy of late-stage disease and avoidance of complications associated with broad kinase 
inhibitors could ultimately be expected. Furthermore, our findings might be applicable to other 
cancers, including therapy-resistant leukemia, prostate cancers, and triple-negative breast cancer, 
for which highly selective XPO1 inhibitors are already in clinical trials [31, 32, 33].  
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Our research represents a new and substantive departure from the status quo by shifting the 
focus to modulating the localization of key proteins rather than modulating their actual activity. 
Most current research efforts in the therapy resistance field have focused on a delineation of the 
underlying mechanisms that lead to increased activity of selective signaling pathways. 
Undoubtedly, interrogating and targeting the end-point kinases in tumors is highly relevant, and 
these studies led to the development of combination therapies involving phosphatidylinositol 3-
kinase inhibitors or mammalian target of rapamycin pathway inhibitors together with endocrine 
agents. However, resistance to these combination therapies also occurs, and in such cases, the 
cancer that develops is considerably more aggressive due to hyperactivation of compensatory 
mitogenic signaling pathways [34]. Moreover, these kinase inhibitors have many adverse side 
effects. More recently, ERα mutations that decrease the sensitivity of the receptor to selective ER 
modulators and selective estrogen receptor degradors were identified in more than 30% of the 
metastatic, but not primary, tumors [35,–39]. However, in two-thirds of ER-positive metastatic 
tumors, the mechanism of therapy resistance is not attributable to ER mutation, and alterations 
often cannot be targeted effectively. 
Our findings strongly suggest that this approach will be effective in allowing the 
relocalization of key proteins, such as ERK5, to the nucleus to improve transcriptional response to 
tamoxifen that would otherwise function to regulate invasiveness and aggressiveness in the 
cytoplasm. In summary, our study reported here is the first attempt in the field to define the causal 
role of the nuclear export pathways in tamoxifen resistance and explore the feasibility of targeting 













Figure 5.1: ERK5 nuclear localization is lost in MCF-7 cells that are tamoxifen resistant. A) ERK5 (upper panel) 
and pERK5 (lower panel) immunostaining after 45 minutes of 4-OH-TAM treatment in tamoxifen-sensitive MCF-7 
cells and tamoxifen-resistant MCF-7 TAM R cells that were kept in 4-OH-TAM for the indicated times. MCF-7 cells 
or MCF-7 TAM R cells at different stages of resistance progression were treated with 1 μM 4-OH-TAM for 45 
minutes, and immunofluorescence microscopy was performed with an antibody specific to ERK5 or pERK5. Nuclei 
were stained with DAPI. Three fields per slide were quantified (n = 3). A one-way ANOVA model was fitted to assess 
the contribution of tamoxifen resistance progression on 4-OH-TAM treatment-induced ERK5 or pERK5 nuclear 
localization. When the main effects were statistically significant at α = .05, pairwise t tests with a Newman-Keuls 
correction were used to identify the time that ERK5 or pERK5 localization was significantly different from parental 
MCF-7 cells. *, P < .05; **, P < .01; ***, P < .001; ****, P < .0001. B) Nuclear localization of pERK5 decreases as 
tamoxifen resistance progresses. MCF-7 parental cells or MCF-7 TAM R cells that were kept in media containing 4-
OH-TAM for 50 or 100 weeks were fractionated, and whole-cell lysate and cytosolic or nuclear fractions were 
subjected to Western blot analysis using pERK5, Lamin1b (as nuclear fraction marker), and β-actin (as cytosolic 
fraction marker) antibodies. C, ERK5 activity regulated migratory potential in MCF-7 TAM R cells. MCF-7 TAM R 
cells were infected with AdCMV or dominant-negative AdERK5 for 24 hours and then seeded on the upper chamber 






Figure 5.2: XPO1 levels increase cell proliferation of tamoxifen-resistant cell lines in the presence of 4-OHT. 
A) XPO1 overexpression in MCF-7 and BT474 cell increase ERK5 activation. MCF7- cells (left panel) or BT474 
cells (right panel) were infected with AdCMV as control or AdXPO1. XPO1mRNA overexpression was detected by 
qPCR. XPO1 protein overexpression was assessed by Western blot of immunofluorescence analysis. A t test was 
applied to assess whether AdXPO1 virus infection resulted in statistically significant overexpression of XPO1 in each 
cell line. *, P < .05 B) XPO1 overexpression in MCF-7 and BT474 cells increase cell proliferation. MCF-7 cells (left 
panel) and BT474 cells (right panel) were infected with AdCMV as control or AdXPO1, and then cells were treated 









Figure 5.3: Impact of XPO1 activity on subcellular localization of pERK5. A) 4-OHT treatment increases nuclear 
pERK5 in MCF-7 cells but cytoplasmic pERK5 in BT474 cells. MCF7- cells and BT474 cells were treated with Veh 
(0.1% EtOH) or 1 μM 4-OH-TAM for 45 minutes. Nuclear and cytoplasmic fractions were prepared as described. The 
increase in pERK5 levels in nuclear or cytoplasmic fractions were assessed by Western blot analysis. The experiment 
was repeated three times and representative results are displayed. B) XPO1 inhibition relocalizes pERK5 into the 
nucleus in the presence of 4-OHT in BT474 cells. BT474 cells were treated with Veh (0.1% EtOH) or 1 μM 4-OHT 
in the presence or absence of 100 nM SEL for 45 minutes. Localization of pERK5 was monitored using 
















Figure 5.4: Model. As ERα (+) breast tumors acquire resistance to tamoxifen, a group of nuclear transport proteins 
including XPO1 will be upregulated, increasing ERK5 export from nucleus. Thus, 1) ERα, which is in the nucleus, 
will not have the partners to elicit proper transcriptional responses to tamoxifen and 2) ERK5, which partners with 
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CHAPTER 6: EXPERIMENTAL PART II: 
COMBINED TARGETING OF ESTROGEN RECEPTOR ALPHA AND XPO1 
PREVENT AKT ACTIVATION, REMODEL METABOLIC PATHWAYS AND INDUCE 
AUTOPHAGY TO OVERCOME TAMOXIFEN RESISTANCE 
 
6.1. Abstract 
A majority of breast cancer specific deaths in women with ERα (+) tumors occur due to 
metastases that are resistant to endocrine therapy. There is a critical need for novel therapeutic 
approaches to resensitize recurrent ERα (+) tumors to endocrine therapies. The objective of this 
study was to elucidate mechanisms of improved effectiveness of combined targeting of ERα and 
the nuclear transport protein XPO1 in overcoming endocrine resistance. Selinexor (SEL), an XPO1 
antagonist, has been evaluated in multiple late stage clinical trials in patients with relapsed and /or 
refractory hematological and solid tumor malignancies. Our transcriptomics analysis showed that 
4-Hydroxytamoxifen (4-OHT), SEL alone or their combination induced differential Akt signaling- 
and metabolism-associated gene expression profiles. Western blot analysis in endocrine resistant 
cell lines and xenograft models validated differential Akt phosphorylation. Using the Seahorse 
metabolic profiler, we showed that ER-XPO1 targeting changed the metabolic phenotype of 
TAM-resistant breast cancer cells from an energetic to a quiescent profile. This finding 
demonstrated that combined targeting of XPO1 and ERα rewired the metabolic pathways and shut 
down both glycolytic and mitochondrial pathways that would eventually lead to autophagy.  
Remodeling metabolic pathways to regenerate new vulnerabilities in endocrine resistant breast 
tumors is novel, and given the need for better strategies to improve therapy response in relapsed 
ERα (+) tumors, our findings show great promise for uncovering the role that ERα-XPO1 crosstalk 
plays in reducing cancer recurrences. 
Keywords: Breast Cancer; Endocrine resistance; Nuclear Transport Pathways; XPO1; ERα; 
Metabolic rewiring 
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The nuclear hormone receptor estrogen receptor alpha (ERα) is present in approximately 
70% of both early and late stage human breast cancers [1, 2]. ERα is targeted by endocrine 
therapies that are well tolerated and provide long-term disease-free survival if patients have 
localized disease [1]. Unfortunately, 30% of patients with ER positive (ER (+)) disease experience 
recurrence and metastasis, and there is a consistent long-term risk of death due to recurrent breast 
cancer with an even greater risk after 7 years [3, 4, 5, 6, 7]. Moreover, the 5-year relative survival 
of patients with ER(+) metastatic disease is 24%- almost none are cured and each year more 
women with recurrent ER (+) metastatic tumors die compared to women with ER (-) tumors [2, 8, 
9].  
Endocrine therapy is regarded as an effective treatment option for ER (+) metastatic cancer. 
Unfortunately, endocrine-resistance develops during the course of initial and subsequent endocrine 
treatment in almost all patients and occurs through various mechanisms including the mutational 
alterations in the ESR1 gene sequence, dysregulation in signaling pathways (i.e. Her2 signaling) 
and changes in drug uptake and metabolism [10]. Endocrine-resistant patients require increasingly 
toxic therapies. These are not optimal in terms of pharmacological properties due to poor tolerance 
and side-effects that decrease the quality of the patient’s life. Thus, endocrine resistance remains 
a significant clinical problem. A novel therapeutic approach to resensitize ER (+) metastatic 
tumors to endocrine therapies together with methods to select patients likely to benefit from this 
approach is needed. Without new strategies, many patients with ER (+) tumors will continue to 
face diminished prospects for long-term survival being prescribed regimens that decrease their 
quality of life without receiving clinical benefit. 
Tamoxifen (TAM) remains the “first-in-line” endocrine therapy and is regarded as one of 
the most effective treatments for patients diagnosed with ER (+) breast cancer. While several 
recent trials showed that aromatase inhibitors (AIs) in combination with ovarian suppression were 
effective in premenopausal breast cancer treatment, the American Society for Clinical Oncology 
(ASCO) continues to recommend TAM for premenopausal women [5]. This may be attributed to 
the observation that AIs may also have significant adverse side effects in some postmenopausal 
women, such as increased joint pain, bone fractures, and risk of cardiovascular disease [1, 5, 11]. 
Therefore, TAM remains as an important endocrine therapeutic agent in both pre- and post-
menopausal women and is expected to continue to be widely used for some time.  
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In our previously published study which sought to understand the mechanism of TAM 
resistance in a preclinical setting, we identified a group of nuclear transport proteins, including 
exportin 1 (XPO1), which were upregulated in TAM-resistant cell lines and tumors [12]. 
Importantly, XPO1 upregulation caused nuclear export of ERK5, which is necessary in the nucleus 
for proper transcriptional response of ERα to TAM. Moreover, when ERK5 translocates to the 
cytoplasm, it can partner with other cytoplasmic proteins, including actin reorganization proteins, 
which contribute to cancer cell motility. However, it is not known whether XPO1 activates other 
mechanisms that may be targeted by therapies in current use, specifically for endocrine therapy 
resistant and ER (+) breast cancers.  
Based on previous studies [12, 13, 14], we hypothesized that ERα and XPO1 work together 
to drive TAM-resistance, and that combined targeting would more effectively sustain tumor 
regression than targeting either protein alone. Specifically, we showed that XPO1 mRNA levels 
were higher in Luminal B subtype of tumors which are more refractory to endocrine treatments, 
and that high XPO1 expression values were associated with a poor outcome in all women who 
were treated with TAM [12]. Therefore, XPO1 could be an excellent therapeutic target in breast 
cancer as XPO1 is already targeted in other therapy-resistant cancers with the highly specific small 
molecule inhibitor SEL, which is an orally active and well-tolerated drug [15, 16]. Our rationale 
is that targeting XPO1 together with ERα is clinically relevant and combining TAM with SEL 
potentially offers higher efficacy, specificity, and lower toxicity for the treatment of endocrine 
resistant, recurrent ER (+) breast cancer.  
To evaluate the effects of combining TAM (4-OHT) with SEL, in the present study we 
used transcriptome analysis and found that the combination differentially modulated Akt 
signaling-associated gene expression as well as glycolytic and mitochondrial gene expression 
programs. Because of differential changes in Akt phosphorylation with 4-OHT and/or SEL, we 
hypothesized that metabolic pathways associated with Akt activity and consequently the metabolic 
profile of breast cancer cells would change in the presence of 4-OHT and SEL.  We demonstrated 
that combined targeting of XPO1 and ERα in TAM-resistant cell lines shuts down metabolic 
pathways that would eventually lead to autophagy. Our studies provide a novel mechanism of 
action of combined targeting of ERα and XPO1 to overcome TAM resistance in recurrent ERα (+) 
breast cancer.  
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6.3. Materials and Methods 
6.3.1. Cell Culture and Ligand Treatments 
All cell lines were obtained from American Type Culture Collection. MCF-7 cells were 
cultured in Improved Minimal Essential Medium (MEM) with NEAA salts (Sigma, St Louis, MO), 
supplemented with 10% fetal bovine serum (FBS) (HyClone, Logan, UT), 100 g/ml 
penicillin/streptomycin (Invitrogen, Carlsbad, CA) and 1500 mg/L sodium bicarbonate (Gibco, 
MA). Acquired resistance was studied from resistance progression cell lines previously derived 
and characterized by long-term exposure of parental MCF-7 cells to 4-OH-Tam (MCF-7 TamR) 
[17, 18]. These cells retain ERα expression, do not require E2 for growth, are not growth inhibited 
by SERMs and 4-OH-Tam stimulates their growth.[17, 18]. Human breast cancer cell lines BT474, 
HCC-1500 and MDA-MB-134, which are 4-OH-Tam-resistant, were used as a model of de novo 
resistance [18, 19, 20]. BT474 were cultured in ATCC recommended Hybri-care medium with 
10% inactivated FBS, sodium bicarbonate and antibiotics. MDA-MB-134 cells were cultured in 
Leibovitz’s medium with 20% FBS (HyClone), and 100 g/ml penicillin/streptomycin (Invitrogen). 
HCC 1500 cells were cultured in ATCC-formulated RPMI1640 media with 10% FBS, sodium 
bicarbonate and antibiotics. Before ligand treatments, cells were grown in the corresponding 
phenol red-free media at least for three days.  
For isobologram analysis, BT474 and MCF-7 TamR cells were seeded at a density of 2x103 
cells/well in a 96-well plate, and were grown overnight in IMEM media without phenol red. On 
day 1, cells were treated with different doses of 4-OHT (from 10-9 M to 10-5 M) (Sigma) and SEL 
(from 10-9 M to 10-5 M) (Selleckchem) alone and in combination. Treatment was repeated again 
on day 4. On day 7, WST1 assay (Roche) was used to quantify cell proliferation ratio. Absorbance 
was measured at 450 nm using BioTek, Cytation5 plate reader. IC50 and isobologram calculations 
were made based on literature [*] by using Microsoft® Office Excel and statistical analyses were 
done by using Graphpad® Prism8 software. All experiment conditions had six technical repeats 
and experiments were repeated at least for three times. 
6.3.2. RNA Sequencing Analysis 
RNASeq analysis was performed as previously described [21, 22, 23]. Briefly, BT474 cells 
were treated with Vehicle (Veh, 0.5% EtOH), 10-6 M 4-OHT (Sigma, St. Louis, MO), 10-7 M 
Selinexor (SEL) (Selleckchem, Houston, TX) or 4-OHT+SEL combination for 24 hours. 
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Concentrations of ligands are based on our previously published study [18] and clinical data [24, 
25, 26]. Total RNA was extracted with TRIzol reagent (Life Technologies) according to 
manufacturer protocol and cleaned using QIAGEN clean-up kit. RNA quality was assessed using 
bioanalyzer. Total RNA from each sample (3 per treatment group) were sequenced at the UIUC 
sequencing center, and data was generated in Fastqc file format to compare the expressions 
between the four treatment groups. 
Preprocessing and Quality Control: Fastqc files containing raw RNA sequencing data were 
trimmed using Trimmomatic (version 0.36) [27]. Next, the reads were mapped to the Homo 
sapiens reference genome (GRCh37) from Ensembl [28] database and aligned using the STAR 
alignment tool (Version 2.5.3) [29]. After this, the read counts were generated from SUBREAD 
(Version 1.5.2) [30] and featured counts were exported for statistical analysis in R. Quality control 
and normalization was conducted in R using edgeR (Version 3.20.9) [31].  
Statistical Analysis and DEGs: Statistical analysis was conducted in R using limma (Version 
3.34.9) [32, 33]. Empirical Bayesian statistics were conducted on the fitted model of the contrast 
matrix. Differentially expressed genes were then determined by fold-change and p-value with 
Benjamini and Hochberg [34] multiple test correction for each gene, for each treatment relative to 
the vehicle control. We considered genes with fold-change >1.5 and p-value < 0.05 as statistically 
significant, differentially expressed. Cluster3 software was used for clustering the differentially 
expressed genes. Data was visualized using Treeview Java. PCA analysis was performed using 
StrandNGS (Version 3.1.1). GSEA [35, 36] analysis was used to identify GO terms associated 
with different treatments.  
6.3.3. In vivo xenograft study, immunohistochemistry staining (IHC) and data analysis 
All experiments involving animals were conducted with protocols approved by the 
University of Illinois at Urbana-Champaign and by the National Institutes of Health standards for 
use and care of animals (IACUC Protocol 14193). Tumor xenograft studies were performed using 
the BT474 cell line in immunocompromised female mice as previously described [12, 37, 38]. 
Briefly, 6-week-old BALB/c athymic, ovariectomized, nude female mice from Taconic 
Biosciences were used. After one week of acclimatization, 0.72 mg, 60-day release E2 pellets from 
Innovative Research of America were implanted subcutaneously to maintain a uniform level of 
estrogen. The next day 2.5 × 107 BT474 cells resuspended in 50% PBS and 50% Matrigel were 
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injected subcutaneously into both right and left flank of each mouse. Once the tumor size reached 
200 mm3, five animals were randomized to each treatment group. Half of the mice were implanted 
with vehicle pellets and the other half were implanted with 25 mg, 60-day release TAM pellets 
from Innovative Research of America. Each group was randomized to Vehicle or SEL injection 
(20 mg/kg). Concentration was selected based on clinically relevant dose [24, 25, 26]. Biweekly 
injections were performed (Monday and Friday) for 4 weeks. Each mouse was housed individually. 
Animals were monitored daily by the veterinarians for any signs of starvation, dehydration, stress, 
and pain. Total weight, food intake, and tumor size was monitored using a digital caliper biweekly. 
Tumors were removed from euthanized mice at the end of the experiment or at the time when 
tumor size reached 1000 mm3 and were fixed in 10% neutral-buffered formalin, processed, and 
embedded in paraffin in 2M sucrose before being frozen in cutting medium. Tissues were cut in 5 
microns by using a microtome (The Leica RM1255, Austria). For both pAkt S473 and pAkt T308 
immunostainings, tissues were deparaffinized and hydrated through graded alcohols to water. 
Antigen retrieval was performed by using citrate buffer, pH 6.0 in a streamer for 1 hour. Samples 
were blocked in hydrogen peroxide for 10 minutes. To remove non-specific protein staining, 
samples were blocked with Background buster (Innovex Biosciences, Richmond, CA) for 10 
minutes and rinsed with TBS-Tween solution, pH 7.6. Then, samples were incubated with pAkt 
S473 primary antibody (#4060, Cell signaling) overnight at 4° C and with pAkt T308 primary 
antibody (#13038, Cell Signaling) for 1 hour at room temperature at 1:100 dilution. After rinsing 
with TBS-Tween solution, pH 7.6., samples were stained with secondary anti-rabbit and anti-
mouse HRP-Polymer (Biocare Medical, Concord, CA) for 30 minutes. Finally, samples were 
incubated with DAB (Innovex, Richmond, CA) for 5 minutes and counterstained with 
hematoxylin, dehydrated and mounted on slides. Results are from at least four tumors per 
treatment. Visualization of the samples were performed with Nanozoomer Slide Scanner 
(Hamamatsu, Japan) at 80X magnification and positive staining quantification was performed by 
NDP.view software. Five fields per tumor were imaged and quantified. Representative images are 
presented.  
For the verification of XPO-1 protein levels in patient tumor samples, BRC1021 tissue 
microarray from Pantomics, Inc containing 95 cases with known ER, PR, AR, Her2, p53, EGFR, 
and Ki67 IHC results was used. Subtype of tumors were based on following criteria: Lum A: ER 
(+), Her2 (-), Ki67<15; Lum B: ER (+), Her2 (+) or ER (+), Her2 (-), Ki67>15; Her2 (+): ER (-), 
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Her2 (+); TNBC: ER (-), PR (-), Her2 (-)[39; 40]. XPO1 antibody was from Bethyl laboratories 
(A300-469A). BRC1021 TMA included 43 Her2 3 LumA 31 Lum B 17 TNBC tumor samples. 
UTSW cohort included 50 Luminal A, 45 Luminal B, 48 TNBC and 35 Her2 positive/amplified 
breast tumors validated by a pathologist. The samples were collected under the STU 102010-051 
IRB protocol number and were collected at UTSW and affiliated hospitals.For each core, a score 
for XPO1 was assigned based on the signal intensity (0=none, 1=low, 2=moderate, and 3=high).   
6.3.4. Western Blot Analysis in Cell Lines 
Cells were seeded on 30 mm cell culture plates at 1x105cells/well concentration in 
corresponding treatment media without phenol red which contains 5% FBS Cells were treated with 
4-OHT (10-6M) (Sigma) and SEL (10-7M) (Selleckchem)-containing treatment media overnight. 
Next day, cells were collected in Lysis buffer (0.5 M EDTA, 1 M TrisHCl pH 8.1, 10% SDS, 10% 
Empigen, ddH2O) with 1x Complete Protease Inhibitor (Roche) and 1x Phosphatase Inhibitor 
(Thermo Scientific). Samples were further processed with sonication and protein concentrations 
were determined by BCA assay (Thermo Scientific). Then, samples were boiled in SDS-containing 
loading buffer and were run in 10% precast gels (BioRad) and transferred to nitrocellulose 
membrane. The membrane was blocked in Blocking Buffer (Odyssey®, Li-Cor) and target 
proteins were probed with XPO1 (sc-74454, Santa Cruz Biotechnology), p-Akt S473 (#4060, Cell 
Signaling), pAkt T308 (#13038, Cell Signaling), Akt (#9272, Cell Signaling), PARP (#9542, Cell 
Signaling), ATG9A (STJ98598, St. John’s Laboratory), AMBRA-1 (STJ98593, St. John’s 
Laboratory) and Beclin-1 (STJ 98594, St. John’s Laboratory), antibodies in 1:1000 dilution and -
actin (Sigma SAB1305546) antibody in 1:10000 dilution. The secondary antibodies were obtained 
from Odyssey were used at 1:10000 dilution. The membranes were visualized by using Licor 
Odyssey CLx infrared imaging device and software. All results were repeated at least three times 
and the results were normalized according to signal, which was received from -actin loading 
control. Represantative blots are presented.  
6.3.5. Seahorse Metabolic Profiling Assays 
MCF-7, MCF-7 TamR and BT474 cells were seeded at a density of 5x104 and MDA-MB-
134 and HCC 1500 cells were seeded at a density of 1x105 in corresponding treatment media 
without phenol red  in each well of the XFp Cell Culture miniplates, respectively (Seahorse 
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Bioscience Inc., Billerica, MA). The FCCP concentration was 0.5 M for MCF-7, BT474, MDA-
MB-134 and HCC 1500 cells. Next day, cells were treated with 4-OHT (10-6M) (Sigma) and/or 
SEL (10-7M) (Selleckchem) -containing treatment media overnight and the cartridges were 
hydrated with the calibration solution and kept in a non-CO2 incubator at 37C overnight. In 
parallel, a duplicate of each plate was used for cell counting to monitor cell number changes after 
24 hours of treatments and Seahorse data was normalized to total cell number. On the assay day, 
cells were washed with XF Base Media without phenol red (Seahorse Bioscience Inc.) 
supplemented with 10 mM L-glucose, 2mM L-glutamine (Gibco) and 1 mM sodium pyruvate 
(Gibco). The ECAR (mpH/min) and OCR (pmol/min) values were obtained by using Seahorse 
XFp Cell Energy Phenotype Test Kit (Seahorse Bioscience Inc.), Seahorse XFp Mito Stress Test 
Kit (Seahorse Bioscience Inc.), Seahorse XFp Glycolytic Stress Kit (Seahorse Bioscience Inc.), 
and Seahorse XFp Mito Fuel Flex Test Kit (Seahorse Bioscience Inc.), which were run with 
Seahorse XFp Analyzer (Seahorse Bioscience Inc.). Experiments were performed in triplicate and 
repeated at least three times.  
6.3.6. Caspase Colorimetric Protease Assay 
MCF-7 and BT474 cells were seeded at a density of 2x103 cells to a 96-well plate and in 
the next day, they were treated with 4-OHT (10-6 M) (Sigma) and SEL (10-7 M) (Selleckchem) 
alone and in combination for 24 hours. The colorimetric caspase activities of Caspase 2, Caspase 
3, Caspase 6, Caspase 8 and Caspase 9 were determined according to the manufacturer 
recommendations by using ApoTarget Caspase Colorimetric Protease Assay Sampler Kit 
(Invitrogen). Changes in colorimetric density were detected by Cytation™ 5 Cell Imaging Multi-
Mode Plate Reader (Biotek Instruments, Inc.) at 400 nm wavelength. Experiments were performed 
in duplicates and repeated three times. 
6.3.7. Autophagy Assay  
MCF-7 and BT474 cells were seeded at a density of 2x103 cells to 96-well plate and in the 
next day, they were treated with 4-OHT (10-6 M) (Sigma) and SEL (10-7 M) (Selleckchem) alone 
and in combination for either 24 or 48 hours. Autophagosome formation was detected through 
GFP-labelled LC3-II protein in live cells using the Cyto-ID Autophagy Detection Kit (Enzo Life 
Sciences, Farmingdale, NY) according to manufacturer recommendations by Cytation™5 Cell 
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Imaging Multi-Mode Plate Reader (Biotek Instruments Inc., VT) at ~480 nm excitation and ~530 
nm emission. In addition, Hoechst 33342 Nuclear Stain was also recorded by means of DAPI filter 
set at ~340 nm excitation and ~480 nm emission. For flow cytometry analysis, BT474 cells were 
seeded at a density of 1x106 cells/plate, and they were grown for 48 hours in IMEM media without 
phenol red. Next day, cells were treated with 4-OHT (10-6 M) (Sigma) and SEL (10-7 M) 
(Selleckchem) alone and in combination for 24 hours. Negative control plates were treated with 
EtOH and positive control plates were also treated with Rapamycin (5x10-6 M) (CytoID) for 24 
hours. Following the treatment process, cells were collected and centrifuged at 1000 rpm for 5 
minutes in 1x Assay buffer provided in the CytoID® Autophagy Detection Kit (Enzo Biosciences 
Inc, Ann Arbor, MI). Cells were resuspended again and incubated with CYTO-ID® Green 
Detection Reagent for 30 minutes at dark. After this incubation time, cells were washed with 1x 
Assay buffer 3 times and results were analyzed with results were analyzed by BD™ LSR II Flow 
cytometry analyzer (BD Biosciences Inc., San Jose, CA). Following analysis, results were 
analyzed by FCS Express 6 Flow Cytometry Software (DeNovo Software) 
(https://www.denovosoftware.com/site/Flow-RUO-Overview.shtml) and all experiments were 
repeated with 3 technical replicates at least three times. Experiments were performed in duplicates 
and repeated three times.  
For the inhibition of autophagy BT474 cells were seeded in 96-well plates at a confluency 
of 2000 cells/well in corresponding treatment media. At day 2, they were treated in a media with 
with 10-6 M 4-OHT and 10-7 M SEL alone or combined in the presence or absence of 10-5 
Chloroquione (Sigma). This treatment was repeated at day 5. Cellular viability was measured with 
WST1 reagent (Roche) at 450 nm wavelength and results were quantified by using Cytation5 cell 
imaging Multi-Mode reader (Biotek Instruments Inc., VT). Statistical analyses were done by using 
GraphPad Prism8© software. 
6.3.8. Cell Cycle Analysis 
Flow cytometry analysis was performed as previously described [12, 41, 42]. Briefly, 
MCF-7 and BT474 cells were seeded at a density of 1x106 cells/ plate and their media was changed 
two times in every two days. Following an overnight treatment with 4-OHT (10-6 M) (Sigma) and 
SEL (10-7 M) (Selleckchem) alone and in combination, cells were collected with 0.1% FBS 
containing 1x PBS, washed, resuspended at 1-2x106 cells/ml and fixed with ice cold ethanol for 24 
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hours. In the next day, cells were washed with 1x PBS and incubated in 10ng/ml RNAase for one 
hour at room temperature. Cells were stained with 0.25% Propidium Iodide (#10008351, Cayman 
Chemicals, Ann Arbor, MI) for one hour and results were analyzed by BD™ LSR II Flow 
cytometry analyzer (BD Biosciences Inc., San Jose, CA). Following analysis, results were 
analyzed by FCS Express 6 Flow Cytometry Software (DeNovo Software) 
(https://www.denovosoftware.com/site/Flow-RUO-Overview.shtml) and all experiments were 
repeated three times. 
6.3.9. Statistical Analyses  
Data from all studies were analyzed using a one-way analysis of variance (ANOVA) model 
to compare different ligand effects, a two-way-ANOVA model to compare time-dependent 
changes. All data was tested for normal distribution using pairwise t tests with a Bonferroni 
correction. All data was normally distributed unless otherwise noted. Normally distributed data 
was analyzed using pairwise t tests with a Bonferroni correction to identify treatments that were 
significantly different from each other (*p < 0.05, **p < 0.01, ***p <0.001, ****p <0.0001). For 
every main effect that was statistically significant at α=0.05, pairwise t-tests were conducted to 
determine which ligand treatment levels were significantly different from each other. For these t-
tests, the Bonferroni correction was employed to control experiment wise type I error rate at α=0.05 
followed by Bonferroni post hoc test. Data that were not normally distributed were analyzed using 
Mann Whitney test for nonparametric data (*p < 0.05, **p < 0.01, ***p <0.001, ****p <0.0001). 
Statistical significance was calculated using GraphPad Prism for Windows (GraphPad Software, 
La Jolla California USA, www.graphpad.com).  
6.3.10. Availability of Data and Materials: 
Gene expression data is submitted to GEO database under the accession number 







6.4. Results  
6.4.1. 4-OHT+SEL treatment synergistically sustains tumor regression in endocrine 
resistant Luminal B subtype breast cancer cells 
Our previous study showed that XPO1 mRNA was overexpressed in the Luminal B subtype 
of tumors, which are more likely to recur on endocrine treatments relative to the Luminal A 
subtype [12]. To validate our results, we performed IHC analysis for XPO1 protein expression in 
two independent breast tumor sets with samples from various breast cancer subtypes. This analysis 
showed that Luminal B subtype tumors have higher overall XPO1 signal intensity and % XPO1 
positive cells in two independent cohorts of breast tumors (Figure 6.1.A and 6.1.B). We then 
treated endocrine resistant BT474 cells with 4-OHT, SEL or both in combination to assess whether 
these treatments synergized to reduce cell viability. The isobologram analysis showed that the 4-
OHT and SEL combination synergized to achieve a greater decrease in cell viability than with 
either agent alone (Figure 6.1.D). These results are consistent with our BT474 xenograft studies in 
nude mice, which showed that the tamoxifen (TAM) and SEL combination provided complete 
tumor regression, which was sustained several weeks after cessation of drug administration (Figure 
6.1.E) [18]. 
6.4.2. 4-OHT+SEL combination treatment causes gene expression changes distinct from 4-
OHT and SEL treatments alone in TAM-resistant cell lines 
To understand how the TAM+SEL combination provide a sustained tumor regression, we 
performed a global gene expression analysis in BT474 cells that were treated with Veh, 4-OHT, 
SEL or 4-OHT+SEL. Hierarchical clustering of the differentially-expressed genes revealed 10 
clusters with different gene regulation patterns. Genes in Clusters 1, 2, 3, 6, 9, and 10 were 
regulated similarly with all treatments. The 4-OHT+SEL combination and 4-OHT alone resulted 
in similar patterns of regulation for genes in Cluster 1. The 4-OHT+SEL combination and SEL 
alone caused similar gene regulation patterns for genes in Clusters 2,3,6,9 and 10. On the other 
hand, Clusters 4 and 5 include genes that were upregulated more with the combination treatment 
than either treatment alone, and genes in Clusters 7 and 8 were downregulated more with the 
combination treatment than either treatment alone (Figure 6.2.A and 6.2.B). Principle component 
analysis (PCA) showed that treatment groups differed significantly (Figure 6.2.C). Venn-diagram 
analysis of up- and downregulated genes revealed that the combination treatment caused gene 
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expression changes similar to as well as different from single agent treatments. The combination 
treatment increased the expression of 101 genes and decreased the expression of 132 genes that 
were not affected by either treatment alone (Fig. 6.2.D and 6.2.E). 
Next, we used Gene Set Enrichment Analysis (GSEA) analysis to identify functional gene 
groups that were associated with different treatments (Figure 6.2a.A, B and C). The 4-OHT 
treatment caused upregulation in genes for cell cycle-, endocrine therapy resistance-, and breast 
cancer invasiveness-related pathways. On the other hand, genes involved in apoptosis and 
decreased tumor invasiveness were downregulated by this treatment. Although SEL was effective 
in decreasing endocrine therapy resistance, breast cancer invasiveness, and metastasis related 
genes, genes that would regulate apoptosis were also downregulated by this treatment. The 4-
OHT+SEL combination was the most effective treatment for down regulating therapy resistance 
and tumor invasiveness. Specifically, the combination treatment was more efficient than either 
treatment alone to upregulate gene sets associated with genes downregulated in Luminal B tumors, 
metastasis, and in bone metastasis. However, the combination treatment was very effective in 
downregulating ERα target genes that were upregulated by AKT1 overexpression and genes that 
were upregulated in Luminal B tumors, endocrine therapy resistance and metastasis that were 
identified in various studies. These findings are consistent with our data showing that differential 
Akt signaling was modulated by the ERα and XPO1 crosstalk. Of note, 4-OHT+SEL reduced 
targets of FGFR1 signaling, recently shown to be associated with Palbociclib+Fulvestrant-resistant 
tumors [43, 44]. Overall, our gene expression analysis showed that the 4-OHT+SEL treatment was 
very effective in downregulating genes associated with endocrine resistance and metastasis. Data 
on other gene sets associated with metabolic regulation and autophagy will be presented in the 
upcoming sections.  
6.4.3. XPO1 inhibition modulates differential Akt phosphorylation in TAM-resistant cells 
and tumor xenografts. 
We next focused on the Akt signaling associated gene sets which were identified as 
differentially downregulated by the 4-OHT+SEL combination (Figure 6.3.A) because they play an 
important role in cell survival and metabolism. We validated differential Akt phosphorylation with 
individual or combined drug treatments in BT474 cells (Figure 6.3.B) and MCF-7 TAM^R cells 
(Figure 6.3a.A, B and C). Of note, 4-OHT treatment induced an increase in the cytoplasmic pAkt 
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Ser473 signal, whereas SEL treatment increased the pAkt Thr305 signal in dividing cells (arrows) 
(Figure 6.3.C). As we previously showed, TAM treatment stimulated tumor growth in BT474 
tumor xenografts, whereas SEL treatment inhibited tumor growth [12]. However, tumor growth 
resumed within 3 weeks after SEL treatment was stopped. By contrast, the combination of SEL 
and TAM not only caused a faster and more complete regression of tumors, but the regression was 
also sustained [12].  To validate our pathway analysis in vivo, we utilized tumor xenograft samples 
from this experiment (Figure 6.3.D).  Our IHC analysis showed that Ser 473 phosphorylation of 
Akt protein increased only in tumors from TAM treated animals, whereas Thr 308 phosphorylation 
of Akt was more prevalent in tumors from SEL treated animals. Both of the phosphorylation events 
were dampened in tumors from animals that were treated with the SEL+TAM combination, 
suggesting that the combination treatment prevented activation of survival pathways that were 
otherwise prominent when tumors were treated with single agents (Figure 6.3.D). These results 
suggest that ERα-XPO1 crosstalk might contribute to drug resistance by regulating differential 
Akt signaling, which is important for survival and metabolic control.  
6.4.4. ER-XPO1 targeting changes the metabolic phenotype of breast cancer cells from an 
energetic to a quiescent profile 
Our gene expression analysis also pinpointed two of the pathways associated with 
metabolic regulation: glycolysis and mitochondrial respiration (Figure 6.4.A and B). Since Akt is 
a major regulator of cell metabolism and TAM responsiveness, we hypothesized that XPO1 
modulates Akt activity to rewire metabolism and provide new survival/escape routes to breast 
cancer cells. We performed a mitochondrial stress test to monitor different parameters of 
mitochondrial respiration, including basal respiration, proton leak, maximal respiration, spare 
respiratory capacity, non-mitochondrial respiration, ATP production, and coupling efficiency. The 
4-OHT+SEL combination did as well as or slightly better than the individual treatments in 
reducing different mitochondrial respiration parameters (Figure 6.4.C). We also validated gene 
expression data related to metabolism using a glycolytic stress test which monitors glycolysis, 
glycolytic capacity and glycolytic reserve. The 4-OHT+SEL combination was as good as or better 
than individual treatments in reducing all three parameters (Figure 6.4.D). Next, we tested the 
individual and combinational effects of 4-OHT and SEL on the metabolic cell phenotypes of 
TAM-sensitive and TAM-resistant cell lines. Our results showed that although treatment with 4-
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OHT alone or SEL alone made all the cell lines less energetic , the cells became even more 
quiescent with the 4-OHT+SEL treatment (Figure 6.4.E, Figure 6.3.E). Of note, combining SEL 
with 4-OHT was as effective as combining a PI3K inhibitor (MK2206) with 4-OHT in reducing 
4-OHT induced cell viability and increase in mitochondrial respiration (Supplementary Figure 3). 
6.4.5. ER-XPO1 targeting induces autophagic cell death 
Our gene expression analyses indicated that gene sets associated with cell cycle and 
regulation of epithelial cell proliferation were downregulated, whereas gene sets associated with 
autophagy and cell death were upregulated (Figure 6.5.A). To validate these results, we performed 
cell cycle analysis in MCF-7 cells and BT474 cells treated with Veh, 4-OHT, SEL or the 4-
OHT+SEL combination. The combination treatment was very effective, particularly in BT474 
cells, in reducing ratio of S-phase cells (Figure 6.5.B). We also validated autophagic vacuole 
formation (Figure 6.5.C, D) and an increase in autophagy related proteins in this cell line (Fig. 
6.5.E). In addition, we examined different apoptotic caspase activities, PARP cleavage and 
changes in apoptotic cells in both cell lines. We did not observe any indicator of apoptosis in either 
of the cell lines at up to 120 hours of treatment (Figure 6.5.G). Finally, treatment of BT474 cells 
with the autophagy inhibitor chloroquine blocked the 4-OHT+SEL mediated reduction in cell 
viability (Fig. 6.5.F). Together, these results reveal that co-inhibition of ER-XPO1 leads to 
autophagic cell death.  
 
6.5. Discussion 
This study is the first of its kind to report the molecular basis of the effectiveness of the 
novel combination therapy of 4-OHT and SEL in providing sustained tumor regression for ER (+), 
Tam-resistant tumors. We showed that individual 4-OHT and SEL treatments increased 
differential Akt signaling in endocrine-resistant cells, but that the combination prevented this 
activation. We also reported transcriptional and functional consequences of combined ERα and 
XPO1 targeting. The combination therapy was the most efficient treatment at reversing the 
expression of endocrine resistance and metastasis-related gene expression programs. In addition, 
glycolytic and mitochondrial pathways were targeted by this combination. As a result, the 4-
OHT+SEL combination effectively blocked glycolysis and mitochondrial respiration and caused 
cell death by activating autophagy.  Our study is the first documented attempt to define the causal 
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role of metabolic programming in therapy resistant ER (+) tumors and to explore the feasibility of 
the combined targeting of these pathways to improve the response to endocrine agents and decrease 
the risk of recurrence.  
Targeting XPO1 together with ERα is clinically relevant for several reason. First, in our 
published analysis from publicly available tumor datasets [12] and data from patient tumor samples 
(Fig 6.1.A) mRNA and protein levels of XPO1 were higher in Luminal B subtype tumors which 
are more likely to recur on endocrine treatments relative to Luminal A subtype. Second, high 
XPO1 mRNA expression was associated with a poor outcome in women who were treated with 
TAM [12]. And last, XPO1 was already being targeted in phase 2 and 3 clinical trials 
(clinicaltrials.gov) by SEL- a specific, covalent, small molecule orally bioavailable inhibitor of 
XPO1, to treat patients with hematological and solid cancers [24, 25, 26, 45, 46]. SEL is well 
tolerated with manageable side effects including nausea, fatigue and anorexia that improve over 
time on treatment.  Even in patients that remained on therapy for more than 8 months, no 
significant cumulative drug toxicities have been identified [16]. Since cancer cells of different 
tumor types have been shown to be more sensitive to XPO1 inhibition than normal cells [47, 48], 
combining TAM with SEL potentially offers higher efficacy, specificity and lower toxicity for 
treatment of endocrine resistant, recurrent ER (+) breast cancer.   
We propose that co-targeting ER and XPO1 is an improved therapeutic strategy because 
inhibiting the proteins in combination caused both a metabolic shift and induced autophagy which 
together led to prolonged tumor regression. The combined targeting of ERα and XPO1 overcame 
TAM resistance, modulated cellular signaling to prevent rewiring of tumor cell metabolism and 
induced cell death by autophagy (Fig. 6.6). We showed that single or combined targeting of ERα 
and XPO1 caused differential regulation of Akt phosphorylation. The Akt pathway is a master 
regulator of cancer cell metabolism [49], components of PI3K/AKT/mTOR pathway are mutated 
in nearly 25% of breast tumors and are associated with drug responses in ER (+) and ER (-) tumors 
[50, 51, 52]. Estrogens stimulate this pathway to regulate migration and invasion of cancer cells 
characteristic of ER (+) tumors [53, 54]. In return, mTOR signaling regulates the expression level 
and activity of ERα and mTOR acts as a coregulator for ERα [55, 56]. Inhibition of PI3K increases 
ER expression and activity [51, 57], and PI3K inhibitor-endocrine agent combinations were tested 
with minor success in clinical trials to treat women with endocrine resistant disease 
(NCT01339442, NCT02273973). Akt signaling regulates both aerobic glycolysis and oxidative 
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phosphorylation and impact phenotypic features of tumor cells [58]. Our pathway activation assay 
showed that two established Akt targets, ENOS [59, 60] and PLCγ-1 [61], which are associated 
with angiogenesis and metastasis [62], had increased phosphorylation levels when cells were 
treated with SEL only but not with the 4-OHT and SEL combination. A similar pattern of 
regulation was observed for p53 phosphorylation at Ser15 by SEL and Ser392 by 4-OHT. 
Interestingly, loss of Ser392 phosphorylation by p70S6K was shown to inhibit autophagy by 
decreasing expression of ULK1 in the context of oxidative stress [63] whereas the same 
modification by p38 MAPK activated autophagy [64]. Of note, p38 MAPK phosphorylation was 
increased only in the 4-OHT+SEL treated cells, which might explain why we observe autophagy 
only in this treatment condition. 
The majority of current research efforts in the therapy resistance field focuses on a 
delineation of the underlying mechanisms that lead to increased activity of selective signaling 
pathways. Undoubtedly, interrogating and targeting the end-point kinases in tumors are highly 
relevant and these studies lead to the development of combination therapies involving PI3K 
inhibitors or mTOR pathway inhibitors together with endocrine agents. However, resistance to 
these combination therapies also occurs, and in such cases, the cancer that develops is considerably 
more aggressive due to hyperactivation of compensatory mitogenic signaling pathways [65]. 
Moreover, these kinase inhibitors have many adverse side effects. More recently, ERα mutations 
that decrease sensitivity of the receptor to selective estrogen receptor modulators (SERMs) and 
selective estrogen receptor degraders (SERDs) were identified in about 15-40% of the metastatic, 
but not primary, tumors after AI treatment [66, 67, 68, 69, 70]. However, in ER (+) metastatic 
tumors that occur after TAM treatment, such mutations were not identified [71, 72, 73]. Our 
proposed treatment approach might prevent/delay the use of AIs and emergence of ESR1 
mutations in tumors that recur after endocrine therapies, which is currently a significant clinical 
challenge.  
Our studies described here provide a vast array of novel and important new information that will 
significantly advance our understanding of adaptive metabolic pathways associated with therapy 
resistance and cancer cell survival. The nuclear export pathways have not previously been 
implicated in TAM resistance and given the need for better strategies for selecting patients to 
receive TAM and improving therapeutic response of relapsed ERα (+) tumors, our results have 
great potential for uncovering the role of these pathways and their combined targeting in reducing 
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recurrences and deaths due to metastatic ER (+) tumors. We expect our studies to establish a novel 
and innovative concept of combined targeting of ERα and XPO1 in TAM resistance that has not 
been previously explored in the field and will advance a new therapeutic strategy to the clinic. 
Successful translation of our findings to the clinic will change the treatment regimens for already 
metastasized patients while on TAM by replacing them with ones that are more effective, less 





Figure 6.1. 4-OHT+SEL treatment synergistically sustains tumor regression in endocrine resistant Luminal B 
subtype breast cancer cells. A) Verification of XPO-1 protein levels in patient tumor samples (BRC1021 from 
Pantomics, Inc containing 95 cases with known ER, PR, AR, Her2, p53, EGFR, and Ki67 IHC results). For each core, 
a score for XPO1 was assigned based on the signal intensity (0=none, 1=low, 2=moderate, and 3=high). B) 
Isobologram analysis of synergy between 4-OHT and SEL in BT474 cells. C) BT474 xenograft experiment showing 








Figure 6.2. The 4-OHT+SEL combination treatment causes gene expression changes distinct from 4-OHT 
or SEL treatments alone in TAM resistant cell lines. A) Hierarchical clustering of differentially expressed 
genes. B) Average expression profiles of clusters that showed differential regulation by the 4-OHT+SEL 




Figure 6.2a. Gene Set Enrichment Analysis (GSEA) analysis to identify functional gene groups that were 
associated with different treatments. A) Representation of the most activated/inactivated genes in specific pathways 











Figure 6.3. XPO1 inhibition modulates differential Akt phosphorylation in TAM-resistant cells and tumor 
xenografts. A) GSEA analysis of RNA-Seq data depicting regulation of Akt signaling by the 4-OHT+SEL 
combination. ER-XPO1 targeting changed XPO1 and pAkt protein expressions in both TAM-sensitive and TAM-
resistant breast cancer cell lines. Western blot analysis B) and immunofluorescence analysis C) of BT474 cells treated 
with 4-OHT (10-6 M) and SEL (10-7M) for 24 hours alone and in combination. Protein expression was quantified and 
is shown in bar graphs. A one-way analysis of variance (ANOVA) model was used for statistical significance of 
treatment effect and values were presented as mean ± SEM from three independent experiments (*p <0.05, **p <0.01). 
D) IHC staining of pAkt T308 and pAkt S473 in tumor samples obtained from BT474 xenografts received individual 
and combined TAM and SEL treatments (from Fig. 6.1.C). In the figure, red-brownish staining represents pAkt T308 
and pAkt S473 proteins. This figure showed that individual 4-OHT and SEL treatments activated two different 
phosphorylation sites of Akt protein. The top panel indicated that SEL treatment activated pAkt T308 phosphorylation 
in BT474 tumor xenografts. The bottom panel showed that TAM treatment activated pAkt S473 phosphorylation in 
BT474 tumor xenografts. Quantification of positive staining was performed digitally by selecting four independent 
regions on the sample slides and the results were given in the corresponding graphs. Statistical significance was 
presented as mean ± SEM by using one-way analysis of variance (ANOVA) model (*p <0.05, ***p <0.001). 
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Figure 6.3a. Differential Akt phosphorylation with individual or combined drug treatments in MCF-7 TAM^R 
cells. A) Isobologram dose-response graphs of TamR_5 weeks and TamR_50 weeks cells. B) Western blot analysis 
of phosphorylated and total Akt protein in TamR_5 week’s cells. C) Seahorse metabolic cell phenotype analysis of 




Figure 6.4. ER-XPO1 targeting changes the metabolic phenotype of breast cancer cells from an energetic 
to a quiescent profile. GSEA analysis of RNA-Seq data depicting the regulation of glycolytic A) and 
mitochondrial respiration B) pathways by the 4-OHT+SEL combination. ER-XPO1 targeting decreased the 
glycolytic activity of BT474 cells. Glycolytic functions were determined by the glycolysis stress test. A two-way 
analysis of variance (ANOVA) model was used for statistical significance of drug treatments alone or in 
combination and values were presented as mean ± SEM from two independent experiments and all experiments 
were performed in triplicates. (*p <0.05, **p <0.01, ***p <0.001, ****p <0.0001). C) ER-XPO1 targeting 
decreased the mitochondrial activity of BT474 cells. Mitochondrial activity parameters were measured by the 
mitochondrial stress test. A two-way analysis of variance (ANOVA) model was used for statistical significance 
calculations and values were presented as mean ± SEM from three independent experiments (*p <0.05, **p 
<0.01, ***p <0.001, ****p <0.0001). Some key parameters of mitochondrial function (Basal respiration, proton 
leak, maximal respiration, spare respiratory capacity, non-mitochondrial respiration, ATP production, coupling 
efficiency and spare respiratory capacity) were calculated and presented for each treatment conditions. E) Cell 
phenotype assay resulted in MCF-7, BT474, MDA-MB-134 and HCC1500 cells which were treated with 4-OHT 
(10-6M) and SEL (10-7M) for 24 hours alone and in combination. Changes in metabolic profile was determined 
by measuring oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) under basal and 




Figure 6.5. ER-XPO1 targeting induces autophagic cell death. A) GSEA analysis of cell proliferation and death 
pathways regulated by the 4-OHT+SEL combination treatment. B) Cell cycle analysis after Veh, 4-OHT, SEL or 4-
OHT+SEL treatments in MCF-7 and BT474 cells. LC3-II specific protein expression increased in TAM-resistant 
BT474 cells in a 24-h period. Comparison of the autophagic markers in BT474 cells treated with 4-OHT (10-6 M) and 
SEL (10-7 M) alone and in combination for 24 hours. Autophagosome formation was detected with a colorimetric 
method C) which measures the level of green fluorescent labeled LC3-II specific signal or by FACS analysis of the 
cells after staining with antibodies specific for LC3-II. D) Rapamycin (50 nM) was used as a positive control for 
autophagy detection. A one-way analysis of variance (ANOVA) model was used for statistical significance of 
treatments. The experiment was performed in triplicates and values were presented as mean ± SEM from two 
independent experiments (***p <0.001). E) The western blot analysis showed that the level of autophagic protein 
markers are higher in BT474 cells treated with both 4-OHT (10-6 M) and SEL (10-7 M) compared to those treated with 
individual 4-OHT+SEL treatment. BT474 cells were seeded at a density of 1x105 cells/well and treated with 4-OHT 
(10-6 M) and SEL (10-7 M) alone and in combination. Protein expressions of autophagic proteins (ATG9A, AMBRA, 
ULK1 and Beclin-1) were detected with target specific antibodies at 1:1000 dilution. Protein signal was quantitated 
using Licor Odyssey. A one-way analysis of variance (ANOVA) model was used for statistical significance of 
treatment and values were presented as mean ± SEM from three independent experimental repeats. F) Autophagy 
inhibitor chloroquine inhibited 4OHT+SEL induced decrease in cell viability.  one-way analysis of variance 





Figure 6.6. Molecular mechanism of sustained tumor regression by combined ERα-XPO1 targeting.                       
A) Individual tamoxifen treatment in tamoxifen-resistant breast cancer cells targets cell metabolism through Akt 
signaling. This effect decreases glycolytic rate and increases mitochondrial respiration and eventually lead cells to cell 
survival. B) Individual selinexor treatment targets XPO1 protein, and changes cellular metabolism through decreasing 
glycolysis and mitochondrial respiration rate and eventually makes breast cancer cells to survive. C) Combined ER 
and XPO1 targeting directly affects cellular metabolism and reduces overall cellular metabolism and activates 
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CHAPTER 7: EXPERIMENTAL PART III: 
ROLE OF MITOCHONDRIA AND GLUTAMINE METABOLISM IN THERAPY 
RESISTANCE: COMBINED TARGETING OF ESTROGEN RECEPTOR ALPHA AND 
EXPORTIN 1 IN ENDOCRINE RESISTANT BREAST CANCERS 
7.1. Abstract 
Majority of breast cancer specific deaths in women with ERα (+) tumor occur due to 
metastases that are resistant to endocrine therapy. There is a critical need for novel therapeutic 
approaches to prevent or delay recurrence of ERα (+) tumors. The objective of this study was to 
elucidate the role of mitochondrial pathways that are activated in the presence of single therapies 
and undermine therapy effectiveness in ER (+) breast cancers. In our previous studies, we 
identified Exportin 1 (XPO1), a nuclear export protein, as an important player in endocrine 
resistance progression. Selinexor (SEL), an XPO1 antagonist, has been evaluated in multiple later 
stage clinical trials in patients with relapsed and /or refractory hematological and solid tumor 
malignancies. Using a combination of transcriptomics, kinase arrays, metabolomics and metabolic 
flux experiments, we identified glutamine metabolism pathways to be rewired during endocrine 
resistance. In limited media conditions mimicking nutrient deprived tumor microenvironment, 
endocrine resistant cells were more dependent on mitochondria for energy production. Their 
glucose and fatty acid dependency decreased in the presence of SEL and cells were more 
dependent on glutamine. The effect of glutamine was dependent on conversion of the glutamine 
to glutamate and mitochondrial complex 1 activity. In order to examine metabolites that might 
result in the observed phenotype we performed GC/MS whole metabolite profiling and identified 
amino acid metabolism pathways to be upregulated when cells were treated with SXR.  We 
demonstrated that combined targeting of XPO1 and ERα rewires metabolic pathways and shuts 
down both glycolytic and mitochondrial pathways that would eventually lead to autophagy.  
Remodelling metabolic pathways to regenerate new vulnerabilities in endocrine resistant breast 
tumors is novel, our findings show great promise for uncovering the role ERα-XPO1 crosstalk 
plays in reducing cancer recurrences. 
Keywords: Breast cancer; Combined drug targeting; Metabolic rewiring; Glutamine 
This part of the project will be published in a paper. Kulkoyluoglu Cotul, E., Smith, B.P., Santaliz-Casiano, A., Tunc 
E., Zuo, Q., Duong, K., Ramesh R., Park B.H., Landesman, Y., Madak-Erdogan, Z. Role of mitochondria and 
glutamine metabolism in therapy resistance: Combined targeting of estrogen receptor alpha and exportin 1 in 
endocrine resistant breast cancers. (in progress) 
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7.2. Introduction  
The nuclear hormone estrogen receptor alpha (ERα) is present in approximately 70% of 
both early and late stage human breast cancers (BCas) [1, 2]. ERα is targeted by endocrine 
therapies, which are well tolerated and provide long term disease free survival if patients have 
localized disease [1]. Unfortunately, 10-40% patients with ER+ disease experience recurrence and 
metastasis within 20 years [3-7]. The recurrence of cancer in ER- patients is higher in the first five 
years after the diagnosis, yet for ER+ patients there is a substantial long-term risk of death due to 
recurrent BCa even 20 years after the initial diagnosis [8]. 5-year relative survival of patients with 
ER+ metastatic disease is 24%, almost none are cured and each year nearly 28,000 women with 
recurrent ER+ metastatic tumors die [2, 9, 10]. 
 Extended endocrine therapy combined with agents, such as CDK inhibitors or mTOR 
inhibitors is the most current treatment option for ER+ metastatic cancer [2]. Yet therapy-
resistance develops during the course of initial and sequential treatment in almost all of patients 
due to alterations of sequence or copy number for critical genes such as ESR1, PIK3CA or 
CCND1, signaling pathways such as Her2, PI3K or FGF signaling, and drug uptake and 
metabolism [5, 11]. Thus, acquired therapy resistance remains a significant clinical problem, a 
problem that indicates a critical need for therapeutic approaches that include novel, targetable 
mechanism-based strategies by which a sustained regression of ER+ metastatic tumors can be 
achieved or tumors can be kept therapy responsive. Identification of pathways that promote 
therapy resistance and metastasis provide an opportunity for developing more effective therapy 
regimens.  
 In our previously published studies we identified a group of nuclear transport proteins, 
including XPO1, which are upregulated in tamoxifen resistant cell lines and tumors. XPO1 up-
regulation caused nuclear export of factors that are required in the nucleus for ERα-dependent 
transcriptional responses [12, 13]. We previously showed that XPO1 mRNA and protein 
expression are higher in Luminal B subtype of tumors that are more refractory to endocrine 
treatments [12] [14]. High XPO1 mRNA expression is associated with a poor outcome in women 
who are treated with TAM [12]. In TAM-resistant cells, combined targeting of ERα and XPO1 
prevented 4-OH-Tam induced cell proliferation and anchorage independent growth [12] and 
induced autophagy [14]. In BT474 tumor xenografts, TAM stimulated tumor growth whereas SEL 
inhibited growth. However, resistance to SEL developed within 3 weeks after therapy was stopped 
 125 
[12]. The combination of SEL and TAM not only caused a faster and more complete regression of 
tumors, but also the regression was sustained. In our follow-up studies, we showed that XPO1 
induce endocrine resistance by modulating PI3K/Akt signaling and increasing survival of BCa 
cells by inducing metabolic rewiring. Combined ERα and XPO1 targeting effectively shut-down 
cell survival mechanisms to provide sustained tumor regression [14]. However, we don’t know if 
we can combine XPO1 inhibitors with other therapies currently used in the clinics for treatment of 
metastatic BCas, which is the focus of this study.  
 In this study, we elucidated the causes and mechanisms of therapy resistance by focusing 
on the role of metabolic changes in tumor cells to adapt to and survive in premetastatic niches 
(PMNs) and test therapeutic potential of combining XPO1 inhibitors with currently utilized 
clinical drugs to prevent therapy resistance during metastatic tumor treatment. Our studies 
established XPO1 as a target, whose inhibition would enhance the effectiveness of current 
therapies, by preventing metabolic adaptation and improved survival in metastatic organ sites 
during sequential therapies.    
 
7.3. Materials and Methods 
7.3.1. Cell Culture, Ligand Treatments  
All cell lines were obtained from American Type Culture Collection (Waltham, MA, 
USA). MCF-7 parental cells were cultured in Roswell Park Memorial Institute (RPMI-1640) with 
NEAA salts (Sigma, St Louis, MO, USA), supplemented with 5% fetal bovine serum (FBS) 
(HyClone, Logan, UT, USA), 100 µg/mL penicillin/streptomycin (Invitrogen, Carlsbad, CA, 
USA) and 50 mg/ml Gentamicin (Gibco, Gaitersburg, MD).  MCF7-ESR1D537S and MCF7- 
ESR1Y537S cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) with NEAA salts 
(Sigma, St Louis, MO, USA), supplemented with 5% FBS, 100 µg/mL penicillin/streptomycin 
and 50 mg/ml Gentamicin (Gibco, Gaitersburg, MD). Human breast cancer cell lines BT474, 
HCC-1500 and MDA-MB-134, which are 4-OH-Tam-resistant, were used as a model of de novo 
resistance [12, 15, 16]. BT474 were cultured in ATCC recommended Hybri-care medium with 
10% inactivated FBS, sodium bicarbonate and antibiotics. MDA-MB-134 cells were cultured in 
Leibovitz’s medium with 20% FBS (HyClone), and 100 g/mL penicillin/streptomycin 
(Invitrogen). HCC-1500 cells were cultured in ATCC-formulated RPMI-1640 media with 10% 
FBS, sodium bicarbonate and antibiotics. Acquired resistance was studied from resistance 
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progression cell lines previously derived and characterized by long-term exposure of parental 
MCF-7 cells to 4-OHT (MCF-7 TamR) [12, 15]. These cells retain ERα expression, do not require 
E2 for growth, are not growth inhibited by SERMs and 4-OHT stimulates their growth [12, 15]. 
For drug treatments, cells were treated with media including 10-6 M 4-hydroxytamoxifen (4-OHT) 
(Sigma), 10-6 M Fulvestrant (Fulv) (Sigma), 10-6 M Palbociclib (Palb) (Sigma) alone or in 
combination with and 10-7 M Selinexor (SEL) (Selleckchem, Houston, TX, USA) for 24 hours. 
For other drug treatments, SR-18292 (PPARGC1a inhibitor) (Selleckchem) and ZLN005 
(PPARGC1a activator) (Selleckchem) were used at concentrations between 1x10-5 M, 5x10-6 M 
and 1x10-6 M. MK2206 (PI3K inhibitor) was used at a concentration of 5x10-5 M [17-19].   
 
7.3.2. Cell Viability Assays and and siRNA Knock Down 
Cells were seeded at a density of 2×103 cells/well in a 96-well plate, and were grown 
overnight in corresponding media with/without phenol red. On day 1, cells were treated with            
drugs alone and in combination. Treatment was repeated again on day 4. On day 7, WST1 assay 
(Roche Molecular Systems, Inc., Pleasanton, CA, USA) was used to quantify cell proliferation 
ratio. Absorbance was measured at 450 nm using a Cytation5 plate reader (BioTek, Winooski, VT, 
USA). Statistical analyses were done by using Graphpad Prism8 software (GraphPad Software 
Inc., La Jolla, CA, USA, www.graphpad.com). All experiment conditions had six technical repeats 
and experiments were repeated at least for three times.  
For siRNA knock down experiments, cells were seeded at a concentration of 2x103 
cells/well in corresponding treatment media without phenol red and antibiotics. Next day, cells 
were incubated with 25 nM siRNAs targeting PPARGC1a (Dharmacon, ON-TARGET plus 
SMARTpool Human PPARGC1a (10891)) and MDH1 (Dharmacon, ON-TARGET plus 
SMARTpool Human MDH1 (4190)) genes. Target sequences of both siRNAs were given as below 
(J-005111-05, PPARGC1a: GAGAAUUCAUGGAGCAAUA), (J-005111-06, PPARGC1a: 
GAAGAGCGCCGUGUGAUUU), (J-005111-07, PPARGC1a: 
ACACUCAGCUAAGUUAUAA), (J-005111-08, PPARGC1a: 
GCAGGUAACAUGUUCCCUA), (J-009264-09, MDH1: CCUUAGAUAAAUACGCCAA), (J-
009264-10, MDH1: GGGAGAAUUUGUCACGACU), (J-009264-11, MDH1: 
CAACAGAUAAAGAAGACGU), (J-009264-12, MDH1: AGGUUAUUGUUGUGGGUAA). 
Cells were incubated with the media containing siRNAs for 48 hours. Cells were treated with 
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different endocrine agents alone or in combination with SEL two times in corresponding in 
antibiotic-free and phenol red-free media on day 3 and day 6. On day 9, cell viability was measured 
and analyzed as explained above. 
For limited media condition mimicking experiments, MCF-7, MCF7-ESR1Y537S, MCF7-
ESR1D538G, and BT474 cells were seeded at a density of 2x103 cells/well in 96 well plates. Next 
day, cells were treated with 10-6 M 4-OHT and 10-7 M SEL alone and on combination in different 
limited media conditions (Plain media: containing only 7.5% sodium bicarbonate, Low glucose 
media: 1 g/L D-Glucose, High glucose media: 4.5 g/L D-Glucose, Glutamine-only media: 2 mM 
L-Glutamine. Treatments were repeated on day 4. On day 7, cell viability was measured with 
WST-1 reagent. 
 For individual amino acid treatments, parental MCF-7, MCF7-ESR1Y537S, MCF7- 
ESR1D538G, and BT474 cells were seeded at a density of 2x103 cells/well in 96 well plates. On day 
1, cells were treated with corresponding media containing 2 mM individual amino acids. Amino 
acid treatments were repeated on day 4. Absorbance was measured at 450 nm using a Cytation5 
plate reader (BioTek, Winooski, VT, USA). 
 
7.3.3. 3-D Cell Culture Models 
To culture cells on different surface of matrix hydrogels (XYLYX TissueSpec Bone, 
Liver and Lung) in a 6mg/ml solution, 2×103 cells/well were mixed with corresponding tissue 
culture matrix in growth media and seeded on 96-well plates. Then, they were incubated at 37C 
in a humidified environment with 5% CO2 for at least 45 minutes to achieve gelation. Cells were 
treated with media containing different endocrine agents alone or in combination with SEL every 
Monday and Friday in line with clinical practice of endocrine treatments for 40 days. Oncosphere 
formations were visualized and captured by Invitrogen EVOS XL Core Light Microscope 
(Waltham, MA, USA). Number of oncospheres were counted automatically after each drug 
treatments with OpenCFU colony counting software (http://opencfu.sourceforge.net/) and all 
statistical analyses were completed by using GraphPad Prism8 software. 
 
7.3.4. Mutation Correlation Analysis 
 cBioPortal for Cancer Genomics (https://www.cbioportal.org/) website was used to see the 
correlation between XPO1 and other most common mutation patterns. To identify co-expression 
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profiles of XPO1 and PIK3CA, XPO1 and ESR1, and XPO1 and CCND1 in different breast tumors, 
METABRIC (Nature 2012 & Nature Commun. 2015) and TCGA (Nature, 2012) databases were 
selected. Selection criteria was narrowed down by selecting ER+ tumors. Then, ER+ tumors with 
PIK3CA, ESR1 and CCND1 mutations were selected individually, and tumors carrying XPO1 and 
these common mutations were specifically selected [20, 21]. 
 
7.3.5. Western Blot Analysis in Cell Lines  
Cells were seeded on 30 mm cell culture plates at 1×105 cells/well concentration in 
corresponding treatment media without phenol red which contains 5% FBS Cells were treated with 
media containing endocrine agent alone and in combination overnight. Next day, cells were 
collected in Lysis buffer (0.5 M EDTA, 1 M TrisHCl pH 8.1, 10% SDS, 10% Empigen, ddH2O) 
with 1× Complete Protease Inhibitor (Roche) and 1× Phosphatase Inhibitor (Thermo Scientific, 
Waltham, MA, USA). Samples were further processed with sonication and protein concentrations 
were determined by BCA assay (Thermo Scientific). Then, samples were boiled in SDS-containing 
loading buffer and were run in 10% precast gels (BioRad) and transferred to nitrocellulose 
membrane. The membrane was blocked in Blocking Buffer (Odyssey®, Li-Cor, Lincoln, NE, 
USA) and target proteins were probed with XPO1 (sc-74454, Santa Cruz Biotechnology, Dallas, 
TX, USA), p-Akt S473 (#4060, Cell Signaling), pAkt T308 (#13038, Cell Signaling), Akt (#9272, 
Cell Signaling), PGC1a (#SAB2500781, Sigma-Aldrich) antibodies in 1:1000 dilution and β-actin 
(Sigma SAB1305546) antibody in 1:10000 dilution. The secondary antibodies were obtained from 
Odyssey were used at 1:10000 dilution. The membranes were visualized by using Licor Odyssey 
CLx infrared imaging device and software. All results were repeated two times and the results 
were normalized according to signal, which was received from β-actin loading control. 
Representative blots are presented.  
 
7.3.6. Gene Expression Analysis 
To identify metabolism related gene sets regulated by SEL only treatment we used our 
previously published RNA-Seq dataset (GSE112883). RNASeq analysis was performed as 
previously described [19–21]. Briefly, BT474 cells were treated with Vehicle (Veh, 0.5% EtOH), 
10−6 M 4-OHT (Sigma), 10−6 M Fulvestrant (Sigma), 10−6 M Palbociclib (Sigma) alone or in 
combination with 10−7 M Selinexor (SEL) (Selleckchem) for 24 h. Concentrations of ligands are 
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based on our previously published study [12] and clinical data [22-24]. Total RNA was extracted 
with TRIzol reagent (Life Technologies, Cancers 2019, 11, 479 4 of 20 Carlsbad, CA, USA) 
according to the manufacturer’s protocol and cleaned using a clean-up kit (QIAGEN, Hilden, 
Germany). RNA quality was assessed using bioanalyzer. Total RNA from each sample (three per 
treatment group) were sequenced at the UIUC sequencing center, and data was generated in Fastqc 
file format to compare the expressions between the four treatment groups. Preprocessing and 
Quality Control: Fastqc files containing raw RNA sequencing data were trimmed using 
Trimmomatic (Version 0.38) [25]. Next, the reads were mapped to the Homo sapiens reference 
genome (GRCh37) from the Ensembl [26] database and aligned using the STAR alignment tool 
(Version 2.7.0f) [27]. After this, the read counts were generated from SUBREAD (Version 1.6.3) 
[28] and featured counts were exported for statistical analysis in R. Quality control and 
normalization was conducted in R using edgeR (Version 3.24.3) [29]. 
 
Statistical Analysis and DEGs: Statistical analysis was conducted in R using limma (Version 
3.38.3) [30, 31]. Empirical Bayesian statistics were conducted on the fitted model of the contrast 
matrix. Differentially expressed genes were then determined by fold-change and p-value with 
Benjamini and Hochberg multiple test correction for each gene, for each treatment relative to the 
vehicle control. We considered genes with fold-change >1.5 and p-value < 0.05 as statistically 
significant, differentially expressed. Cluster3 software was used for clustering the differentially 
expressed genes. Data was visualized using Treeview Java. PCA analysis was performed using 
StrandNGS (Version 3.1.1). GSEA [32, 33] analysis was used to identify GO terms associated 
with different treatments. 
 
7.3.7. Metabolomics analysis 
BT-474 cells were seeded at a density of 2x105 cells/plate in treatment media. Next day, 
they were treated with 10-6 M 4-OHT and 10-7 M SEL alone or in combination for 24 hours. After 
this incubation period, samples were submitted to the Metabolomics Center at UIUC. GC/MS 
whole metabolite profiling was performed to detect and quantify the metabolites by using Gas 
chromatography-mass spectrometry (GC/MS) analysis. Metabolites were extracted from samples 
according to Agilent Inc. application notes. The hentriacontanoic acid was added to each sample 
as the internal standard prior to derivatization. Metabolite profiles were acquired using an Agilent 
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GC-MS system (Agilent 7890 gas chromatograph, an Agilent 5975 MSD, and an HP 7683B 
autosampler). The spectra of all chromatogram peaks were evaluated using the AMDIS 2.71 and 
a custom-built database with 460 unique metabolites. All known artificial peaks were identified 
and removed prior data mining. To allow comparison between samples, all data were normalized 
to the internal standard in each chromatogram. Metabolomics data with sample class annotations 
(healthy and susceptible) were uploaded to the Statistical Analysis tool of MetaboAnalyst software 
version 4.0 [34]. Features with more than 50% missing values were removed. Datawere 
normalized based on values from “Healthy” samples. Data were log transformed and scaled using 
Auto scaling feature. VIP scores for top 25 metabolites that discriminate between healthy and 
susceptible individuals were calculated and displayed using the Partial Least Squares-Discriminant 
analysis tool. Heatmap of class averages of 25 metabolites was generated using Heatmap feature 
using default options for clustering and restricting the data to top 25 metabolites ranked by t-test. 
Heatmap for abundance of each metabolite and association with class, menopausal status and 
BMIwere generated using Cluster3 and visualized using Java Treeview. We calculated the 
correlation between all identified circulating factors (metabolite and protein) using the Pearson 
correlation coefficient using R software (R Core Team, 2015). R Code to calculate correlation 
coefficients and p-values are available upon request. Correlation coefficients and p-values were 
clustered using Cluster3 software and visualized using Treeview Java tool. 
 
7.3.8. Seahorse Metabolic Profiling Assays  
MCF-7, MCF-7 TamR and BT474 cells were seeded at a density of 5×104 and MDA-MB-
134 and HCC 1500 cells were seeded at a density of 1×105, and MCF-7 ESR1D537S and MCF-7 
ESR1Y537S cells were seeded at a density of 3×104 in corresponding treatment media without phenol 
red in each well of the XFp Cell Culture miniplates, respectively (Seahorse Bioscience Inc., 
Billerica, MA, USA). The FCCP concentration was 0.5 µM for MCF-7, BT474, MDA-MB-134 
and HCC 1500 cells. Next day, cells were treated with treatments media containing endocrine 
agents alone or in combination with SEL overnight and the cartridges were hydrated with the 
calibration solution and kept in a non-CO2 incubator at 37 C overnight. In parallel, a duplicate of 
each plate was used for cell counting to monitor cell number changes after 24 h of treatments and 
Seahorse data was normalized to total cell number. On the assay day, cells were washed with XF 
Base Media without phenol red (Seahorse Bioscience Inc.) supplemented with 10 mM L-glucose, 
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2 mM L-glutamine (Gibco) and 1 mM sodium pyruvate (Gibco, Waltham, MA, USA). The ECAR 
(mpH/min) and OCR (pmol/min) values were obtained by using Seahorse XFp Cell Energy 
Phenotype Test Kit (Seahorse Bioscience Inc.), which were run with Seahorse XFp Analyzer 
(Seahorse Bioscience Inc.). Experiments were performed in triplicate and repeated at least three 
times. 
For the Seahorse experiments conducted in different extracellular matrix conditions, 
Seahorse XFp plates were coated with different Native Coat ECMs for bone, lung and liver 
(XYLYX, NY, USA). Then, these 2D coats were incubated at 37C in a humidified environment 
with 5% CO2 for at least for 1 hour. Cells were seeded in these coated Seahorse plates after 
removing native coat mixtures. The rest of the treatment and assay processes were applied as 
explained above. 
 
7.3.9. Luminescence-Based Assays 
NAD+/NADH-Glo Assay (Promega, Madison, WI), NADP+/NADPH-Glo Assay 
(Promega, Madison, WI), Reactive oxygen species (ROS)-Glo (Promega, Madison, WI), 
Glutathione (GSH)–Glo Assay (Promega, Madison, WI) were run based on same procedure.       
BT-474 cells were seeded at a concentration of 2x103 cells/well in 96-well plates in corresponding 
phenol red-free media. Next day, cells were treated with endocrine agents alone or in combination 
with SEL in corresponding concentrations, and they were incubated with drugs for 24 hours. All 
assays were run according to the supplier’s instructions for use of products. After 24 hours 
incubation with drugs, luminescence values were measured using a Cytation5 plate reader 
(BioTek, Winooski, VT, USA). Standard curve and sample values were analyzed after subtraction 
of values from blank sample, and all statistical analyses were done by using Graphpad Prism8 
software (GraphPad Software Inc., La Jolla, CA, USA, www.graphpad.com). All experiment 
conditions had six technical repeats and experiments were repeated in six technical repeats at least 
for two times.  
 
7.3.10. Statistical Analyses  
Data from all studies were analyzed using a one-way analysis of variance (ANOVA) model 
to compare different ligand effects, a two-way-ANOVA model to compare time-dependent 
changes. All data was tested for normal distribution using pairwise t tests with a Bonferroni 
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correction. All data was normally distributed unless otherwise noted. Normally distributed data 
was analyzed using pairwise t tests with a Bonferroni correction to identify treatments that were 
significantly different from each other (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001). 
For every main effect that was statistically significant at α = 0.05, pairwise t-tests were conducted 
to determine which ligand treatment levels were significantly different from each other. For these 
t-tests, the Bonferroni correction was employed to control experiment wise type I error rate at α = 
0.05 followed by Bonferroni post hoc test. Data that were not normally distributed were analyzed 
using Mann Whitney test for nonparametric data (* p < 0.05, ** p < 0.01, *** p < 0.0001). 
Statistical significance was calculated using GraphPad Prism for Windows.  
 
7.3.11. Availability of Data and Materials  
Gene expression data is submitted to GEO database under the accession number 
GSE112883 and going to be available from the day of the acceptance of the manuscript.  
 
7.4. Results 
7.4.1. Clinical relevance of combining XPO1 inhibitors with current therapies in metastatic 
ER (+) tumors 
   To assess viability of XPO1 as a therapeutic target we utilized TCGA and METABRIC 
datasets and studied XPO1 mRNA expression with other biomarkers that help clinicians make 
decisions in the clinic. In both datasets, XPO1 mRNA level correlated with ESR1, PIK3CA and 
CCND1 mRNAs in ER(+) tumors, as well as in ER(+) tumors with PIK3CA mutations (most 
common mutation found in breast tumors) or CCND1 amplification, rendering this protein a viable 
target in tumors with various genomic mutations or amplifications (Figure 7.1.A and 7.1a). To 
examine pathways that might be affected by XPO1 and ER crosstalk in MCF7 cells with ESR1 
mutations, we performed a RNASeq experiment. We treated MCF7-ESR1Y537S cells with 4-OHT, 
Fulv and Palb in the presence or absence of SEL (Figure 7.1.B). For all treatments, cotreatment 
with SEL decreased genes associated with cell cycle, and increased genes associated with 
apoptosis and p53 signaling (Figure 7.1.C). Validating our results from gene expression analysis, 
in endocrine resistant MCF7-ESR1Y537S , MCF7-ESR1D538G, HCC1500 and BT474 cells 
combining SEL with Fulv, 4-OHT Tam or Palb reduced agonist activities of these drugs to increase 
cell viability (Figure 7.1.D).  
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7.4.2.   Combination of SEL with other treatments decrease colony formation of BCa cells in 
hydrogels from major metastatic tissues 
Next, we cultured various endocrine-responsive and -resistant BCa cell lines in hydrogels 
mimicking tissue extracellular matrices from liver, bone and lung. We have observed tissue 
extracellular matrix-specific responses to drugs. For example, for MCF-7 ESR1Y537S treatment 
with 4-OHT blocked growth in lung but increased it in bone and liver hydrogels. Fulv and SEL 
were agonists in all three-tissue matrices. Palb increased colony size and number in liver but not 
in bone or lung . Finally, combining each agent with SEL prevented agonistic activities of these 
drugs in different tissue hydrogels (Figure 7.2.A and B).These results showed feasibility of 
combining SEL with other therapies to treat already metastasized ER+ tumors.   
7.4.3.   ER-XPO1 targeting changes metabolic phenotype of BCa cells from an energetic to 
quiescent profile 
 Previously, to understand how TAM+SEL combination provides a sustained tumor regression, 
previously we performed a global gene expression analysis in BT474 cells that were treated with 
Veh, 4-OHT, SEL or 4-OHT+SEL. This analysis identified Akt signaling associated gene circuits 
as well as two additional pathways associated with metabolic regulation: glycolysis and 
mitochondrial respiration. We hypothesized that XPO1 modulates Akt activity to rewire 
metabolism and provide new survival/escape routes to BCa cells. We observed that different 
endocrine resistant models (HCC-1500, BT474, MCF7/TamR, MCF7-ESR1D538G and ESR1Y537S) 
had higher mitochondrial and glycolytic respiration (Energetic phenotype) compared to endocrine 
sensitive cell lines (Figure 7.3.A). We tested the individual and combinational effects of 4-OHT 
and SEL on metabolic cell phenotypes of TAM-resistant cell lines, which showed that combining 
4-OHT with SEL induced a quiescent phenotype, where both glycolysis and mitochondrial 
respiration is reduced, in all models tested [14]. We next cataloged the metabolic phenotype of 
therapy-resistant BCa cell lines using Seahorse metabolic profiler. Growing endocrine-sensitive 
or –resistant BCa cells on an extracellular matrix from the bone, liver or lung tissue (major sites 
for BCa metastasis) resulted in an increase in both glycolytic and mitochondrial activity, 




7.4.4. Single agent treatments rewire metabolic pathways to enhance survival of BCa cells 
 In our in vivo, tumors that initially regressed while on SEL came back within 3 weeks after 
the treatment was stopped [12]. To identify any survival pathways that might be activated with 
SEL only treatment, we compared gene sets that were differentially activated or repressed with 
SEL treatment, but not with 4-OHT or 4-OHT+SEL treatments. We found that SEL treatment of 
BT474 cells activated a glutamine (Gln) deprivation gene program (Figure 7.4.A). We then 
monitored mitochondrial fuel dependency of BT474 cells when we treated them with SEL only 
(Figure 7.4.B). This analysis showed that Gln, but not glucose or free fatty acids, was not used for 
ATP production, but it was necessary for maintenance of mitochondrial respiration (Figure 7.4.B). 
Metabolomics analysis also showed that Gln levels in the cells treated with SEL were lower 
(Figure 7.4.C).  
SEL is an inhibitor of cell viability in our cell culture models, but in vivo fails to provide 
sustained tumor regression. Under limiting nutrient conditions, tumors can activate different stress 
mechanisms to acquire vital nutrients [35]. We next tested, in a scenario where limited nutrient 
availability activates glutamine acquisition from tumor microenvironment, if Gln supplementation 
would reverse cell inhibitory effect of SEL. In limiting media conditions with no glucose or serum 
supplementation, glutamine addition converted SEL to an activator for cell viability in BT474 
(Figure 7.4.D). This effect was blocked by BPTES, a glutamine uptake inhibitor (Figure 7.4.E) 
To identify if Gln supplementation with SEL increased production of metabolites, which 
were previously shown to be dependent on Gln [36], we monitored NAD+/NADH ration, 
NADP+/NADPH ratio, reactive oxygen species and glutathione production and found that the 
increase in NAD+/NADH ratio was highest in cells that are grown in limited media conditions 
supplemented with Gln and SEL (Figure 7.5.A, B, C and D). NAD+ is a critical metabolite that 
links cellular metabolism, signaling and transcription [37]. In addition to providing ATP, TCA 
cycle and glycolysis regenerates NAD+ levels. When glycolysis is inhibited (low pyruvate levels, 
Figure 7.5.E), Gln, through conversion to glutamate and α-Ketoglutarate, is utilized by the TCA 
cycle to produce ATP and regenerate NAD+. When glycolysis and TCA cycle is blocked, Gln is 
converted to aspartate through a series of steps that regenerates NAD+ by cytosolic MDH1 [38, 
39]. Our metabolomics analysis showed that SEL treatment reduced cellular pyruvate level, 
whereas aspartate level was increased (Figure 7.5.E). In limited media supplemented with Gln, 
SEL-dependent cell viability was blocked by knock-down of MDH1 (Figure 7.5.F), suggesting 
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that in limited conditions, which might mimic tumor microenvironment, or when glycolysis and 
TCA cycle is inhibited, Gln is shunted to replenish NAD+ in a MDH1-dependent manner and 
increased cell survival (Figure 7.5.G).  
7.4.5. PGC1α level determines the metabolic plasticity and response to therapies 
 Our RNASeq analysis showed that PPARGC1A (PGC1α) to be induced by combination 
treatments with SEL (Figure 7.6.A and B). PGC-1α is a major regulator of mitochondrial 
biogenesis, and overexpression of this protein was implicated in regulation of Gln metabolism [40] 
and resistance to metabolic drugs [41]. However, PGC1α was also indicated as an autophagy 
regulator [42]. Therefore, we hypothesized that this protein might be involved in the metabolic 
rewiring and different outcomes we observed with different treatments. In our models of endocrine 
resistant BCa cells had higher PGC1α expression (Figure 7.6.C), consistent with higher 
mitochondrial and glycolytic respiration in these cell lines compared to endocrine sensitive cell 
lines (Figure 7.3.A). Importantly, knockdown of PGC-1α prevented survival of BCa cells under 
limiting media conditions with Gln, underscoring the importance of this protein in cell survival in 
these conditions (Figure 7.6.D). Interestingly, small molecule activator of PGC1α, ZLN005 
increased therapy resistant cell line viability with 4-OHT (T), Fulv (F) or Palb (P) at low dose, 
which was blocked by SEL (S) (Figure 7.6.E). Interestingly, inhibition of PI3K/Akt signaling or 
PGC1α activity using a small molecule inhibitor reduced energetic phenotype of endocrine 
resistant cells (Figure 7.6.F). Our results showed that extracellular matrix composition affected 
metabolic phenotype of BCa cells and inhibiting PI3K pathway, PGC1α or XPO1 reduced the 
effect of extracellular matrix. However, the effect of the combined therapies with SEL was even 
more effective in inducing quiescence in different hydrogels (Figure 7.7.A), consistent with our 
colony formation assays (Figure 7.2). In addition, SEL combinations were very effective in 
preventing SEL induced cell viability in limited media conditions with various amino acids (Figure 
7.7.B), emphasizing the therapeutic potential of these combinations in reducing metastatic tumor 
growth and adaptation to stress conditions and preventing therapy resistance in already 






In this study, we elucidated the causes and mechanisms of therapy resistance by focusing 
on the role of metabolic changes in tumor cells to adapt to and survive in PMNs and test therapeutic 
potential of combining XPO1 inhibitors with currently utilized clinical drugs to prevent therapy 
resistance during metastatic tumor treatment. In this study, we started understanding the clinical 
relevance of combining XPO1 inhibitors with current therapies in metastatic ER (+) tumors, and 
we found out that XPO1 mutations in these tumors are highly correlated with other most common 
mutations (e.g. PIK3CA, ESR1 and CCDN1) in these tumors. Then, we looked at the effect of this 
combined treatment in different premetastatic tumor environments in breast cancer, and we 
identified that combined endocrine and SEL treatment works better than individual treatments to 
reduce colony area, but SEL only treatment decreases number of colonies. After that, we looked 
at the effect of this combined treatment on cellular metabolic phenotype of endocrine-resistant 
breast cancer cells, and we found that endocrine-resistant cells have a higher metabolic phenotype. 
Furthermore, our results showed that endocrine-resistant cells growing in metastatic environments 
have a higher cellular metabolic profile. Then, we investigated the reason behind poor outcome of 
individual SEL treatment, and our results showed that SEL treatment increases Gln dependency in 
endocrine-resistant breast cancer cells through a mechanism, which converts glutamine to other 
TCA cycle intermediates to sustain NAD+ levels in endocrine-resistant breast cancer cells. Then, 
we elucidated the mechanism behind combined endocrine agent and SEL treatment, and we found 
out that PGC1 levels determines the metabolic plasticity and response to therapies. 
Our studies established XPO1 as a target, whose inhibition would enhance the effectiveness 
of current therapies, by preventing metabolic adaptation and improved survival in metastatic organ 
sites during sequential therapies. Resistance to therapies is a significant concern for metastatic 
breast cancer patients. The majority of current research efforts in the therapy resistance field 
focused on a delineation of the underlying mechanisms that lead to increased activity of selective 
signaling pathways. Undoubtedly, interrogating and targeting the end-point kinases in tumors is 
highly relevant and these studies led to the development of combination therapies involving PI3K 
inhibitors or mTOR pathway inhibitors together with endocrine agents. However, resistance to 
these combination therapies also occurs, and in such cases, the cancer that develops is considerably 
more aggressive due to hyperactivation of compensatory mitogenic signaling pathways. Moreover, 
these kinase inhibitors have many adverse side effects. Additionally, ESR1 mutations that decrease 
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sensitivity of the receptor to endocrine therapies were identified in about 15-40% of the metastatic, 
but not primary tumors. Our proposed approach might offer an alternative treatment strategy to 
prevent emergence of these adaptive strategies for cancer cells and therapy resistance, which is a 
significant clinical challenge currently. Further, what is learned may serve to help us understand 
therapy responsiveness of other cancers, including therapy-resistant TNBC for which XPO1 
inhibitors are already in line for phase two clinical trials. The most obvious benefit of successful 
completion of our aims to the breast cancer community is reduced mortality from breast cancer, 
due to improved therapies.  
Tumor cells can create favorable environments in target metastatic tissues by secreting 
various factors even before they metastasize [43]. These PMNs are characterized by altered local 
deposition of extracellular matrices, a rudimentary vascular network, recruitment of bone marrow 
derived cells (BMDCs) and presence of proinflammatory molecules and cells [44]. There is a 
current shortfall of relevant in vitro models that accurately reflect the PMNs for ER+ BCa cells, 
as well as novel analysis tools to understand the molecular mechanisms driving adaptation and 
survival of metastatic ER+ BCa cells in these environments. Therefore, adaptation of previously 
published PMN models [43, 45] using tissue-specific extracellular matrices to mimic metastatic 
tissue sites for ER+ BCa cells enabled us to study the impact of PMN microenvironment on how 
ER+ BCa cells behave, adapt, and respond to therapy agents in metastatic tissue environments.  
Our research represents a new and substantive departure from the status quo by shifting 
focus to inhibiting dynamic mechanisms enabling adaptation to metastatic tissue environments and 
therapies. PGC1α was previously implicated in metabolic rewiring and drug resistance of triple 
negative BCa, yet the role of PGC1α has been controversial [41, 42, 46, 47]. Our hypothesis that 
lenient activation of PGC1α, but not the chronic overexpression, promote survival and adaptation 
mechanisms is novel. In addition, none of the publications addressed the impact of different 
PGC1α isoforms on ER+ BCa cell metabolism and metastasis. Our data supports our hypothesis 
that the expression level of PGC1α might determine whether the cancer cells will find escape 
routes (lower PGC1α) or regress due to autophagy or other cell death mechanisms  (very high level 
of PGC1α) (Figure 7.7.C).  
Through our study, we evaluated the combining SEL with current therapies to overcome 
therapy resistance in ER+ metastatic tumors.  Using our molecular characterization methods in 
clinically relevant cell lines we analyzed how combined XPO1 targeting affects PGC1α level, 
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therapy responsiveness, ERα signaling and tumor outcome, thereby evaluating the potential of its 
inhibition as a means to prevent metastatic tumor adaptation and therapy resistance. Overall, 
results of our studies validated XPO1 as a target whose co-inhibition should enhance the 
effectiveness of therapies in metastatic ER+ breast tumors. XPO1 and acute regulation of PGC1α 
have not been implicated in adaptation to metastatic environments and therapy resistance of ER+ 
metastatic tumors before. Given the need for better strategies for improving therapy response of 
relapsed ER+ tumors and avoid increasingly toxic therapy applied in this setting, our proposed 
research has great significance and potential for uncovering the role of this protein and its targeting 
in reducing therapy resistance in recurrent ER+ tumors. In summary, the nuclear export pathways 
have not previously been implicated or examined in the metastatic tissue adaptation and therapy 
resistance, and given the need for better strategies for improving or maintaining therapy response 
of metastatic ER+ tumors, our proposed studies carry high potential for uncovering the role of these 






















Figure 7.1. Clinical relevance of combining XPO1 inhibitors with current therapies in metastatic ER (+) 
tumors. A) We assessed the correlation between mRNA levels of XPO1 with  ESR1, PIK3CA and CCND1 mRNAs 
in ER(+) tumors by using TCGA and METABRIC tumor databases (cBioPortal for Cancer Genomics 
(https://www.cbioportal.org/). Correlated mutations were shown in different colors in the figure. Spearman and 
Pearson correlation analyses were given in each figure. B) RNA sequencing experiment was performed in MCF7 
ESR1Y537S cells, treated with with 4-OHT [10-6], Fulv [10-6] and Palb [10-6] in the presence or absence of SEL [10-7]. 
C) Most important pathways gets activated with combined treatment strategy based on GSEA results of RNA 
sequencing experiment. D) Cell viability assay in different endocrine-resistant breast cancer cell lines (MCF7-
ESR1Y537S , MCF7-ESR1D538G, HCC1500 and BT474), cotreated with 4-OHT [10-6 M], Fulv [10-6 M] and Palb [10-6 
M] and SEL [10-7 M]. A one-way analysis of variance (ANOVA) model was used for statistical significance of 
treatment and values were presented as mean ± SEM from three independent experimental repeats. Significances were 
compared according to Veh condition for each treatment condition.
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Figure 7.1a. Clinical relevance of combining XPO1 inhibitors with current therapies in metastatic ER (+) 
tumors. We assessed the correlation between mRNA levels of XPO1 with  ESR1, PIK3CA and CCND1 mRNAs in 
ER(+) tumors by using METABRIC tumor databases (cBioPortal for Cancer Genomics (https://www.cbioportal.org/). 
Correlated mutations were shown in different colors in the figure. Spearman and Pearson correlation analyses were 






Figure 7.2. Combination of SEL with other treatments decrease colony formation of BCa cells in hydrogels 
from major metastatic tissues. A) MCF7-ESR1Y537S cells were cultured at a density of 2x103 cells/well and 
embedded in 3-D hydrogel environments to mimic different premetastatic niches (bone, liver, lung) in breast cancer 
cells, and they were treated with different endocrine agents (4-OHT [10-6], Fulv [10-6] and Palb [10-6]) and in 
combination with SEL [10-7]. B) Colony area and C) colony number parameters were quantified with OpenCFU 
colony counting software (http://opencfu.sourceforge.net/). Experimental statistics were analyzed by using GraphPad 
Prism8 software. A one-way analysis of variance (ANOVA) model was used for statistical significance of treatment 
and values were presented as mean ± SEM from three independent experimental repeats. Significances were compared 
according to first measurement values for each treatment condition. (*p <0.05, **p <0.01, ***p <0.001). 
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Figure 7.3. ER-XPO1 targeting changes metabolic phenotype of BCa cells from an energetic to quiescent 
profile. A) Cellular metabolic changes in different endocrine-resistant models were monitored with Seahorse 
metabolic profiling. Different de novo endocrine-resistant cell models (HCC-1500, BT474, MCF7-ESR1D538G and 
ESR1Y537S) and acquired resistant models (MCF7/TamR cells generated with a consistent drug treatment strategy) were 
cultured at a density of 3x104 cells/XFp plate wells, and treated with different endocrine agents (4-OHT [10-6], Fulv 
[10-6] and Palb [10-6]) and in combination with SEL [10-7]. B) Different endocrine-sensitive and -resistant cell models 
were grown on an extracellular matrix from bone, liver or lung tissue (major sites for BCa metastasis) at a density of 
3x104 cells/XFp plate wells. All experimental conditions were repeated at least two times and Seahorse metabolic 
profiling values were normalized according to cell number for each assay. 
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Figure 7.4. Single agent treatments rewire metabolic pathways to enhance survival of BCa cells. A) GSEA 
analysis showing activation of Gln deprivation genes in de novo endocrine-resistant BT474 cells. B) Mitochondrial 
Fuel Flex Test results in BT474 cells showing glutamine dependency. BT474 cells were cultured at a density of 
3x104/XFp plate wells, and treated with different endocrine agents (4-OHT [10-6], Fulv [10-6] and Palb [10-6]) and in 
combination with SEL [10-7]. All results were visualized after normalizing OCR and ECAR values according to cell 
number. C) Metabolomics analysis result showing Gln levels in SEL-only treated BT474 cells. For this experiment, 
BT474 cells were cultured at a density of 2x105 cells/10 cm plates in two technical repeats, and treated with different 
endocrine agents (4-OHT [10-6], Fulv [10-6] and Palb [10-6]) and in combination with SEL [10-7]. D) Cell viability 
assay showing the effect of Gln addition to the media. BT474 cells were cultured at a density of 2x103 cells/well in a 
96-well plate and treated with 4-OHT [10-6] alone and in combination with SEL [10-7] in different limited media 
conditions. E) Similar experimental conditions were tested in presence of Glutaminase inhibitor, BPTES [10-6]. A 
one-way analysis of variance (ANOVA) model was used for statistical significance of treatment and values were 











Figure 7.5. Single agent treatments rewire metabolic pathways to enhance survival of BCa cells.                                 
A) NAD+/NADH and B) NADP+/NADPH ratios and C) Reactive oxygen species (ROS) and D) GSH levels were 
quantified by using different luminescence-base assays. For each test kit, BT474 cells were seeded at a density of 
2x103 in 96-well plates and treated with different endocrine agents (4-OHT [10-6], Fulv [10-6] and Palb [10-6]) and in 
combination with SEL [10-7]. Experimental statistics were analyzed by using GraphPad Prism8 software. A two-way 
analysis of variance (ANOVA) model was used for statistical significance of treatment and values were presented as 
mean ± SEM from three independent experimental repeats. Significances were compared according to first 
measurement values for each treatment condition. E) Metabolomics analysis result showing pyruvate and aspartate 
levels in SEL-only treated BT474 cells. For this experiment, BT474 cells were cultured at a density of 2x105 cells/10 
cm plates in two technical repeats, and treated with different endocrine agents (4-OHT [10-6], Fulv [10-6] and Palb [10-
6]) and in combination with SEL [10-7]. A one-way analysis of variance (ANOVA) model was used for statistical 
significance of treatment and values were presented as mean ± SEM from three independent experimental repeats. 
Significances were compared according to first measurement values for each treatment condition. F) The function of 
MDH1 gene on the cell viability of BT474 cells was tested. BT474 cells were seeded in 96-well plates, and treated 
with 4-OHT [10-6] alone and in combination with SEL [10-7]. A one-way analysis of variance (ANOVA) model was 
used for statistical significance of treatment and values were presented as mean ± SEM from three independent 
experimental repeats. Significances were compared according to first measurement values for each treatment 
condition. G) A model explaining how Gln is used in mitochondria, and shunt into malate-aspartate shuttle to sustain 
NAD+/NADH ratio in cancer cells.
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Figure 7.6. PGC1α level determines the metabolic plasticity and response to therapies. A) RNA sequencing 
results showing SEL treatment induces PPARGC1A (PGC1α) mRNA expression in combination with other endocrine 
therapy agents. Statistical analyses were analyzed according to one-way ANOVA test. B and C) Western blot analyses 
showing that PGC1α protein expression were relatively higher in endocrine-resistant breast cancer cells. All cell lines 
were seeded at a density of 2x105 cells/30 mm plates and levels of each target proteins were detected after protein 
extraction. D) The function of PGC1α gene on the cell viability of BT474 cells was tested. BT474 cells were seeded 
in 96-well plates, and treated with 4-OHT [10-6] alone and in combination with SEL [10-7]. A one-way analysis of 
variance (ANOVA) model was used for statistical significance of treatment and values were presented as mean ± SEM 
from three independent experimental repeats. Significances were compared according to first measurement values for 
each treatment condition. E) MCF7-ESR1D538G and ESR1Y537S cells were treated with different doses of PGC1α 
activator (ZLN005) and PGC1α inhibitor (SR-18292) in combination with different endocrine agents (4-OHT [10-6], 
Fulv [10-6] and Palb [10-6]) and in combination with SEL [10-7]. Data visualization was done by GraphPad Prism 8. 
F) Cellular metabolic phenotypes of MCF7- ESR1Y537S cells were determined by seeding 3x104 cells/XFp plate well 
in different extracellular matrix environments, and the effect of small molecule inhibitors for PGC1α [10 -6] (SR-
18292), XPO1[10-7] (SEL) and PI3K/Akt [5x10-6] (MK2206) targets. All Seahorse assays were repeated two times in 




Figure 7.7. PGC1α level determines the metabolic plasticity and response to therapies. A) Cellular metabolic 
phenotypes of endocrine-sensitive MCF7 Parental cells and endocrine-resistant MCF7- ESR1Y537S and HCC1500 cells 
were determined by seeding 3x104 cells/XFp plate well in different extracellular matrix environments, and they were 
treated with different endocrine agents (4-OHT [10-6], Fulv [10-6] and Palb [10-6]) and in combination with SEL [10-
7]. B) Endocrine-sensitive MCF7 Parental cells and endocrine-resistant MCF7- ESR1Y537S and ESR1D538G cells were 
grown in limited media conditions containing only 2 mM individual amino acids. Cells were treated with different 
endocrine agents (4-OHT [10-6], Fulv [10-6] and Palb [10-6]) and in combination with SEL [10-7], and cell viability of 
cells were quantified with WST-1 assay. All experiment conditions were repeated in six technical replicates and 
statistical significance values were calculated according to two-way ANOVA test. C) A model explaining overall 
effect of PGC1 in endocrine resistance in breast cancer cells. 
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CHAPTER 8: CONCLUSIONS 
 
In the first three chapters of this thesis, we mainly investigated molecular mechanism and 
clinical significance of estrogen receptor regulation. We also reviewed literature for the metabolic 
aspects of estrogen receptor signaling and the translational efficacy of metabolism-directed 
treatments in current clinical practice of ER (+) breast cancer treatment. In chapter 4, we built main 
hypothesis and long-term aim of the project based on the literature review in the first three 
chapters.  
In chapter 5, we focused on the characterization of XPO1 protein in terms of tamoxifen 
resistance in ER (+) breast cancers, and showed that XPO1 overexpression is associated with 
tamoxifen resistance in breast cancer cells. Also, a nuclear export signature can be used as a 
promising biomarker to predict tamoxifen responsiveness in ER (+) breast cancer patients. XPO1 
overexpression increases cell proliferation, and this effect can be blocked by XPO1 knock down. 
Nuclear localization of active ERK5 (pERK5) is lost during tamoxifen resistance progression. In 
presence of 4-OHT, pERK5 is extranuclear, but combined 4-OHT and SEL treatment relocates 
pERK5 back to nucleus.   
In chapter 6, we concentrated on the molecular mechanism and the clinical significance of 
combined tamoxifen and selinexor treatment strategy in de novo resistant ER (+) breast cancer 
patients, and we showed that combined ER-XPO1 targeting modulates Akt signaling to rewire 
tumor cell metabolism and induce autophagy. Based on this overall conclusion, our results were 
suggesting that XPO1 protein is upregulated in Luminal B subtype of tumors. Combined 4-
OHT+SEL treatment causes gene expression changes distinct from 4-OHT and SEL treatments 
alone in tamoxifen-resistant cell lines. Different phosphorylation sites of Akt are activated with 4-
OHT, SEL and in combined treatments. Combined ER-XPO1 inhibition reduces Akt 
phosphorylation that was observed with single treatments in tamoxifen-resistant cells and tumor 
xenografts. Combined ER-XPO1targeting changes metabolic phenotype of tamoxifen-resistant 
breast cancer cells from an energetic to quiescent profile. 4-OHT and SEL combination reduces 
mitochondrial activity in tamoxifen-resistant cells. Combined ER-XPO1 targeting activates 
autophagy markers, but not result in apoptosis. 
In chapter 7, we directed our interest on the efficacy of ER-XPO1 dual targeting in 
different potential metastatic sites of breast cancer, and found that single agent treatments are not 
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as effective as combined treatments due to metabolic rewiring. In addition, Combined 4-
OHT+SEL treatment is an effective strategy to target endocrine resistant breast cancer cells. Other 
results that we gathered from this part of the project indicated that XPO1 mutations are highly 
correlated with ESR1 and PIK3CA mutations in breast cancer. Selinexor alone and in combination 
with other endocrine and chemotherapy agents decreases cell viability of endocrine resistant breast 
cancers better. Endocrine resistant cells have a more energetic phenotype. Selinexor works better 
in combination with other endocrine treatment agents to stop oncosphere formation in possible 
breast cancer metastatic sites (e.g. lung, liver, bone). Endocrine resistant breast cancer have a 
higher capacity in the lung and liver compared to bone. Energetic phenotype of both endocrine 
sensitive and resistant breast cancer cells decreases with SEL + endocrine agent combinations 
compared to individual treatments. in vivo and ex vivo models indicated that SEL-treated tumors 
come back after treatment. SEL-treatment makes resistant cells more dependent on glutamine. 
Glutamine is necessary for cells treated with SEL. Glutamine cannot alone compensate the lack of 
other fuels for continued mitochondrial respiration (Excess glutamine is not used for ATP 
production). Combined 4-OHT + SEL treatment reduces the rate of synthesis of glycolysis and 
mitochondrial respiration. Aspartate production increases with SEL treatment, and this excess 
aspartate is used for NAD+ synthesis via malate-aspartate shuttle. MDH1 is essential for glutamine 
usage. 
Overall, our results showed that combination of selinexor with current endocrine therapy 
agents is a promising adjuvant treatment strategy, which can be easily applicable to clinic. This 












CHAPTER 9: FUTURE DIRECTIONS 
 
 Studies we conducted in this project indicated that 4-OHT+SEL treatment offer a 
promising treatment option especially for treatment ER (+) breast cancer patients. An increasing 
number of clinical trials started in the last decade due to beneficial effects of selinexor treatment 
in other cancer types (leukemia, lymphoma, prostate cancer). In parallel, our next aim is to validate 
the impact of this combined drug strategy on in vitro drug resistant breast cancer cell models, 
which were exposed to drug treatments for several weeks. We are going to test the effect of 
combined and individual drug treatments on the cell viability of these cell lines generated as 
acquired drug resistance models. 
 As a next step, we will evaluate the efficacy of these treatment strategies with in vivo 
models, which is the best way to mimic metastatic breast tumor environment. Specifically, we 
want to analyze how combined XPO1 targeting affects PGC1α level, therapy responsiveness, ERα 
signaling and tumor outcome, thereby evaluating the potential of its inhibition as a means to 
prevent metastatic tumor adaptation and therapy resistance. 
 Eventually, we want to test the translational impact of this combined treatment with clinical 
trials with the help of our collaborators at University of Texas MD Anderson Cancer Center.  
 Overall, results of our studies should validate XPO1 as a target whose co-inhibition should 
enhance the effectiveness of therapies in metastatic ER (+) breast tumors. XPO1 and acute 
regulation of PGC1-α have not been implicated in adaptation to metastatic environments and 
therapy resistance of ER (+) metastatic tumors before. Given the need for better strategies for 
improving therapy response of relapsed ER (+) tumors and avoid increasingly toxic therapy 
applied in this setting, our proposed researches have great significance and potential for 
uncovering the role of this protein and its targeting in reducing therapy resistance in recurrent ER 
(+) tumors.  
 In summary, the nuclear export pathways have not previously been implicated or examined 
in the metastatic tissue adaptation and therapy resistance, and given the need for better strategies 
for improving or maintaining therapy response of metastatic ER (+) tumors, our proposed studies 
carry high potential for uncovering the role of these pathways and their use in reducing deaths due 
to metastatic BCas. 
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APPENDIX A: Abbreviations 
 
ACC Acetyl-CoA carboxylase 
ACS Acetyl-CoA synthases 
ACLY ATP citrate lyase 
AdCMV Adenovirus with a cytomegalovirus construct 
AdXPO1 Adenovirus with an XPO1 construct 
AI Aromatase inhibitor 
AF-1 Activation factor-1  
ATP S ATP synthase 
ASL Argininosuccinate lyase 
CD Charcoal dextran 
CDK 4/6 Cyclin-dependent kinase 4/6 
CD-36 Cluster of differentiation 36 
CDO Cysteine dioxygenase 
CSAD Cysteine sulfinic acid decarboxylase 
DAPI 4′,6′-diamino-2-phenylindole 
DBD DNA binding factor 
DCIS Ductal carcinoma in situ 
DES Diethylstilbestrol 
E2 17β-estradiol 
EGRF Epidermal growth factor receptor 
ER Estrogen receptor 
ERα [+] Estrogen receptor positive 
ERα [-] Estrogen receptor negative 
ER Estrogen receptor beta 
ERE Estrogen receptor element 
ERK-5 Extracellular-regulated kinase-5  
FASN Fatty acid synthase 
FBS Fetal bovine serum 
FFA Free fatty acid 
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FFPE Formalin fixed, paraffin embedded 
FULV Fulvestrant 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
G6P isomerase Glucose-6-phosphate isomerase 
G6PD Glucose-6-phosphate dehydrogenase 
GPER G-protein coupled ER 
GLUTs Glucose transporters 
GSL-1 Glutaminase-1 
GS Glutamine synthase 
HER Human epidermal growth factor 
HIF-1 Hypoxia-inducible factor-1 
HK Hexokinase 
HMG-CoA 3-Hydroxy-3-methylglutaryl-CoA 
HMG-CoAR 3-Hydroxy-3-methylglutaryl-CoA reductase 
HSP Heat-shock protein 
LBD Ligand binding domain 
LCIS Lobular carcinoma in situ 
LDHA Lactate dehydrogenase-A, 
MAGL Monoacylglycerol lipase 
MAPK Mitogen-activated kinase pathway 
MNAR Modulator of non-genomic activity of estrogen receptor 
NCoR Nuclear receptor corepressor 
NO Nitric oxide 
PALB Palbociclib 
PCAF p300 coactivator associated factor 
PDH Pyruvate dehydrogenase 
pERK-5 Phosphorylated ERK-5 
PFKs Phosphofructokinase 
PFKBPs Phosphofructokinase fructose biphosphatases 
PGAM Phosphoglycerate mutase 
PGDH Phosphoglycerate dehydrogenase 
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PKA Protein kinase  
PKM2 Pyruvate kinase isoenzyme M2 
PR Progesterone Receptor 
PSP Phosphoserine phosphatase 
PTM Post-translational modification 
RIP140 Receptor interacting protein 140 
RARα Retinoic acid receptor alpha 
RSK Ribosomal S6 kinase 
qPCR Quantitative PCR 
SCD1 Stearoyl-CoA desaturase-1 
SEL Selinexor 
SERM Selective estrogen receptor modulator 
SERD Selective estrogen receptor degrader 
SLC1A5:  Solute carrier family 1 member 5 
SMRT Silencing mediator for retinoid and thyroid receptor 
SphKP-1 Sphingosine-1 phosphate kinase 
SRC-1 Steroid receptor coactivator-1 
TNBC Triple negative breast cancer 
TPR Tetratricopeptide repeat motif 
Veh Vehicle 
WST-1 Water-soluble tetrazolium-1 
XPO1 Exportin 1 
4-OH-TAM 4-hydroxytamoxifen 
 
 
 
 
 
 
 
 
